NZ629884B - SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF - Google Patents

Abstract

Provided herein are solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer such as fumaric acid, benzoic acid, gentisic acid or maleic acid. Pharmaceutical compositions comprising such solid forms (e.g., cocrystals) and methods of use for treating, preventing, and managing various disorders are also provided herein, particularly with regard to reducing tumour load in cancer. g., cocrystals) and methods of use for treating, preventing, and managing various disorders are also provided herein, particularly with regard to reducing tumour load in cancer.

Description

Patents Form No. 5 N.Z. No. 629884 NEW ZEALAND s Act 1953 COMPLETE SPECIFICATION SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPANYL)PYRIDINYL) ((TRANS)METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN- 2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF We, SIGNAL PHARMACEUTICALS, LLC, a company of the United States of America of 10300 Campus Point Drive, Suite 100, San Diego CA 92121, United States of America, do hereby e the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPANYL)PYRIDINYL) ((TRANS)METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN- 2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF 1. FIELD Provided herein are solid forms comprising 2-hydroxypropanyl)pyridin- 3-yl)((trans)methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer. Pharmaceutical compositions comprising such solid forms (e.g., tals) and methods of use for treating, preventing, and managing various disorders are also ed herein. 2. BACKGROUND The identification and selection of a solid form of a pharmaceutical nd is complex, given that a change in solid form may affect a variety of physical and chemical ties, which may e benefits or drawbacks in processing, formulation, stability and bioavailability, among other ant pharmaceutical characteristics. Potential pharmaceutical solids include crystalline solids and amorphous solids. ous solids are characterized by a lack of long-range ural order, whereas crystalline solids are characterized by structural periodicity. The desired class of pharmaceutical solid depends upon the specific application; amorphous solids are sometimes selected on the basis of, e.g., an enhanced dissolution profile, while crystalline solids may be desirable for properties such as, e.g., physical or chemical stability (see e.g., S. R. Vippagunta et al., Adv. Drug. Deliv. Rev., (2001) 48:3-26; L. Yu, Adv.

Drug. Deliv. Rev., (2001) 48:27-42).

Whether crystalline or amorphous, potential solid forms of a pharmaceutical compound include single-component and le-component solids. Single-component solids t essentially of the pharmaceutical nd in the absence of other compounds. Variety among single-component crystalline materials may potentially arise from the phenomenon of polymorphism, wherein multiple three-dimensional arrangements exist for a particular pharmaceutical compound (see e.g., S. R. Byrn et al., Solid State Chemistry of Drugs, (1999) SSCI, West Lafayette). The importance of discovering polymorphs was underscored by the case of Ritonavir, an HIV protease inhibitor that was formulated as soft gelatin capsules. About two years after the product was launched, the unanticipated precipitation of a new, less soluble polymorph in the ation necessitated the withdrawal of the t from the market until a more tent formulation could be developed (see S. R. Chemburkar et al., Org. Process Res.

Dev., (2000) 4:413-417).

Additional diversity among the potential solid forms of a pharmaceutical compound may arise from the possibility of multiple-component solids. Crystalline solids comprising two or more ionic species are termed salts (see e.g., Handbook of ceutical Salts: Properties, Selection and Use, P. H. Stahl and C. G. Wermuth, Eds., (2002), Wiley, Weinheim). onal types of multiple-component solids that may potentially offer other property improvements for a pharmaceutical compound or salt f include, e.g., hydrates, solvates, cocrystals and clathrates, among others (see e.g., S. R. Byrn et al., Solid State Chemistry of Drugs, (1999) SSCI, West Lafayette). er, multiple-component crystal forms may potentially be susceptible to polymorphism, wherein a given multiple-component composition may exist in more than one three-dimensional crystalline arrangement. The discovery of solid forms is of great importance in the pment of a safe, effective, stable and marketable pharmaceutical compound. y, it is not possible to predict a priori if crystalline forms of a compound even exist, let alone how to successfully prepare them (see e.g., Braga and Grepioni, 2005, “Making crystals from crystals: a green route to crystal engineering and polymorphism,” Chem.

Commun.:3635-3645 (with respect to crystal engineering, if instructions are not very precise and/or if other external factors affect the process, the result can be unpredictable); Jones et al., 2006, Pharmaceutical Cocrystals: An Emerging Approach to Physical Property ement,” MRS Bulletin 31:875-879 (At present it is not generally possible to computationally predict the number of observable polymorphs of even the simplest molecules); Price, 2004, “The computational prediction of ceutical crystal structures and polymorphism,” Advanced Drug Delivery Reviews 56:301-319 (“Price”); and ein, 2004, “Crystal Structure Prediction and Polymorphism,” ACA Transactions 39:14-23 (a great deal still needs to be learned and done before one can state with any degree of confidence the ability to predict a crystal structure, much less polymorphic forms)). tals are crystalline molecular complexes of two or more non-volatile compounds bound together in a l lattice by non-ionic interactions. Pharmaceutical cocrystals are cocrystals of a therapeutic compound, e.g., an active pharmaceutical ingredient (API), and one or more non-volatile compound(s) (referred to herein as coformer). A coformer in a pharmaceutical cocrystal is typically ed from non-toxic pharmaceutically able molecules, such as, for example, food ves, preservatives, pharmaceutical excipients, or other APIs. In recent years, pharmaceutical cocrystals have emerged as a possible alternative approach to enhance ochemical properties ofdrug ts. The variety of possible solid forms creates potential diversity in physical and chemical properties for a given ceutical compound.

The compound chemically named 7-(6-(2-hydroxypropanyl)pyridinyl) s)methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(lH)-one and tautomers thereof (collectively referred to herein as “Compound 1”) are disclosed in US. Pat. No. 8,110,578, issued on February 7, 2012, and International Pub. No. , the entireties of each ofwhich are incorporated by reference herein.

Citation or identification ofany reference in Section 2 of this application is not to be ued as an admission that the reference is prior art to the present application. 3. SUMMARY Provided herein are solid forms (e.g., cocrystal forms or mixtures thereof) comprising Compound 1: having the name 2-hydroxypropanyl)pyridinyl)((trans) methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, including tautomers thereof, and a coformer. Also provided are methods ofpreparing, isolating, and characterizing the solid forms.

Also provided herein are pharmaceutical compositions and single unit dosage forms, which se one or more solid forms provided herein.

In certain ments, solid forms of Compound 1 are useful for treating or preventing cancer and conditions treatable or preventable by inhibition of a kinase pathway, for example, the mTOR/PI3K/Akt pathway.

The present ments can be understood more fully by reference to the detailed description and examples, which are ed to exemplify non-limiting embodiments. 4. BRIEF DESCRIPTION OF THE DRAWINGS depicts an X-ray powder ctogram stack plot of Compound 1, Form 1, Form 2 and fumaric acid. depicts a thermogravimetric analysis coupled with mass spectroscopy of Form 1. depicts a thermogravimetrical analysis and single differential thermal analysis of Form 1. depicts high performance liquid chromatography d with mass spectrometry of Form 1. depicts a fourier transform infrared spectroscopy (FTIR) overlay of Compound 1, Form 1 and fumaric acid. depicts a FTIR overlay of Compound 1, Form 1 and fumaric acid in the region of 1800-400 cm-1. depicts a thermogravimetric is coupled with mass spectroscopy of Form 2. depicts a thermogravimetrical is and single differential thermal analysis of Form 2. depicts high performance liquid chromatography d with mass spectrometry of Form 2. depicts a fourier transform infrared spectroscopy (FTIR) overlay of Compound 1, Form 2 and fumaric acid. depicts a FTIR overlay of Compound 1, Form 2 and fumaric acid in the region of 1800-400 cm-1. depicts the molecular structure and atom ing scheme for protonated Compound 1 and its chemical first ination sphere in Form 2. depicts a crystal packing pattern and H-bond scheme of Form 2. depicts an overlay of the simulated XRPD pattern (bottom) and the experimental XRPD pattern (top) of Form 2. s an X-ray powder diffractogram stack plot of Compound 1, Form 3, Form 4 and benzoic acid. depicts a thermogravimetric is coupled with mass spectroscopy of Form 3. depicts a thermogravimetrical analysis and single ential thermal analysis of Form 3. depicts high performance liquid chromatography coupled with mass spectrometry of Form 3. depicts a FTIR overlay of Compound 1, Form 3 and benzoic acid. depicts a FTIR overlay of Compound 1, Form 3 and c acid in the region of 1800-400 cm-1. depicts a thermogravimetric analysis coupled with mass spectroscopy of Form 4. depicts a thermogravimetrical analysis and single differential thermal analysis of Form 4. depicts high performance liquid chromatography coupled with mass spectrometry of Form 4. depicts a FTIR overlay of Compound 1, Form 4 and c acid. depicts a FTIR overlay of Compound 1, Form 4 and benzoic acid in the region of 1800-400 cm-1. depicts an X-ray powder ctogram stack plot of Compound 1, Form , Form 6 and gentisic acid. depicts a thermogravimetric analysis coupled with mass spectroscopy of Form 5. depicts a thermogravimetrical analysis and single differential thermal analysis of Form 5. depicts high performance liquid chromatography coupled with mass spectrometry of Form 5. depicts a fourier transform infrared oscopy (FTIR) overlay of Compound 1, Form 5 and gentisic acid. depicts a FTIR overlay of nd 1, Form 5 and gentisic acid in the region of 1800-400 cm-1. s a thermogravimetric analysis coupled with mass spectroscopy of Form 6. depicts a thermogravimetrical analysis and single differential thermal analysis of Form 6. depicts high performance liquid chromatography coupled with mass spectrometry of Form 6. depicts a fourier orm infrared spectroscopy (FTIR) overlay of Compound 1, Form 6 and gentisic acid. s a FTIR overlay of Compound 1, Form 6 and gentisic acid in the region of 1800-400 cm-1. depicts an X-ray powder diffractogram stack plot of Compound 1, Form 7, Form 8 and maleic acid. depicts a thermogravimetric analysis coupled with mass spectroscopy of Form 7. depicts a thermogravimetrical analysis and single differential thermal analysis of Form 7. depicts high performance liquid chromatography coupled with mass spectrometry of Form 7. depicts a r transform infrared spectroscopy (FTIR) overlay of nd 1, Form 7 and maleic acid. depicts a FTIR overlay of Compound 1, Form 7 and maleic acid in the region of 1800-400 cm-1. depicts a thermogravimetric is coupled with mass spectroscopy of Form 8. depicts a thermogravimetrical analysis and single differential thermal analysis of Form 8. depicts high performance liquid chromatography coupled with mass spectrometry of Form 8. depicts a fourier transform infrared spectroscopy (FTIR) overlay of Compound 1, Form 8 and maleic acid. depicts a FTIR overlay of Compound 1, Form 8 and maleic acid in the region of 1800-400 cm-1.

. DETAILED DESCRIPTION .1 TIONS As used herein, and in the specification and the anying claims, the indefinite articles “a” and “an” and the definite article “the” include plural as well as single referents, unless the context clearly indicates otherwise.

As used herein, and unless otherwise specified, the terms ” and ximately,” when used in connection with doses, amounts, or weight percents of ingredients of a ition or a dosage form, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. In certain embodiments, the terms ” and “approximately,” when used in this context, contemplate a dose, amount, or weight percent within 30%, within 20%, within 15%, within 10%, or within 5%, of the specified dose, amount, or weight t.

As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection with a numeric value or range of values which is ed to characterize a ular solid form, e.g., a ic temperature or temperature range, such as, for example, that describes a melting, dehydration, desolvation, or glass transition temperature; a mass change, such as, for example, a mass change as a function of temperature or humidity; a solvent or water content, in terms of, for example, mass or a percentage; or a peak position, such as, for example, in analysis by, for example, IR or Raman spectroscopy or XRPD; te that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the solid form. Techniques for characterizing crystal forms and amorphous forms include, but are not limited to, thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC), X-ray powder ctometry , singlecrystal X-ray diffractometry, vibrational spectroscopy, e.g., infrared (IR) and Raman spectroscopy, solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and ution studies. In certain embodiments, the terms “about” and “approximately,” when used in this context, indicate that the numeric value or range of values may vary within 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the recited value or range of . For example, in some embodiments, the value of an XRPD peak position may vary by up to ±0.2 s two theta while still describing the particular XRPD peak.

As used herein, and unless otherwise specified, a crystalline that is “pure,” i.e., ntially free of other crystalline or amorphous forms, contains less than about 10% by weight of one or more other lline or amorphous forms, less than about 5% by weight of one or more other crystalline or amorphous forms, less than about 3% by weight of one or more other crystalline or amorphous forms, or less than about 1% by weight of one or more other crystalline or amorphous forms.

As used herein, and unless otherwise specified, a solid form that is “substantially physically pure” is substantially free from other solid forms. In certain ments, a crystal form that is ntially physically pure contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other solid forms on a weight basis. The detection of other solid forms can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, diffraction analysis, thermal analysis, elemental combustion analysis and/or oscopic analysis.

As used herein, and unless otherwise specified, a solid form that is “substantially chemically pure” is substantially free from other chemical compounds (i.e., al impurities).

In certain embodiments, a solid form that is substantially ally pure contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other chemical compounds on a weight basis. The detection of other chemical compounds can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, s of chemical analysis, such as, e.g., mass spectrometry analysis, spectroscopic analysis, thermal analysis, elemental combustion analysis and/or chromatographic analysis.

As used herein, and unless otherwise indicated, a chemical compound, solid form, or composition that is “substantially free” of r chemical compound, solid form, or ition means that the compound, solid form, or composition ns, in certain embodiments, less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2% 0.1%, 0.05%, or 0.01% by weight of the other compound, solid form, or composition.

Unless otherwise specified, the terms “solvate” and “solvated,” as used , refer to a solid form of a substance which ns solvent. The terms “hydrate” and “hydrated” refer to a solvate wherein the t is water. “Polymorphs of solvates” refer to the existence of more than one solid form for a ular solvate composition. Similarly, “polymorphs of hydrates” refer to the existence of more than one solid form for a ular hydrate ition.

The term “desolvated solvate,” as used herein, refers to a solid form of a substance which can be made by removing the solvent from a solvate. The terms “solvate” and “solvated,” as used herein, can also refer to a solvate of a salt, cocrystal, or molecular complex. The terms “hydrate” and ted,” as used herein, can also refer to a hydrate of a salt, cocrystal, or molecular complex.

“Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the ing isomeric forms, which are referred to as tautomers of each other: N N HN N As readily understood by one skilled in the art, a wide variety of functional groups and other structures may exhibit tautomerism and all tautomers of Compound 1 are within the scope of the present ion.

Unless otherwise specified, the term “composition” as used herein is intended to encompass a product comprising the specified ingredient(s) (and in the specified amount(s), if indicated), as well as any product which results, directly or indirectly, from combination of the ied ingredient(s) in the specified amount(s). By “pharmaceutically acceptable,” it is meant a diluent, excipient, or carrier in a formulation must be compatible with the other ingredient(s) of the formulation and not deleterious to the recipient f.

The term “solid form” refers to a physical form which is not predominantly in a liquid or a gaseous state. As used herein and unless otherwise specified, the term “solid form,” when used herein to refer to Compound 1, refers to a physical form comprising Compound 1 which is not predominantly in a liquid or a gaseous state. A solid form may be a lline form or a mixture thereof. In certain embodiments, a solid form may be a liquid crystal. In certain embodiments, the term “solid forms comprising Compound 1” includes crystal forms comprising nd 1. In certain embodiments, the solid form of Compound 1 is Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8 or a mixture thereof.

As used herein and unless otherwise specified, the term “crystalline” when used to describe a compound, substance, modification, al, component or product, unless otherwise specified, means that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21st edition, cott, Williams and s, Baltimore, MD (2005); The United States Pharmacopeia, 23rd ed., 1843-1844 (1995).

The term “crystal form” or “crystalline form” refers to a solid form that is crystalline. In n embodiments, crystal forms include salts. In certain embodiments, a crystal form of a substance may be substantially free of amorphous forms and/or other crystal forms. In n embodiments, a crystal form of a nce may contain less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, or less than about 50% by weight of one or more amorphous forms and/or other crystal forms. In certain embodiments, a crystal form of a substance may be physically and/or chemically pure. In certain embodiments, a crystal form of a substance may be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and/or chemically pure.

Unless ise specified, the term “cocrystal” as used herein, refers to a crystalline material comprised of Compound 1, including tautomers thereof, and one or more non-volative compounds bound together in a crystal lattice by non-covalent interactions.

Unless otherwise specified, the term “amorphous” or “amorphous form” means that the substance, component, or product in question is not substantially crystalline as ined by X-ray diffraction. In particular, the term “amorphous form” describes a disordered solid form, i.e., a solid form lacking long range crystalline order. In n embodiments, an ous form of a substance may be substantially free of other amorphous forms and/or crystal forms. In certain embodiments, an amorphous form of a substance may n less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, or less than about 50% by weight of one or more other amorphous forms and/or crystal forms on a weight basis. In certain embodiments, an amorphous form of a substance may be physically and/or chemically pure. In certain embodiments, an amorphous form of a substance be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and/or chemically pure.

Unless otherwise specified, the terms “polymorph,” “polymorphic form,” “polymorphs,” “polymorphic forms,” and related terms herein refer to two or more crystal forms that consist essentially of the same molecule, molecules or ions. Different polymorphs may have different physical properties, such as, for e, melting temperatures, heats of fusion, solubilities, dissolution rates, and/or vibrational spectra as a result of a different ement or conformation of the les or ions in the crystal lattice. The differences in physical properties exhibited by polymorphs may affect pharmaceutical parameters, such as storage stability, compressibility and density (important in formulation and product manufacturing), and dissolution rate (an important factor in bioavailability). Differences in stability can result from changes in chemical reactivity (e.g., differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when sed of another polymorph) or mechanical s (e.g., tablets crumble on storage as a kinetically d rph converts to thermodynamically a more stable polymorph) or both (e.g., tablets of one polymorph are more susceptible to own at high humidity). As a result of solubility/dissolution differences, in the extreme case, some polymorphic transitions may result in lack of potency or, at the other extreme, toxicity. In addition, the physical properties of the crystal may be important in processing; for example, one polymorph might be more likely to form solvates or might be ult to filter and wash free of impurities (e.g., particle shape and size distribution might be different between polymorphs).

The term “subject” refers to an animal, including, but not limited to, a primate (e.g., human), cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms “subject” and “patient” are used herein hangeably in reference, for example, to a mammalian subject, such as a human subject, in one embodiment, a human. In one embodiment, the subject has or is susceptible to having a disease, disorder, or condition provided herein.

The term “treat,” “treating,” or “treatment” means an alleviation, in whole or in part, of a disease, disorder, or condition provided herein, or one or more symptoms associated with the disease, disorder, or ion, or slowing, or halting of further progression or worsening of the disease, disorder, or condition, or one or more ms associated with the disease, er, or condition.

The term “prevent,” “preventing,” or ntion” means prevention of the onset, recurrence, or spread of a disease, disorder, or condition provided herein, or one or more ms associated with the disease, disorder, or condition, in a subject at risk for developing the disease, disorder, or condition.

The term “effective ” or “therapeutically effective amount” refers to, in one embodiment, an amount of Compound 1 capable of alleviating, in whole or in part, one or more symptoms associated with a disease, disorder, or condition provided , or slowing or halting further progression or worsening of one or more of the symptoms of the disease, disorder, or condition; in another embodiment, an amount capable of preventing or providing prophylaxis for the disease, disorder, or condition in a subject at risk for developing the disease, er, or condition, such as , inflammatory conditions, immunological conditions, neurodegenerative es, diabetes, obesity, neurological disorders, age-related diseases, and/or cardiovascular conditions, and/or diseases, disorders, and conditions treatable or preventable by inhibition of a kinase y, for example, the mTOR/PI3K/Akt pathway. In one embodiment, an ive amount of a compound is an amount that ts a kinase in a cell, such as, for example, in vitro or in vivo. In one embodiment the kinase is TOR kinase. In certain embodiments, the effective amount of a compound inhibits the kinase in a cell by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99%, compared to the activity of the kinase in an untreated cell. In one embodiment, “effective amount” refers to the amount of Compound 1 e of ating, in whole or in part, symptoms associated with a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast , colorectal cancer, salivary cancer, atic cancer, adenocystic cancer, adrenal cancer, geal cancer, renal cancer, leiomyosarcoma, or paraganglioma, including advanced solid tumors), non- Hodgkin lymphoma or multiple myeloma, or slowing or halting further progression or worsening of those symptoms, or treating or preventing a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple myeloma in a subject having or at risk for having a solid tumor, non-Hodgkin lymphoma or multiple a. As will be apparent to those skilled in the art, it is to be expected that the ive amount of a compound disclosed herein may vary depending on the indication being treated, e.g., the effective amount of the compound would likely be different for treating patients ing from, or at risk for, inflammatory conditions relative to the effective amount of the compound for treating patients suffering from, or at risk of, a different disorder, e.g., a er provided .

The term “cancer” refers to any of various malignant neoplasms characterized by the proliferation of cells that can invade surrounding tissue and metastasize to new body sites.

Both benign and malignant tumors are classified according to the type of tissue in which they are found. For example, fibromas are sms of s connective tissue, and melanomas are abnormal growths of t (melanin) cells. Malignant tumors originating from lial tissue, e.g., in skin, bronchi, and stomach, are termed carcinomas. Malignancies of epithelial glandular tissue such as are found in the breast, te, and colon, are known as adenocarcinomas. ant growths of connective tissue, e.g., muscle, cartilage, lymph tissue, and bone, are called sarcomas. Lymphomas and leukemias are malignancies arising among white blood cells. Through the process of metastasis, tumor cell migration to other areas of the body establishes neoplasms in areas away from the site of initial ance. Bone tissues are one of the most favored sites of metastases of malignant tumors, ing in about 30% of all cancer cases. Among malignant tumors, s of the lung, breast, prostate or the like are particularly known to be likely to asize to bone.

In the context of a solid tumor (for example, a ndocrine tumor, all cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal , geal cancer, renal , leiomyosarcoma, or paraganglioma, including advanced solid tumors), non- Hodgkin lymphoma or multiple myeloma, inhibition may be assessed by inhibition or ing of disease progression, inhibition of tumor growth, reduction or regression of primary and/or secondary tumor (s), relief of tumor-related symptoms, improvement in quality of life, inhibition of tumor secreted factors (including tumor secreted es, such as those that contribute to carcinoid syndrome), reductions in endocrine hormone markers (for example, chromogranin, gastrin, serotonin, and/or glucagon), delayed appearance or recurrence of primary or secondary tumors, slowed development of primary and/or secondary tumors, decreased occurrence of primary and/or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and/or sion of tumors, increased Time To Progression (TTP), increased Progression Free Survival (PFS), sed Overall Survival (OS), among others. OS as used herein means the time from randomization until death from any cause, and is measured in the intent-to-treat population. TTP as used herein means the time from randomization until objective tumor progression; TTP does not include deaths. As used herein, PFS means the time from ization until objective tumor progression or death. In one embodiment, PFS rates will be ed using the Kaplan-Meier estimates. In the extreme, complete inhibition, is referred to herein as prevention or chemoprevention. In this context, the term “prevention” includes either preventing the onset of clinically evident solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular oma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, ystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma, including advanced solid tumors), non-Hodgkin lymphoma or multiple myeloma altogether or preventing the onset of a nically evident stage of a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, ry cancer, pancreatic cancer, adenocystic , adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma, including advanced solid tumors), non-Hodgkin lymphoma or multiple myeloma. Also intended to be encompassed by this definition is the prevention of transformation into malignant cells or to arrest or e the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma orme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal cancer, geal cancer, renal cancer, osarcoma, or paraganglioma, including ed solid ), non-Hodgkin lymphoma or multiple myeloma.

An “advanced solid tumor” as used herein, means a solid tumor that has spread locally, or asized or spread to another part of the body.

In certain embodiments, the treatment may be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (see Thereasse P., et al. New Guidelines to Evaluate the Response to Treatment in Solid . J. of the National Cancer Institute; 2000; (92) 205-216 and Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European J. Cancer; 2009; (45) 228–247).

Overall responses for all possible ations of tumor responses in target and non-target lesions with our without the appearance of new lesions are as follows: Target s Non-target lesions New lesions Overall response CR CR No CR CR Incomplete No PR response/SD PR Non-PD No PR SD Non-PD No SD PD Any Yes or no PD Any PD Yes or no PD Any Any Yes PD CR = te response; PR = partial response; SD = stable disease; and PD = progressive disease.

With respect to the evaluation of target lesions, complete response (CR) is the disappearance of all target lesions, partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, progressive disease (PD) is at least a 20% increase in the sum of the longest er of target lesions, taking as reference the smallest sum longest er recorded since the treatment started or the appearance of one or more new lesions and stable disease (SD) is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum t diameter since the treatment started.

With respect to the evaluation of non-target s, complete se (CR) is the disappearance of all non-target lesions and normalization of tumor marker level; lete response/stable disease (SD) is the persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits, and progressive disease (PD) is the appearance of one or more new lesions and/or unequivocal progression of existing non-target In certain embodiments, the treatment of lymphoma may be assessed by the International Workshop Criteria (IWC) for non-Hodgkin lymphoma (NHL) (see Cheson BD, Pfistner B, Juweid, ME, et. al. Revised Response Criteria for Malignant Lymphoma. J. Clin.

Oncol: 2007: (25) 6), using the response and endpoint definitions shown below: Response Definition Nodal Masses Spleen, liver Bone Marrow CR Disappearance (a) FDG-avid or PET Not palpable, Infiltrate of all evidence positive prior to therapy; nodules cleared on of disease mass of any size ted disappeared repeat biopsy; if PET negative if (b) Variably FDG-avid or indeterminate PET negative; regression by to normal size on CT logy, immunohistochemistry should be negative Response Definition Nodal Masses Spleen, liver Bone Marrow PR Regression of ≥50% decrease in SPD of ≥50% Irrelevant if measurable up to 6 largest nt se in positive prior disease and no masses; no increase in size SPD of to therapy; cell new sites of other nodes nodules (for type should be (a) FDG-avid or PET single nodule specified positive prior to y; in greatest one or more PET positive transverse at previously involved site diameter); no (b) Variably FDG-avid or increase in PET negative; regression size of liver on CT or spleen SD Failure to (a) FDG-avid or PET attain CR/PR positive prior to therapy; or PD PET positive at prior sites of disease and no new sites on CT or PET (b) Variably id or PET negative; no change in size of previous lesions on CT PD or Any new ance of a new ≥50% New or relapsed lesion or (s) ≥1.5 cm in any increase recurrent disease increase by ≥ axis, ≥50% increase in from nadir in involvement 50% of SPD of more than one the SPD of previously node, any previous involved sites or ≥50% increase in lesions from nadir longest diameter of a previously identifed node ≥1 cm in short axis Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy Abbreviations: CR, complete remission; FDG, [18F]fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PR, partial remission; SPD, sum of the t of the diameters; SD, stable disease; PD, progressive disease.

End point Patients Definition Measured from Primary Overall survival All Death as a result of any cause Entry onto study Progression-free All Disease progression or death as a result of Entry onto study al any cause Secondary Event-free survival All Failure of ent or death as result of Entry onto study any cause Time to progression All Time to progression or death as a result of Entry onto study lymphoma Disease-free al In CR Time to relapse or death as a result of Documentation lymphoma or acute toxicity of treatment of response Response duration In CR or Time to relapse or progression Documentation PR of response Lymphoma-specific All Time to death as a result of ma Entry onto study survival Time to next treatment All Time to new treatment End of y treatment Abbreviations: CR: complete remission; PR: partial remission.

In one embodiment, the end point for lymphoma is evidence of clinical benefit.

Clinical benefit may t improvement in quality of life, or reduction in patient symptoms, transfusion requirements, frequent infections, or other parameters. Time to reappearance or progression of lymphoma-related ms can also be used in this end point.

In n embodiments, the treatment of multiple myeloma may be assessed by the International Uniform Response Criteria for Multiple Myeloma (IURC) (see Durie BGM, Harousseau J-L, Miguel JS, et al. International m response criteria for multiple myeloma.

Leukemia, 2006; (10) 10: 1-7), using the response and endpoint definitions shown below: Response Subcategory Response Criteriaa sCR CR as defined below plus Normal FLC ratio and Absence of clonal cells in bone marrowb by immunohistochemistry or immunofluorescencec CR Negative immunofixation on the serum and urine and Disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrowb Response Subcategory Response Criteriaa VGPR Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M- protein plus urine ein level <100mg per 24 h PR ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by≥90% or to <200mg per 24 h If the serum and urine M-protein are unmeasurable,d a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30% In addition to the above listed criteria, if present at baseline, a ≥50% ion in the size of soft tissue cytomas is also required SD (not ended for use Not meeting criteria for CR, VGPR, PR or progressive disease as an indicator of response; stability of disease is best described by providing the time to progression estimates) iations: CR, complete response; FLC, free light chain; PR, partial response; SD, stable disease; sCR, stringent complete response; VGPR, very good l response; aAll response ries e two consecutive ments made at anytime before the institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic s were performed. Radiographic s are not required to satisfy these response requirements; bConfirmation with repeat bone marrow biopsy not needed; cPresence/absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is κ/λ of >4:1 or <1:2. dMeasurable disease defined by at least one of the following measurements: Bone marrow plasma cells ≥30%; Serum M-protein ≥1 g/dl (≥10 gm/l)[10 g/l]; Urine M-protein ≥200 mg/24 h; Serum FLC assay: ed FLC level ≥10 mg/dl (≥100 mg/l); provided serum FLC ratio is abnormal.

The procedures, conventions, and definitions described below provide guidance for implementing the recommendations from the Response Assessment for Neuro-Oncology (RANO) Working Group ing response criteria for high-grade gliomas (Wen P., Macdonald, DR., Reardon, DA., et al. Updated response assessment criteria for highgrade gliomas: se assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972). y modifications to the RANO criteria for Criteria for Time Point Responses (TPR) can include the on of operational conventions for defining changes in glucocorticoid dose, and the removal of subjects’ clinical deterioration component to focus on objective radiologic assessments. The baseline MRI scan is defined as the assessment performed at the end of the post-surgery rest , prior to re-initiating compound treatment. The baseline MRI is used as the reference for assessing complete response (CR) and partial response (PR).

Whereas, the st SPD (sum of the products of perpendicular diameters) ed either at baseline or at subsequent assessments will be designated the nadir assessment and utilized as the reference for ining progression. For the 5 days preceding any protocol-defined MRI scan, subjects receive either no orticoids or are on a stable dose of glucocorticoids. A stable dose is defined as the same daily dose for the 5 consecutive days preceding the MRI scan. If the ibed glucocorticoid dose is changed in the 5 days before the baseline scan, a new baseline scan is required with glucocorticoid use meeting the criteria described above. The following definitions will be used.

Measurable Lesions: Measurable s are contrast-enhancing lesions that can be measured nsionally. A measurement is made of the maximal enhancing tumor diameter (also known as the longest diameter, LD). The greatest perpendicular diameter is measured on the same image. The cross hairs of bidimensional measurements should cross and the product of these diameters will be calculated.

Minimal Diameter: ghted image in which the ns are 5 mm with 1 mm skip. The l LD of a measurable lesion is set as 5 mm by 5 mm. Larger diameters may be required for inclusion and/or designation as target lesions. After baseline, target lesions that become smaller than the minimum requirement for measurement or become no longer amenable to bidimensional measurement will be recorded at the default value of 5 mm for each diameter below 5 mm. Lesions that disappear will be recorded as 0 mm by 0 mm.

Multicentric s: Lesions that are considered multicentric (as opposed to continuous) are lesions where there is normal intervening brain tissue between the two (or more) lesions. For multicentric lesions that are discrete foci of enhancement, the approach is to separately measure each enhancing lesion that meets the inclusion criteria. If there is no normal brain tissue between two (or more) lesions, they will be considered the same lesion.

Nonmeasurable Lesions: All lesions that do not meet the criteria for measurable e as defined above will be considered non-measurable lesions, as well as all nonenhancing and other truly nonmeasurable lesions. Nonmeasurable lesions include foci of enhancement that are less than the specified smallest er (ie., less than 5 mm by 5 mm), nonenhancing lesions (eg., as seen on T1-weighted post-contrast, T2-weighted, or fluid-attenuated inversion ry (FLAIR) images), hemorrhagic or predominantly cystic or necrotic lesions, and leptomeningeal tumor. Hemorrhagic lesions often have intrinsic T1-weighted hyperintensity that could be misinterpreted as enhancing tumor, and for this reason, the ntrast T1-weighted image may be examined to e baseline or interval sub-acute hemorrhage.

At baseline, lesions will be classified as follows: Target lesions: Up to measurable s can be selected as target lesions with each measuring at least 10 mm by mm, entative of the t’s disease; Non-target lesions: All other lesions, including all surable lesions (including mass effects and T2/FLAIR findings) and any measurable lesion not selected as a target lesion. At ne, target lesions are to be measured as described in the definition for measurable lesions and the SPD of all target lesions is to be determined. The presence of all other lesions is to be documented. At all post-treatment evaluations, the baseline classification of lesions as target and non-target lesions will be ined and lesions will be documented and described in a consistent fashion over time (eg., recorded in the same order on source documents and eCRFs). All able and surable lesions must be assessed using the same technique as at baseline (e.g., subjects should be imaged on the same MRI scanner or at least with the same magnet strength) for the on of the study to reduce difficulties in interpreting changes. At each evaluation, target lesions will be measured and the SPD calculated. Non-target lesions will be assessed qualitatively and new lesions, if any, will be documented separately. At each evaluation, a time point response will be determined for target s, non-target lesions, and new lesion. Tumor progression can be established even if only a subset of lesions is assessed. However, unless progression is ed, objective status (stable disease, PR or CR) can only be determined when all lesions are assessed.

Confirmation assessments for overall time point responses of CR and PR will be performed at the next scheduled assessment, but confirmation may not occur if scans have an interval of < 28 days. Best response, incorporating confirmation requirements, will be derived from the series of time points.

The term “contacting” or ct” is meant to refer to bringing together of a therapeutic agent and cell or tissue such that a physiological and/or chemical effect takes place as a result of such contact. ting can take place in vitro, ex vivo, or in vivo. In one embodiment, a eutic agent is contacted with a cell in cell culture (in vitro) to determine the effect of the therapeutic agent on the cell. In another embodiment, the contacting of a therapeutic agent with a cell or tissue includes the administration of a therapeutic agent to a subject having the cell or tissue to be contacted.

Techniques for characterizing crystal forms and amorphous forms include, but are not limited to, thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC), X- ray powder diffractometry (XRPD), single-crystal X-ray diffractometry, ional spectroscopy, e.g., infrared (IR) and Raman spectroscopy, solid-state and on nuclear magnetic resonance (NMR) spectroscopy, l microscopy, hot stage optical microscopy, ng electron microscopy (SEM), electron llography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility ements, dissolution measurements, elemental analysis, and Karl Fischer is. Characteristic unit cell ters may be determined using one or more techniques such as, but not limited to, X-ray diffraction and neutron diffraction, including single-crystal diffraction and powder diffraction. Techniques useful for analyzing powder diffraction data include profile refinement, such as Rietveld refinement, which may be used, e.g., to analyze ction peaks associated with a single phase in a sample comprising more than one solid phase. Other methods useful for analyzing powder diffraction data include unit cell indexing, which allows one of skill in the art to determine unit cell parameters from a sample comprising lline powder.

Unless otherwise specified, to the extent that there is a discrepancy between a depicted chemical structure of a compound provided herein and a chemical name of a compound provided herein, the chemical structure shall control. .2 COMPOUND 1 The solid forms, formulations and methods of use provided herein relate to solid forms (e.g., cocrystals) of Compound 1: OH (El mz N/ N No having the name 7-(6-(2-hydroxypropan—2-yl)pyridinyl)((trans) methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, including tautomers thereof.

Compound 1 can be prepared using reagents and methods known in the art, including the methods provided in US Patent No. 8,110,578, issued on February 7, 2012; US Patent Publication Application No. 2011/0137028, published on June 9, 2011; and US Provisional Patent ation No. 61/813,064, filed on April 17, 2013, the entire contents of each ofwhich are incorporated herein by reference.

It should be noted that if there is a discrepancy between a depicted structure and a name given that structure, the ed structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the ure is to be reted as encompassing all stereoisomers of it. .3 SOLID FORM COCRYSTALS OF COMPOUND 1 While not intending to be bound by any ular theory, certain solid form cocrystals are terized by physical properties, e.g., stability, solubility and dissolution rate, appropriate for pharmaceutical and therapeutic dosage forms. Moreover, while not wishing to be bound by any particular theory, certain solid form cocrystals are terized by physical properties (e.g., density, compressibility, hardness, logy, ge, stickiness, solubility, water uptake, electrical properties, thermal behavior, solid-state reactivity, physical stability, and chemical stability) affecting particular processes (e.g., yield, filtration, washing, drying, milling, mixing, tableting, flowability, dissolution, formulation, and lyophilization) which make certain solid form tals suitable for the manufacture of a solid dosage form. Such properties can be determined using particular analytical chemical techniques, including solid-state analytical techniques (e.g., X-ray ction, copy, spectroscopy and thermal analysis), as described herein and known in the art.

In one embodiment, provided herein are solid forms (e.g., crystal forms or mixtures thereof) comprising (a) Compound 1; and (b) a coformer. In one embodiment, provided herein are solid forms (e.g., crystal forms or mixtures thereof) comprising (a) a free base of Compound 1; and (b) a er. Compound 1 can be synthesized or obtained according to a method known in the literature or based upon the teachings herein, including the s described in detail in the examples herein.

In certain embodiments, the coformer is fumaric acid, benzoic acid, ic acid, or maleic acid.

In one embodiment, provided herein is a cocrystal comprising (a) Compound 1; and (b) a coformer. In one embodiment, provided herein is a mixture comprising (i) a cocrystal comprising (a) Compound 1; and (b) a coformer; and (ii) a crystal form of Compound 1. In one ment, provided herein is a e comprising (i) a cocrystal comprising (a) Compound 1; and (b) a coformer; and (ii) an amorphous form of Compound 1.

In one embodiment, provided herein is a solid form sing (a) Compound 1 and (b) a er that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal comprising (a) Compound 1 and (b) a coformer. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising (a) Compound 1 and (b) a coformer and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a tal comprising (a) Compound 1 and (b) a coformer and (ii) one or more onal crystal forms of Compound 1.

In one embodiment, provided herein is an unsolvated solid form comprising (a) Compound 1 and (b) a coformer. In one embodiment, provided herein is an anhydrous solid form comprising (a) nd 1 and (b) a coformer. In one embodiment, provided herein is an unsolvated crystal form comprising (a) nd 1 and (b) a coformer. In one embodiment, provided herein is an anhydrous crystal form comprising (a) Compound 1 and (b) a coformer. In one embodiment, provided herein is a ed solid form comprising (a) Compound 1 and (b) a er. In one embodiment, provided herein is a hydrated solid form comprising (a) Compound 1 and (b) a coformer (e.g., a hydrate having a stoichiometric or non-stoichiometric amount of water). In one embodiment, provided herein is a hydrated form of (a) Compound 1 and (b) a er, ing, but not limited to, a hemihydrate, a monohydrate, a dihydrate, a trihydrate, and the like. In one embodiment, the hydrated form is substantially crystalline. In one embodiment, the anhydrous form is substantially crystalline. In one embodiment, provided herein is an unsolvated cocrystal comprising (a) Compound 1 and (b) a er. In one embodiment, provided herein is an anhydrous cocrystal comprising (a) Compound 1 and (b) a coformer. In one embodiment, provided herein is a hydrated cocrystal comprising (a) Compound 1 and (b) a er. In one embodiment, provided herein is a solvated cocrystal sing (a) Compound 1 and (b) a coformer.

Solid forms ed herein can be prepared by the methods described herein, or by techniques, ing, but not limited to, heating, cooling, freeze drying, spray drying, lization, quench cooling the melt, rapid solvent evaporation, slow solvent evaporation, solvent recrystallization, antisolvent addition, slurry recrystallization, crystallization from the melt, desolvation, tallization in confined spaces, such as, e.g., in res or capillaries, recrystallization on surfaces or templates, such as, e.g., on rs, tallization in the presence of additives, such as, e.g., cocrystal counter-molecules, desolvation, dehydration, rapid cooling, slow cooling, exposure to solvent and/or water, drying, including, e.g., vacuum drying, vapor diffusion, sublimation, grinding (including, e.g., cryo-grinding and solvent-drop grinding), microwave-induced precipitation, sonication-induced precipitation, laser-induced precipitation, and precipitation from a supercritical fluid. The particle size of the resulting solid forms, which can vary (e.g., from nanometer dimensions to eter dimensions), can be controlled, e.g., by varying crystallization conditions, such as, e.g., the rate of crystallization and/or the crystallization t system, or by particle-size reduction techniques, e.g., grinding, milling, micronizing, or sonication.

In some embodiments, the cocrystal comprising (a) Compound 1 and (b) a er can be obtained by crystallization from certain solvent systems, for example, solvent systems comprising one or more of the following solvents: ethanol, a mixture of ethanol and water (e.g., about 10/90 or about 50/50), a e of methanol and water (e.g., about 50/50), a mixture of THF and water (e.g., about 50/50), acetonitrile, ethyl acetate, a mixture of acetone and water (e.g., about 10/90), cyclohexane, p-xylene and water. In certain embodiments, a solid form provided herein (e.g., a cocrystal comprising (a) Compound 1 and (b) a coformer) can be obtained by cooling evaporation experiments, powder in saturated solutions experiments, slurry experiments, and grinding experiments.

In certain embodiments, the non-covalent forces are one or more hydrogen bonds (H-bonds). The coformer may be H-bonded directly to Compound 1 or may be H-bonded to an additional molecule which is bound to Compound 1. The additional molecule may be ed to Compound 1 or bound ionically or covalently to Compound 1. The additional molecule could also be a different active or inactive ingredient. In certain embodiments, the cocrystals may include one or more e molecules in the crystalline lattice, i.e., es of cocrystals, or a cocrystal further comprising a solvent or compound that is a liquid at room temperature. In certain ments, the cocrystals may be a cocrystal between a coformer and a salt of nd 1. In certain ments, the non-covalent forces are pi-stacking, host complexation and/or van der Waals interactions. Hydrogen g can result in l different olecular configurations. For example, hydrogen bonds can result in the ion of dimers, linear chains, or cyclic structures. These configurations can further include extended (two-dimensional) hydrogen bond networks and ed triads.

In certain embodiments, the coformer is a solid under ambient temperature conditions when in its pure form.

In certain ments, cocrystals can be prepared using solid-state s such as solid-state grinding and solvent-drop grinding. In certain embodiments, cocrystals can be prepared using high-throughput screening. In certain embodiments cocrystals can be prepared using solution-based crystallization.

In n embodiments, cocrystals formation can lead to enchancment of physical properties of the resulting solid forms, such as solubility, dissolution rate, bioavailablity, physical stability, chemical stability, flowability, fractability, or compressibility.

In n embodiments, provided herein are cooling evaporative methods for making a solid form cocrystal of Compound 1, comprising 1) obtaining a close-to saturated solution of Compound 1 and coformers in a ratio (e.g., about 1:1.1 or about 1:1.4) in a solvent; 2) heating the solution to a first temperature (e.g., about 30°C to about 50°C); 3) cooling the solution to a second temperature (e.g., about -5°C to about 15°C); 4) keeping the solution at the second temperature for a period of time (e.g., 48 hours); 5) filtering the solution to yield a solid if there is precipitation; and 6) ating the solvent to collect a solid if there is no precipitation after step 4. In certain embodiments, provided herein are cooling evaporative methods for making a solid form cocrystal of Compound 1, sing 1) ing a close-to saturated solution of nd 1 and coformers in a solvent; 2) g the solution to about 40°C); 3) cooling the solution to about 2°C); 4) keeping the solution at about 2°C for about 48 hours; 5) filtering the solution to yield a solid if there is itation; and 6) evaporating the solvent to collect a solid if there is no precipitation after step 4. In certain embodiements, the solvent is ethanol, a mixture of ethanol and water (e.g., about 50/50), a mixture of methanol and water (e.g., about 50/50), a mixture of THF and water (e.g., about 50/50), acetonitrile or ethyl acetate.

In one embodiment, the molar ratio of Compound 1 and the coformers in step 1 is about 1:1.1 or about 1:1.4.

In certain embodiments, provided herein are slurry experiments for making a solid form cocrystal of Compound 1, comprising 1) obtaining a slurry of Compound 1 and coformers in a ratio in a solvent; 2) stirring the slurry for a period of time; and 3) collecting a solid from the slurry by filtration (e.g., centrifuge filtration). In certain embodiements, the solvent is acetonitrile, a mixture of acetone and water (e.g., about 10/90), cyclohexane, p-xylene, water or a mixture of ethanol and water (e.g., about 10/90). In one embodiment, the molar ratio of nd 1 and the coformers is about 1:1.1. In one embodiment, the period of time is about 3 days.

In certain embodiments, provided herein are powder in saturated solutions methods for making a solid form cocrystal of Compound 1, sing 1) obtaining a close-to saturated solution of Compound 1 in a solvent; 2) adding coformers into the solution; 3) stirring the solution at ambient temperature for a period of time; 4) ing the solution to yield a first solid; and 5) evaporating the solvent to collect a second solid. In certain embodiements, the solvent is ethanol, a mixture of l and water (e.g., about 50/50), a mixture of methanol and water (e.g., about 50/50), a mixture of THF and water (e.g., about 50/50), acetonitrile or ethyl acetate. In one embodiment, the molar ratio of Compound 1 and the coformers is about 1:1. In one embodiment, the period of time is about 4 hours.

In certain embodiments, provided herein are grinding s for making a solid form cocrystal of Compound 1, comprising 1) adding Compound 1, coformers and a solvent into a grinding machine; 2) shaking the container for a period of time at a particular frequency; and 3) collecting the resulting solid by filtration (e.g., centrifuge filtration). In certain ements, the solvent is acetonitrile, a mixture of e and water (e.g., about 10/90), cyclohexane, pxylene , water, or a mixture of ethanol and water (e.g., about 10/90). In one embodiment, the molar ratio of Compound 1 and the coformers is about 1:1.1. In one embodiment, the period of time is about 1 hour. In one embodiment, the frequency is about 30 Hz.

The solid form cocrystals ed herein (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 and Form 8) may be characterized using a number of methods known to a person having ordinary skill in the art, including, but not limited to, single crystal X-ray diffraction, X-ray powder diffraction , microscopy (e.g., scanning electron microscopy (SEM)), thermal analysis (e.g., differential scanning calorimetry (DSC), l etric analysis (TGA), and hot-stage microscopy), spectroscopy (e.g., infrared, Raman, and solid-state nuclear magnetic resonance), single differential l analysis (SDTA), high performance liquid chromatography coupled with mass spectroscopy (HPLC-MS), thermogravimetrical analysis coupled with single differential thermal analysis (TGA-SDTA), and gravimetric analysis coupled with mass oscopy (TGA-MS). The particle size and size bution of the solid form provided herein may be determined by conventional methods, such as laser light scattering technique.

The purity of the solid form cocrystals provided herein may be determined by standard analytical methods, such as thin layer chromatography (TLC), gel electrophoresis, gas chromatography, high performance liquid chromatography , and mass spectrometry (MS).

It should be understood that the numerical values of the peaks of an X-ray powder diffraction pattern may vary slightly from one machine to another or from one sample to another, and so the values quoted are not to be construed as absolute, but with an ble variability, such as ±0.2 degrees 2 theta (see United State Pharmacopoeia, page 2228 (2003)). .3.1 Cocrystal Form 1 comprising Compound 1 and Fumaric Acid Provided herein is cocrystal Form 1 comprising Compound 1 and fumaric acid.

In one embodiment, provided herein is a solid form comprising Compound 1 and fumaric acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal comprising Compound 1 and fumaric acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal sing Compound 1 and c acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and fumaric acid and (ii) one or more additional crystal forms of Compound 1. Provided herein are various embodiments, preparations, or modifications of a cocrystal sing Compound 1 and fumaric acid.

In one embodiment, Form 1 is an anhydrous solid form comprising Compound 1 and fumaric acid. In another embodiment, Form 1 is crystalline. In one embodiment, Form 1 is a cocrystal solid form of Compound 1 and fumaric acid in a 1:1 stoichiometric ratio.

In certain embodiments, Form 1 is obtained by cooling evaporative ments comprising 1) obtaining a close-to saturated solution of Compound 1 and fumaric acid in a ratio (e.g., about 1:1.1) in a solvent; 2) heating the solution to a first temperature (e.g., about 30°C to about 50°C); 3) cooling the solution to a second temperature (e.g., about -5°C to about 15°C); 4) keeping the solution at the second temperature for a period of time (e.g., about 48 hours); 5) filtering the solution to yield a solid if there is itation; and 6) evaporating the solvent to collect a solid if there is no precipitation after step 4. In certain ments, Form 1 is obtained by cooling evaporative experiments, comprising 1) obtaining a close-to saturated solution of Compound 1 and fumaric acid in a solvent; 2) heating the solution to about 40°C); 3) cooling the solution to about 2°C); 4) keeping the solution at about 2°C for about 48 hours; 5) filtering the solution to yield a solid if there is itation; and 6) evaporating the solvent to collect a solid if there is no itation after step 4. In one embodiement, the solvent is ethyl acetate. In one ment, the molar ratio of Compound 1 and fumaric acid in step 1 is about 1:1.1.

In certain embodiments, a solid form provided herein, e.g., Form 1, is substantially crystalline, as ted by, e.g., X-ray powder diffraction measurements. In one embodiment, Form 1 has an X-ray powder diffraction pattern ntially as shown in (the second pattern from bottom). In one ment, Form 1 has one or more characteristic X- ray powder diffraction peaks at a two-theta angle of imately 7.14, 11.42, 12.82, 14.66, 16.1, 22.7 or 25.5 s as depicted in In another embodiment, Form 1 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 7.14, 11.42, 12.82 or 22.7 degrees. In another embodiment, Form 1 has one, two, three, four, five, six or seven characteristic X-ray powder diffraction peaks as set forth in Table 12.

In one embodiment, provided herein is Form 1 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA thermogram as depicted in In certain embodiments, the crystalline form exhibits a TGA thermogram comprising no significant mass of the sample between approximately 25°C and approximately 100°C when heated from approximately 25°C to approximately 300°C. Thus, in certain embodiments, the lline form has no significant mass when heated from about ambient temperature to about 300 °C.

In one embodiment, provided herein is Form 1 having a single differential thermal analysis (SDTA) gram as depicted in comprising an ermic event with a maximum at about 187.6°C, followed by immediate decomposition, when heated from approximately 25 °C to approximately 300 °C.

In still another embodiment, Form 1 is ntially pure. In certain embodiments, the substantially pure Form 1 is substantially free of other solid forms, e.g., amorphous form. In certain embodiments, the purity of the substantially pure Form 1 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.2 Cocrystal Form 2 comprising Compound 1 and Fumaric Acid Provided herein is cocrystal Form 2 sing Compound 1 and c acid.

In one embodiment, provided herein is a solid form comprising Compound 1 and fumaric acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal comprising Compound 1 and c acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and fumaric acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form sing (i) a cocrystal comprising Compound 1 and fumaric acid and (ii) one or more additional l forms of Compound 1. Provided herein are various ments, preparations, or modifications of a cocrystal comprising Compound 1 and fumaric acid.

In one embodiment, Form 2 is a hydrated solid form comprising Compound 1 and c acid. Form 2 is a ydrate. In another embodiment, Form 2 is crystalline. In one embodiment, Form 2 is a cocrystal solid form of Compound 1 fumaric salt and c acid in a 1:1 stoichiometric ratio.

In certain embodiments, Form 2 is obtained by cooling evaporative experiments comprising 1) obtaining a close-to saturated solution of Compound 1 and fumaric acid in a ratio (e.g., about 1:1.1) in a solvent; 2) heating the solution to a first temperature (e.g., about 30°C to about 50°C); 3) g the solution to a second temperature (e.g., about -5°C to about 15°C); 4) keeping the solution at the second temperature for a period of time (e.g., about 48 hours); 5) filtering the solution to yield a solid if there is precipitation; and 6) evaporating the t to t a solid if there is no precipitation after step 4. In certain ments, Form 2 is obtained by cooling evaporative experiments, comprising 1) obtaining a close-to saturated solution of Compound 1 and fumaric acid in a solvent; 2) heating the solution to about 40°C); 3) cooling the solution to about 2°C); 4) keeping the solution at about 2°C for about 48 hrs; 5) filtering the solution to yield a solid if there is itation; and 6) evaporating the solvent to collect a solid if there is no precipitation after step 4. In one ement, the solvent is a mixture of methanol and water (50/50). In one embodiment, the molar ratio of Compound 1 and fumaric acid in step 1 is about 1:1.4.

In certain embodiments, a solid form provided herein, e.g., Form 2, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, Form 2 has an X-ray powder diffraction pattern ntially as shown in (the third pattern from bottom). In one embodiment, Form 2 has one or more characteristic X- ray powder diffraction peaks at a two-theta angle of approximately 7.42, 10.38, 13.7, 15.94, 17.9, 18.3, 19.42, 22.42, 23.38, 23.82, 25.46 or 26.78 degrees as depicted in In a specific embodiment, Form 2 has one, two, three, four, five, six, seven or eight characteristic X-ray powder diffraction peaks at a eta angle of approximately 7.42, 10.38, 15.94, 17.9, 18.3, 19.42, 23.82 or 26.78 degrees. In another embodiment, Form 2 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 7.42, 15.94, 18.3 or 23.82 degrees. In another embodiment, Form 2 has one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve characteristic X-ray powder diffraction peaks as set forth in Table 13.

In one embodiment, provided herein is Form 2 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA thermogram as depicted in In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of imately 1.12% of the total mass of the sample between approximately °C and approximately 175°C when heated from approximately 25°C to approximately 300°C.

Thus, in certain embodiments, the crystalline form loses about 1.12% of its total mass when heated from about ambient temperature to about 300 °C.

In one embodiment, provided herein is Form 2 having a single differential thermal analysis (SDTA) thermogram as depicted in sing an endothermic event with a maximum at about 146°C, followed by an endothermic melt event at about 193.5°C and then immediate decomposition, when heated from approximately 25 °C to approximately 300 °C.

In one embodiment, a single-crystal X-ray diffraction analysis is employed to determine the crystal structure of Form 2 (see ). Table 14 and Table 15 present a summary of the crystallographic data from the crystal-structure determination. In one embodiment, Form 2 has a crystal packing pattern substantially as shown in . In one embodiment, Form 2 is a ed solid form crystallizing in a triclinic symmetry with P-1 space group and having a Z equal to 2.

In still another embodiment, Form 2 is substantially pure. In certain embodiments, the substantially pure Form 2 is substantially free of other solid forms, e.g., ous form. In certain embodiments, the purity of the substantially pure Form 2 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.3 tal Form 3 sing Compound 1 and c Acid Provided herein is cocrystal Form 3 comprising Compound 1 and benzoic acid.

In one embodiment, ed herein is a solid form comprising Compound 1 and benzoic acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal sing Compound 1 and benzoic acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal sing Compound 1 and benzoic acid and (ii) an amorphous form of nd 1. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and benzoic acid and (ii) one or more additional crystal forms of Compound 1. Provided herein are various embodiments, preparations, or modifications of a cocrystal comprising Compound 1 and benzoic acid.

In one embodiment, Form 3 is a hydrated solid form comprising Compound 1 and benzoic acid. In another embodiment, Form 3 is crystalline.

In certain embodiments, Form 3 is obtained by slurry experiements, comprising 1) obtaining a slurry of Compound 1 and benzoic acid in a ratio in a solvent; 2) stirring the slurry for a period of time; 3) collecting a solid from the slurry by filtration (e.g., centrifuge filtration).

In one embodiement, the solvent is water. In one embodiment, the molar ratio of Compound 1 and benzoic acid is about 1:1.1. In one embodiment, the period of time is about 3 days.

In certain ments, a solid form provided herein, e.g., Form 3, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, Form 3 has an X-ray powder diffraction pattern substantially as shown in (the second pattern from bottom). In one embodiment, Form 3 has one or more characteristic X- ray powder diffraction peaks at a two-theta angle of approximately 7.3, 8.02, 11.86, 12.78, 14.38, 16.9, 18.74, 21.14, 21.9, 23.78, 25.14, 25.82 or 26.74 degrees as depicted in (the second pattern from bottom). In a specific embodiment, Form 3 has one, two, three, four, five, six, seven or eight characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 7.3, 11.86, 12.78, 16.9, 18.74, 21.9, 25.14 or 26.74 degrees. In another embodiment, Form 3 has one, two, three or four characteristic X-ray powder ction peaks at a eta angle of imately 7.3, 11.86, 12.78 or 21.9 degrees. In another ment, Form 3 has one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or thirteen characteristic X-ray powder diffraction peaks as set forth in Table 16.

In one embodiment, provided herein is Form 3 having a thermogravimetric (TGA) thermograph ponding substantially to the representative TGA thermogram as depicted in . In n embodiments, the lline form exhibits a TGA thermogram comprising no significant mass loss between imately 25°C and approximately 100°C when heated from approximately 25 °C to approximately 300 °C.

In one embodiment, provided herein is Form 3 having a single differential thermal is (SDTA) gram as depicted in comprising three endothermic events with the maximums at about 67.7°C, about 108°C and about 158°C, respectively, when heated from approximately 25 °C to approximately 300 °C.

In still another embodiment, Form 3 is substantially pure. In certain embodiments, the substantially pure Form 3 is substantially free of other solid forms, e.g., amorphous form. In certain embodiments, the purity of the substantially pure Form 3 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.4 Cocrystal Form 4 comprising Compound 1 and Benzoic Acid Provided herein is cocrystal Form 4 comprising Compound 1 and benzoic acid.

In one embodiment, ed herein is a solid form comprising Compound 1 and benzoic acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal comprising Compound 1 and benzoic acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal sing Compound 1 and benzoic acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and benzoic acid and (ii) one or more additional crystal forms of Compound 1. ed herein are various embodiments, preparations, or modifications of a cocrystal comprising nd 1 and c acid.

In one embodiment, Form 4 is an acetone ed solid form comprising Compound 1 and benzoic acid. In another embodiment, Form 4 is crystalline.

In certain embodiments, Form 4 is ed by slurry experiements, comprising 1) obtaining a slurry of Compound 1 and c acid in a ratio in a solvent; 2) stirring the slurry for a period of time; 3) collecting a solid from the slurry by filtration (e.g., centrifuge filtration).

In one embodiement, the t is a mixture of acetone and water (about 10/90). In one embodiment, the molar ratio of Compound 1 and benzoic acid is about 1:1.1. In one embodiment, the period of time is about 3 days.

In certain embodiments, a solid form provided herein, e.g., Form 4, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, Form 4 has an X-ray powder diffraction pattern substantially as shown in (the third pattern from bottom). In one embodiment, Form 4 has one or more characteristic X- ray powder diffraction peaks at a eta angle of approximately 8.02, 8.86, 9.74, 12.78, 13.82, .58, 17.94, 19.82, 20.5, 21.02, 22.58, 24.38, 25.02 or 27.66 degrees as depicted in (the third pattern from bottom). In a specific embodiment, Form 4 has one, two, three, four, five, six, seven or eight characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 8.02, 9.74, 13.82, 15.58, 19.82, 21.02, 24.38 or 25.02 degrees. In r embodiment, Form 4 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 8.02, 13.82, 19.82 or 25.02 degrees. In another embodiment, Form 4 has one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen or sixteen characteristic X-ray powder diffraction peaks as set forth in Table 17.

In one embodiment, provided herein is Form 4 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA thermogram as depicted in . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 1.7% of the total mass of the sample between approximately °C and approximately 110°C when heated from approximately 25°C to approximately 300°C.

Thus, in certain embodiments, the crystalline form loses about 1.7% of its total mass when heated from about t ature to about 300°C.

In one embodiment, ed herein is Form 4 having a single differential thermal analysis (SDTA) thermogram as depicted in comprising an endothermic event with a maximums at about 83.2°C, followed by decomposition starting from about 180°C, when heated from approximately 25°C to approximately 300°C.

In still another embodiment, Form 4 is ntially pure. In certain embodiments, the substantially pure Form 4 is ntially free of other solid forms, e.g., ous form. In certain embodiments, the purity of the substantially pure Form 4 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.5 Cocrystal Form 5 comprising Compound 1 and Gentisic Acid ] Provided herein is cocrystal Form 5 comprising Compound 1 and gentisic acid.

In one embodiment, ed herein is a solid form comprising Compound 1 and gentisic acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal sing Compound 1 and gentisic acid. In one ment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and gentisic acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and gentisic acid and (ii) one or more additional crystal forms of Compound 1. Provided herein are various embodiments, preparations, or modifications of a tal comprising Compound 1 and gentisic acid.

In one embodiment, Form 5 is an acetone and water solvated solild form comprising Compound 1 and ic acid. In another embodiment, Form 5 is crystalline.

In certain embodiments, Form 5 is obtained by slurry experiements, comprising 1) obtaining a slurry of Compound 1 and gentisic acid in a ratio in a solvent; 2) stirring the slurry for a period of time; 3) collecting a solid from the slurry by filtration (e.g., fuge filtration).

In one embodiement, the solvent is a mixture of acetone and water (about 10/90). In one embodiment, the molar ratio of Compound 1 and gentisic acid is about 1:1.1. In one embodiment, the period of time is about 3 days.

In n embodiments, a solid form provided herein, e.g., Form 5, is ntially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, Form 5 has an X-ray powder diffraction pattern substantially as shown in (the second n from bottom). In one embodiment, Form 5 has one or more characteristic X- ray powder diffraction peaks at a eta angle of approximately 4.1, 6.34, 8.3, 15.78, 20.06, .7 or 25.78 degrees as depicted in (the second pattern from bottom). In another embodiment, Form 5 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of imately 4.1, 15.78, 20.06 or 25.78 s. In another embodiment, Form 5 has one, two, three, four, five, six or seven characteristic X-ray powder diffraction peaks as set forth in Table 18.

In one embodiment, provided herein is Form 5 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA thermogram as depicted in . In certain embodiments, the crystalline form ts a TGA thermogram comprising a total mass loss of approximately 4.6% of the total mass of the sample between approximately °C and approximately 120°C when heated from approximately 25 °C to approximately 300 °C. Thus, in certain embodiments, the crystalline form loses about 4.6% of its total mass when heated from about ambient temperature to about 300 °C.

In one embodiment, provided herein is Form 5 having a single ential thermal analysis (SDTA) thermogram as ed in comprising an endothermic event with a m at about 95.5°C, followed by decomposition starting from 180°C, when heated from approximately 25 °C to approximately 300 °C.

In still another embodiment, Form 5 is substantially pure. In certain embodiments, the substantially pure Form 5 is substantially free of other solid forms, e.g., amorphous form. In certain embodiments, the purity of the ntially pure Form 5 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.6 Cocrystal Form 6 comprising Compound 1 and Gentisic acid Provided herein is cocrystal Form 6 comprising Compound 1 and gentisic acid.

In one embodiment, provided herein is a solid form comprising Compound 1 and ic acid that is substantially crystalline. In one ment, provided herein is a solid form comprising a cocrystal comprising Compound 1 and gentisic acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and gentisic acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and gentisic acid and (ii) one or more onal crystal forms of Compound 1. Provided herein are various embodiments, preparations, or cations of a tal comprising Compound 1 and gentisic acid.

In one embodiment, Form 6 is an acetonitrile solvate comprising Compound 1 and gentisic acid. In another embodiment, Form 6 is crystalline.

In certain embodiments, Form 6 is obtained by slurry ements, comprising 1) obtaining a slurry of Compound 1 and gentisic acid in a ratio in a solvent; 2) stirring the slurry for a period of time; 3) collecting a solid from the slurry by filtration (e.g., centrifuge filtration).

In one ement, the solvent is aceonitrile. In one embodiment, the molar ratio of Compound 1 and gentisic acid is about 1:1.1. In one embodiment, the period of time is about 3 days.

In certain embodiments, a solid form provided herein, e.g., Form 6, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one ment, Form 6 has an X-ray powder diffraction pattern substantially as shown in (the third n from bottom). In one embodiment, Form 6 has one or more characteristic X- ray powder diffraction peaks at a two-theta angle of imately 4.26, 13.02, 13.5, 14.22, 17.78, 19.22, 21.7 or 25.82 degrees as depicted in (the third pattern from bottom). In another embodiment, Form 6 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 4.26, 17.78, 21.7 or 25.82 degrees. In another embodiment, Form 6 has one, two, three, four, five, six, seven or eight characteristic X-ray powder diffraction peaks as set forth in Table 19.

In one embodiment, provided herein is Form 6 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA gram as depicted in . In certain embodiments, the crystalline form ts a TGA thermogram comprising a total mass loss of approximately 0.9% of the total mass of the sample between about 70°C and about 160°C when heated from approximately 25°C to approximately 300°C. Thus, in certain embodiments, the crystalline form loses about 0.9% of its total mass when heated from about ambient temperature to about 300°C.

In one embodiment, provided herein is Form 6 having a single differential thermal analysis (SDTA) thermogram as depicted in comprising an endothermic event with a maximum at about 148°C, followed by immediate decomposition, when heated from approximately 25 °C to approximately 300 °C.

In still r embodiment, Form 6 is substantially pure. In certain embodiments, the substantially pure Form 6 is substantially free of other solid forms, e.g., ous form. In certain embodiments, the purity of the substantially pure Form 6 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.7 Cocrystal Form 7 comprising nd 1 and Maleic acid Provided herein is cocrystal Form 7 comprising Compound 1 and maleic acid. In one embodiment, provided herein is a solid form comprising Compound 1 and maleic acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a tal comprising Compound 1 and maleic acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and maleic acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a tal comprising Compound 1 and maleic acid and (ii) one or more additional crystal forms of Compound 1. Provided herein are various embodiments, ations, or modifications of a tal comprising Compound 1 and maleic acid.

In one embodiment, Form 7 is an itrile and water solvate comprising Compound 1 and maleic acid. In another embodiment, Form 7 is crystalline.

In certain embodiments, Form 7 is obtained by slurry experiements, comprising 1) obtaining a slurry of Compound 1 and maleic acid in a ratio in a solvent; 2) stirring the slurry for a period of time; 3) collecting a solid from the slurry by filtration (e.g., centrifuge filtration). In one embodiement, the solvent is aceonitrile. In one embodiment, the molar ratio of Compound 1 and maleic acid is about 1:1.1. In one embodiment, the period of time is about 3 days.

In certain embodiments, a solid form provided , e.g., Form 7, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction measurements. In one embodiment, Form 7 has an X-ray powder diffraction n substantially as shown in (the second pattern from bottom). In one embodiment, Form 7 has one or more characteristic X- ray powder diffraction peaks at a eta angle of approximately 6.54, 9.42, 13.66, 18.42, 26.02 or 26.82 degrees as depicted in (the second pattern from bottom). In another embodiment, Form 7 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 6.54, 13.66, 18.42 or 26.02 degrees. In another embodiment, Form 7 has one, two, three, four, five or six characteristic X-ray powder diffraction peaks as set forth in Table 20.

] In one embodiment, provided herein is Form 7 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA thermogram as depicted in . In certain embodiments, the crystalline form exhibits a TGA thermogram sing a total mass loss of approximately 4% of the total mass of the sample between approximately °Cand approximately 110°C when heated from approximately 25 °C to imately 300 °C.

Thus, in certain embodiments, the crystalline form loses about 4% of its total mass when heated from about ambient temperature to about 300 °C.

] In one embodiment, provided herein is Form 7 having a single differential thermal analysis (SDTA) thermogram as depicted in sing an endothermic event with a m at about 86°C, followed by decomposition starting from about 115°C, when heated from approximately 25 °C to approximately 300 °C.

In still another embodiment, Form 7 is substantially pure. In certain embodiments, the substantially pure Form 7 is ntially free of other solid forms, e.g., amorphous form. In certain embodiments, the purity of the substantially pure Form 7 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .3.8 Cocrystal Form 8 comprising Compound 1 and Maleic acid Provided herein is cocrystal Form 8 comprising Compound 1 and maleic acid. In one embodiment, provided herein is a solid form comprising Compound 1 and maleic acid that is substantially crystalline. In one embodiment, provided herein is a solid form comprising a cocrystal comprising Compound 1 and maleic acid. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and maleic acid and (ii) an amorphous form of Compound 1. In one embodiment, provided herein is a solid form comprising (i) a cocrystal comprising Compound 1 and maleic acid and (ii) one or more additional crystal forms of Compound 1. Provided herein are various embodiments, preparations, or modifications of a cocrystal comprising Compound 1 and maleic acid.

In one ment, Form 8 is an ethyl acetate solvate comprising Compound 1 and maleic acid. In another embodiment, Form 8 is lline.

In n embodiments, Form 8 is obtained by cooling evaporative experiments comprising 1) obtaining a close-to saturated solution of Compound 1 and maleic acid in a ratio (e.g., about 1:1.1) in a solvent; 2) heating the solution to a first temperature (e.g., about 30°C to about 50°C); 3) g the solution to a second temperature (e.g., about -5°C to about 15°C); 4) keeping the solution at the second temperature for a period of time (e.g., about 48 hours); 5) filtering the solution to yield a solid if there is precipitation; and 6) ating the solvent to collect a solid if there is no precipitation after step 4. In certain embodiments, Form 2 is ed by cooling evaporative experiments, sing 1) obtaining a close-to saturated solution of Compound 1 and maleic acid in a solvent; 2) heating the solution to about 40°C); 3) cooling the solution to about 2°C); 4) keeping the on at about 2°C for about 48 hrs; 5) filtering the solution to yield a solid if there is precipitation; and 6) evaporating the solvent to collect a solid if there is no precipitation after step 4. In one embodiement, the solvent is ethyl acetate. In one ment, the molar ratio of Compound 1 and maleic acid in step 1 is about 1:1.4.

In certain embodiments, a solid form provided , e.g., Form 8, is substantially crystalline, as indicated by, e.g., X-ray powder diffraction ements. In one embodiment, Form 8 has an X-ray powder diffraction pattern substantially as shown in (the third pattern from bottom). In one embodiment, Form 8 has one or more characteristic X- ray powder diffraction peaks at a two-theta angle of approximately 6.14, 7.42, 15.5, 17.3, 18.46, 26.78 or 28.38 degrees as depicted in (the third pattern from bottom). In another embodiment, Form 8 has one, two, three or four characteristic X-ray powder diffraction peaks at a two-theta angle of approximately 6.14, 17.3, 26.78 or 28.38 degrees. In another embodiment, Form 8 has one, two, three, four, five, six or seven characteristic X-ray powder diffraction peaks as set forth in Table 21.

] In one embodiment, provided herein is Form 8 having a thermogravimetric (TGA) thermograph corresponding substantially to the representative TGA thermogram as depicted in . In certain embodiments, the crystalline form exhibits a TGA thermogram comprising a total mass loss of approximately 1% of the total mass of the sample between approximately 35°C and imately 110°C when heated from approximately 25°C to approximately 300°C. Thus, in certain embodiments, the crystalline form loses about 1% of its total mass when heated from about ambient temperature to about 300°C.

In one ment, provided herein is Form 8 having a single differential l analysis (SDTA) thermogram as depicted in comprising an endothermic event with a m at about 118.8°C, followed by decomposition, when heated from approximately 25°C to approximately 300°C.

In still another ment, Form 8 is substantially pure. In certain embodiments, the substantially pure Form 8 is ntially free of other solid forms, e.g., amorphous form. In certain embodiments, the purity of the substantially pure Form 8 is no less than about 95% pure, no less than about 96% pure, no less than about 97% pure, no less than about 98% pure, no less than about 98.5% pure, no less than about 99% pure, no less than about 99.5% pure, or no less than about 99.8% pure. .4 METHODS OF USE The solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) have utility as ceuticals to treat or t a disease in a subject, e.g., a proliferative disease. Further, the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein are active against kinases (e.g., protein kinases), including those involved in cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological ers, age-related diseases, and/or vascular conditions. Thus, in an embodiment, provided herein is a use of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein in the manufacture of a medicament for treating or ting , an inflammatory condition, an immunological condition, a neurodegenerative disease, e, obesity, a neurological disorder, an age-related disease, a cardiovascular condition, or a conditions treatable or preventable by inhibition of a kinase pathway. Without being limited by theory, it is thought the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form , Form 6, Form 7 or Form 8) provided herein are effective for treating and preventing diseases and conditions due to its ability to modulate (e.g., inhibit) kinases that are involved in the etiology of the diseases and conditions. Accordingly, provided herein are uses of the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein, ing the treatment or tion of those diseases set forth herein. In certain embodiments, the methods provided herein comprise administering a solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein, wherein the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) is part of a kit provided herein.

In one embodiment, provided herein is a method of treating and preventing a disease or condition in a subject, comprising the stration of an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to the subject.

Representative immunological ions that the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) ed herein are useful for treating or preventing include, but are not limited to, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, multiple sclerosis, lupus, matory bowel disease, tive colitis, Crohn’s disease, myasthenia gravis, Graves disease, encephalomyelitis, Type II diabetes, dermatomyositis, and transplant rejection (e.g., in the ent of recipients of heart, lung, combined lung, liver, , pancreatic, skin, or corneal transplants; or graft-versus-host disease, such as following bone marrow transplantation).

Representative inflammatory conditions that the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) ed herein are useful for treating or preventing include, but are not limited to, psoriasis, asthma and allergic rhinitis, bronchitis, chronic ctive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, s disease, mucous s, tive colitis, and obesity.

Representative cardiovascular diseases that the solids form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein are useful for treating or preventing include, but are not limited to, restenosis, Wolf-Parkinson-White Syndrome, stroke, myocardial infarction or ischemic damage to the heart, lung, gut, kidney, liver, pancreas, spleen or brain.

Representative neurodegenerative diseases that the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein are useful for treating or preventing include, but are not limited to, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, dementias caused by tau mutations, spinocerebellar ataxia type 3, motor neuron disease caused by SOD1 ons, neuronal ceroid lipofucinoses/Batten disease (pediatric neurodegene ration) and HIV-associated encephalitis.

Representative lated diseases that the solid forms of nd 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) ed herein are useful for treating or preventing include, but are not limited to, cancer, obesity, type II diabetes mellitus, autoimmune disease, cardiovascular diseases and al degeneration.

In certain embodiments, the disease or condition is a ic disease or disorder.

Thus, in one ment, provided herein is a method for treating or preventing a fibrotic disease or disorder in a subject, comprising the administration of an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to the subject. In another embodiment, provided herein is a method of treating or preventing scleroderma, idiopathic pulmonary fibrosis, renal fibrosis, cystic fibrosis, myelofibrosis, c fibrosis, steatofibrosis or steatohepatitis in a subject, comprising the administration of an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to the subject.

] Representative cancers that the solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein are useful for treating or preventing include, but are not limited to, cancers of the head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, y bladder, e, , breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system. The solid forms of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided hereinare also useful for treating or preventing solid tumors and bloodborne tumors.

In some ments, the cancers within the scope of the methods ed herein include those associated with the pathways involving mTOR, PI3K, or Akt s and mutants or isoforms thereof. In some embodiments, the cancers within the scope of the methods provided herein include those associated with the pathways of the following kinases: PI3K, PI3K, PI3K, KDR, GSK3, GSK3, ATM, ATX, ATR, cFMS, and/or DNA-PK kinases and mutants or ms thereof. In some embodiments, the cancers associated with mTOR/ PI3K/Akt pathways include solid and borne tumors, for example, multiple myeloma, mantle cell lymphoma, diffused large B-cell lymphoma, acute myeloid lymphoma, follicular lymphoma, chronic cytic leukemia; breast, lung, endometrial, ovarian, gastric, cervical, and prostate cancer; glioblastoma; renal carcinoma; cellular carcinoma; colon carcinoma; neuroendocrine tumors; head and neck tumors; and sarcomas.

In one embodiment, provided herein is a method for treating or preventing a disease or disorder associated with activation of mTOR signaling, comprising the administration of an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject in need thereof. Examples of diseases or disorders associated with activation of mTOR signaling include, but are not limited to, tumor syndromes resulting directly or indirectly from genetic defects in PTEN (Phosphatase and tensin homologue deleted on some 10), TSC1 (Tuberous sclerosis 1), TSC2 (Tuberous sclerosis 2), NF1 (Neurofibromin 1), AMPK (AMP-dependent protein kinase STK11, serine/threonine kinase 11), LKB1, VHL (von Hippel-Lindau disease) and PKD1 ystin-1).

Without being limited by theory, it is thought that genetic defects associated with these proteins results in hyperactivation of the mTOR/PI3K/Akt pathway. In n embodiments, the diseases which are treatable or preventable through inhibition of the mTOR/PI3K/Akt pathway include, but are not limited to, Cowden’s disease, Cowden syndrome, Cowden-like syndrome, Bannayan- Zonana syndrome, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease, trial carcinoma, tuberous sclerosis complex, lymphangioleiomyomatosis, neurofibromatosis 1, Peutz- Jeghers syndrome, renal cell carcinoma, von Hippel-Lindau disease, Proteus syndrome, and polycystic kidney disease.

In another embodiment, provided herein is a method for treating or ting a disease or disorder associated with mTOR, PI3K, Akt, and/or DNA-PK signaling, comprising the administration of an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided here into a subject in need f. Examples of diseases which are treatable or preventable by inhibiting mTOR, PI3K, Akt and/or DNA-PK ing, include, but are not limited to, rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout; asthma, itis; allergic rhinitis; chronic obstructive pulmonary disease; cystic fibrosis; inflammatory bowel disease; irritable bowel syndrome; mucous colitis; ulcerative colitis; Crohn’s e; Huntington’s disease; gastritis; esophagitis; hepatitis; pancreatitis; nephritis; multiple sclerosis; lupus erythematosus; atherosclerosis; restenosis following angioplasty; left ventricular hypertrophy; myocardial infarction; stroke; ischemic damages of heart, lung, gut, kidney, liver, pancreas, spleen and brain; acute or chronic organ transplant rejection; preservation of the organ for transplantation; organ e or loss of limb (e.g., including, but not limited to, that resulting from ischemia-reperfusion , trauma, gross bodily , car accident, crush injury or lant failure); graft versus host e; endotoxin shock; multiple organ failure; sis; burn from exposure to fire, chemicals or ion; eczema; dermatitis; skin graft; ischemia; ischemic conditions associated with surgery or traumatic injury (e.g., vehicle accident, gunshot wound or limb crush); epilepsy; Alzheimer’s disease; Parkinson’s e; immunological se to bacterial or viral infection; cachexia; angiogenic and proliferative diseases ding retinitis pigmentosa), solid tumors, and cancers of a variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, as, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, urinary bladder, ovary or uterine.

In yet another embodiment, ed herein is a method of inhibiting a kinase in a cell expressing the kinase, comprising contacting the cell with an effective amount of the solid form of nd 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein. In one embodiment, the kinase is TOR kinase. In certain embodiments, the cell is in a subject. In certain embodiments, the cell is from a subject.

In yet another embodiment, provided herein is a method of treating or ting a condition treatable or preventable by the inhibition of a kinase pathway, in one embodiment, the mTOR/PI3K/Akt and/or DNA-PK pathway, comprising administering to a subject in need thereof an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein. Conditions treatable or preventable by the inhibition of the mTOR/ PI3K/Akt pathway include, but are not limited to, solid and blood-borne , for example, multiple myeloma, mantle cell lymphoma, diffused large B-cell lymphoma, acute d lymphoma, follicular lymphoma, chronic lymphocytic leukemia; breast, lung, endometrial, ovarian, gastric, cervical, and prostate cancer; glioblastoma; renal carcinoma; hepatocellular carcinoma; colon carcinoma; neuroendocrine ; head and neck tumors; sarcomas; tumor mes resulting directly or indirectly from genetic defects in PTEN (Phosphatase and tensin homologue d on chromosome 10), TSC1 (Tuberous sis 1), TSC2 (Tuberous sclerosis 2), NF1 (Neurofibromin 1), AMPK (AMP-dependent protein kinase STK11, serine/threonine kinase 11), and LKB1, VHL (von Hippel-Lindau disease) and PKD1 (polycystin-1); Cowden’s disease, Cowden syndrome, Cowden-like syndrome, Bannayan-Zonana syndrome, Bannayan-Riley-Ruvalcaba syndrome, tte- Duclos disease, endometrial carcinoma, tuberous sclerosis complex, lymphangioleiomyomatosis, ibromatosis 1, Peutz-Jeghers syndrome, renal cell carcinoma, von Hippel-Lindau disease, Proteus syndrome, and polycystic kidney disease; rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout; asthma, bronchitis; allergic rhinitis; chronic obstructive ary e; cystic fibrosis; inflammatory bowel disease; irritable bowel syndrome; mucous colitis; ulcerative colitis; Crohn’s disease; Huntington’s e; tis; esophagitis; hepatitis; pancreatitis; tis; le sclerosis; lupus erythematosus; atherosclerosis; restenosis following angioplasty; left ventricular hypertrophy; myocardial infarction; stroke; ischemic s of heart, lung, gut, kidney, liver, pancreas, spleen and brain; acute or chronic organ transplant rejection; preservation of the organ for transplantation; organ failure or loss of limb (e.g., including, but not limited to, that resulting from ischemia-reperfusion , trauma, gross bodily injury, car accident, crush injury or transplant failure); graft versus host disease; endotoxin shock; multiple organ failure; psoriasis; burn from exposure to fire, chemicals or radiation; eczema; dermatitis; skin graft; ischemia; ischemic conditions associated with surgery or traumatic injury (e.g., e accident, gunshot wound or limb crush); epilepsy; Alzheimer’s disease; Parkinson’s disease; immunological response to bacterial or viral ion; cachexia; angiogenic and proliferative diseases, ing retinitis tosa, solid tumors, and cancers of a variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, , cervix, blood, , esophagus, mouth, pharynx, urinary bladder, ovary or uterine.

Provided herein are methods for treating or ting a solid tumor, non- Hodgkin lymphoma or multiple myeloma, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, non-Hodgkin lymphoma or multiple myeloma. In one embodiment, the solid tumor, non-Hodgkin lymphoma or multiple myeloma, is rapamycin resistant.

In one embodiment, the non-Hodgkin ma is diffuse large B-cell lymphoma ), follicular lymphoma (FL), acute myeloid leukemia (AML), mantle cell lymphoma (MCL), or ALK+ stic large cell lymphoma. In one embodiment, the non- Hodgkin lymphoma is advanced solid non-Hodgkin lymphoma.

In one embodiment, the solid tumor is a neuroendocrine tumor. In certain embodiments, the ndocrine tumor is a neuroendocrine tumor of gut origin. In certain embodiments, the neuroendocrine tumor is of non-pancreatic . In certain embodiments, the neuroendocrine tumor is non-pancreatic of gut origin. In certain embodiments, the neuroendocrine tumor is of unknown primary origin. In some embodiments, the neuroendocrine tumor is of non-gut , for example a bronchial neuroendocrine tumor, or a ndocrine tumor with origin in an organ above the diaphragm, for example, a laryngeal neuroendocrine tumor, a pharyngeal neuroendocrine tumor, or a thyroid neuroendocrine tumor. In certain embodiments, the neuroendocrine tumor is a symptomatic endocrine producing tumor or a nonfunctional tumor. In certain embodiments, the neuroendocrine tumor is locally unresectable, atic moderate, well differentiated, low (grade 1) or intermediate (grade 2).

In one embodiment, the solid tumor is non-small cell lung cancer (NSCLC).

In another embodiments the solid tumor is glioblastoma multiforme (GBM).

In another embodiment, the solid tumor is hepatocellular carcinoma (HCC).

In another embodiment, the solid tumor is breast cancer. In one embodiment, the breast cancer is estrogen receptor positive (ER+, ER+/Her2- or ER+/Her2+). In one embodiment, the breast cancer is estrogen receptor negative (ER-/Her2+). In one embodiment, the breast cancer is triple ve (TN) t cancer that does not express the genes and/or protein corresponding to the en receptor (ER), progesterone or (PR), and that does not overexpress the Her2/neu protein).

In another embodiment, the solid tumor is colorectal cancer.

] In another embodiment, the solid tumor is salivary cancer.

In another embodiment, the solid tumor is pancreatic cancer.

In another embodiment, the solid tumor is adenocystic cancer.

In another ment, the solid tumor is adrenal cancer.

] In another embodiment, the solid tumor is esophageal cancer.

In another embodiment, the solid tumor is renal cancer.

In another embodiment, the solid tumor is leiomyosarcoma.

In another embodiment, the solid tumor is paraganglioma.

In one embodiment, the solid tumor is an advanced solid tumor.

In one embodiment, the advanced solid tumor is a neuroendocrine tumor. In certain embodiments, the neuroendocrine tumor is a neuroendocrine tumor of gut origin. In certain ments, the ndocrine tumor is of non-pancreatic . In certain embodiments, the neuroendocrine tumor is non-pancreatic of gut origin. In certain embodiments, the neuroendocrine tumor is of unknown primary origin. In some embodiments, the neuroendocrine tumor is of t origin, for example a bronchial neuroendocrine tumor, or a neuroendocrine tumor with origin in an organ above the diaphragm, for example, a laryngeal neuroendocrine tumor, a pharyngeal neuroendocrine tumor, or a thyroid neuroendocrine tumor.

In n embodiments, the neuroendocrine tumor is a symptomatic endocrine ing tumor or a nonfunctional tumor. In certain embodiments, the neuroendocrine tumor is locally unresectable, metastatic moderate, well differentiated, low (grade 1) or intermediate (grade 2).

In one embodiment, the advanced solid tumor is non-small cell lung cancer (NSCLC).

In another embodiments the advanced solid tumor is glioblastoma multiforme (GBM).

In another embodiment, the advanced solid tumor is hepatocellular carcinoma (HCC).

In another embodiment, the advanced solid tumor is breast cancer. In one embodiment, the ed solid tumor is estrogen receptor ve (ER+, ER+/Her2- or ER+/Her2+) breast cancer. In one embodiment, the advanced solid tumor is ER+/Her2- breast cancer. In one embodiment, the advanced solid tumor is ER+/Her2+ breast cancer. In one embodiment, the advanced solid tumor is ER-/Her2+ breast cancer. In one ment, the advanced solid tumor is triple negative (TN) breast cancer.

In another embodiment, the advanced solid tumor is ctal cancer.

In another embodiment, the advanced solid tumor is salivary cancer.

In another embodiment, the advanced solid tumor is pancreatic cancer.

In another embodiment, the advanced solid tumor is adenocystic cancer.

In another ment, the advanced solid tumor is adrenal cancer.

] In r embodiment, the advanced solid tumor is esophageal cancer.

In another embodiment, the advanced solid tumor is renal cancer.

In r embodiment, the advanced solid tumor is leiomyosarcoma.

] In another embodiment, the advanced solid tumor is or paraganglioma.

In one embodiment, the non-Hodgkin lymphoma is diffuse large B-cell ma (DLBCL).

] In one embodiment, provided herein are methods for achieving a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (see Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European J. Cancer; 2009; (45) 228–247) of complete response, partial response or stable disease in a patient comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor. In a related embodiment, provided herein is a use of a solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein in the manufacture of a medicament for achieving a Response Evaluation Criteria in Solid Tumors T 1.1) of complete response, partial response or stable disease in a subject having a solid tumor.

In one ment, provided herein are s for preventing or delaying a Response Evaluation Criteria in Solid Tumors T 1.1) of progressive disease in a subject, comprising stering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor. In one embodiment the prevention or delaying of progressive disease is characterized or achieved by a change in overall size of the target lesions, of for example, between -30% and +20% compared to pre-treatment. In another embodiment, the change in size of the target lesions is a reduction in overall size of more than %, for example, more than 50% reduction in target lesion size compared to pre-treatment. In another, the prevention is characterized or achieved by a reduction in size or a delay in progression of non-target lesions compared to pre-treatment. In one embodiment, the tion is achieved or characterized by a reduction in the number of target lesions ed to pretreatment.

In another, the prevention is ed or characterized by a ion in the number or quality of non-target lesions ed to pre-treatment. In one embodiment, the tion is achieved or characterized by the absence or the disappearance of target lesions compared to pretreatment.

In another, the prevention is achieved or characterized by the absence or the earance of rget lesions compared to pre-treatment. In another embodiment, the prevention is ed or characterized by the prevention of new lesions ed to pretreatment.

In yet another embodiment, the prevention is achieved or characterized by the prevention of clinical signs or symptoms of disease progression compared to pre-treatment, such as cancer-related ia or increased pain.

In certain embodiments, provided herein are s for decreasing the size of target lesions in a subject compared to pre-treatment, comprising administering an ive amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for decreasing the size of a non-target lesion in a subject compared to pre-treatment, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for achieving a reduction in the number of target s in a subject compared to pre-treatment, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form , Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for achieving a reduction in the number of non-target lesions in a subject compared to pre-treatment, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor.

In certain ments, ed herein are methods for achieving an absence of all target lesions in a subject, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor.

In certain embodiments, provided herein are methods for achieving an absence of all non-target lesions in a subject, sing administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a t having a solid tumor, such as an advanced solid tumor.

A method of treating a solid tumor, such as an advanced solid tumor, the method comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor, wherein the treatment results in a complete response, partial response or stable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

A method of treating a solid tumor, such as an advanced solid tumor, the method comprising administering an effective amount of the solid form of nd 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor, n the treatment results in a reduction in target lesion size, a reduction in non-target lesion size and/or the e of new target and/or non-target lesions, compared to eatment.

A method of treating a solid tumor, such as an advanced solid tumor, the method comprising administering an effective amount of the solid form of nd 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a solid tumor, such as an advanced solid tumor, wherein the treatment results in prevention or retarding of clinical progression, such as cancer-related cachexia or increased pain.

In another embodiment, provided herein are methods for improving the International Workshop Criteria (IWC) for NHL (see Cheson BD, Pfistner B, Juweid, ME, et. al.

Revised Response Criteria for Malignant Lymphoma. J. Clin. Oncol: 2007: (25) 579-586.) of a subject comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a t having non-Hodgkin lymphoma. In another embodiment, provided herein are methods to increase Progression Free Survival rates, as determined by Kaplan-Meier estimates. In one embodiment, the treatment results in a complete remission, l ion or stable disease, as determined by the International Workshop Criteria (IWC) for NHL. In r embodiment, the treatment results in an increase in overall survival, ssion-free survival, event-free survival, time to progression, disease-free survival or lymphoma-free survival.

In another embodiment, provided herein are methods for inducing a therapeutic response characterized with the International Uniform Response ia for Multiple Myeloma (IURC) (see Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform se criteria for multiple a. Leukemia, 2006; (10) 10: 1-7) of a subject comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having multiple myeloma. In one embodiment, the treatment results in a ent complete response, te response, or very good l response, as ined by the the International Uniform Response Criteria for Multiple Myeloma (IURC). In another embodiment, the treatment results in an increase in overall al, progression-free survival, event-free survival, time to progression, or disease-free survival.

In another embodiment, provided herein are methods for ng a therapeutic response assessed with Response Assessment for Neuro-Oncology (RANO) Working Group for GBM (see Wen P., Macdonald, DR., Reardon, DA., et al. Updated response assessment criteria for highgrade gliomas: Response assessment in neuro-oncology working group. J. Clin. Oncol. 2010; 28: 1963-1972) of a subject comprising administering an effective amount of the solid form of nd 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having stoma multiforme.

] In another embodiment, provided herein are s for improving the Eastern Cooperative gy Group Performance Status (ECOG) of a subject comprising administering an ive amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a tumor, such as an advanced solid tumor. [00239A] In a related embodiment, provided herein is a use of a solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein in the manufacture of a medicament for improving International Workshop ia (IWC) for NHL, International Uniform Response Criteria for Multiple Myeloma (IURC), Eastern Cooperative Oncology Group Performance Status (ECOG) or Response Assessment for Neuro- Oncology (RANO) Working Group for GBM, in a subject in need thereof.

In another embodiment, ed herein are methods for inducing a therapeutic response assessed by Positron on Tomography (PET) e of a subject comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to a subject having a tumor, such as an advanced solid tumor. In certain embodiments, provided herein are s for treating a solid tumor, such as an advanced solid tumor, the methods comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, such as an advanced solid tumor, wherein the treatment results in a reduction in tumor metabolic activity, for e, as measured by PET imaging.

In another embodiment, ed herein are methods for inducing a therapeutic response assessed by a reduction in carcinoid syndrome-related symptoms, such as diarrhea and/or flushing, and/or a reduction in endocrine hormone markers, such as chromogranin, gastrin, serotonin, and/or glucagon.

In one embodiment, ed herein are methods for inhibiting phosphorylation of S6RP, 4E-BP1 and/or AKT in a subject having a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal , leiomyosarcoma, or paraganglioma), non-Hodgkin ma or multiple myeloma, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to said t. In some such embodiments, the inhibition of phosphorylation is assessed in a biological sample of the subject, such as in circulating blood and/or tumor cells, skin es and/or tumor biopsies or aspirate. In such embodiments, the amount of inhibition of phosphorylation is assessed by comparison of the amount of phospho- S6RP, 4E-BP1 and/or AKT before and after administration of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein. In certain embodiments, provided herein are methods for measuring inhibition of phosphorylation of S6RP, 4E-BP1 or AKT in a subject having a solid tumor (for example, a ndocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary , pancreatic cancer, adenocystic cancer, adrenal , esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple myeloma, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to said subject, measuring the amount of phosphorylated S6RP, 4E-BP1 and/or AKT in said subject, and comparing said amount of phosphorylated S6RP, 4E-BP1 and/or AKT to that of said subject prior to administration of an effective amount of the solid form of nd 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein. In some embodiments, the inhibition of phosphorylation of S6RP, 4E-BP1 and/or AKT is assessed in s, T-cells and/or monocytes.

In certain embodiments, ed herein are methods for inhibiting phosphorylation of S6RP, 4E-BP1 and/or AKT in a biological sample of a subject having a solid tumor (for e, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, ry cancer, pancreatic cancer, adenocystic , adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple myeloma, comprising administering an ive amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to said subject and comparing the amount of phosphorylated S6RP, 4E-BP1 and/or AKT in a biological sample of a subject obtained prior to and after administration of said solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein, n less phosphorylated S6RP, 4E-BP1 and/or AKT in said biological sample obtained after administration of said solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein relative to the amount of phosphorylated S6RP, 4EBP1 and/or AKT in said biological sample obtained prior to administration of said solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) or pharmaceutical composition provided herein indicates inhibition. In some embodiments, the inhibition of phosphorylation of S6RP, 4E-BP1 and/or AKT is assessed in B-cells, s and/or monocytes.

In one embodiment, provided herein are methods for inhibiting DNA-dependent protein kinase (DNA-PK) ty in a t having a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma orme, cellular carcinoma, breast , colorectal cancer, salivary , atic cancer, adenocystic cancer, adrenal , esophageal cancer, renal , leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or le myeloma, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein to said subject. In some embodiments, DNA-PK inhibition is assessed in the skin of the subject having a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, l cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple myeloma, in one example in a UV light-irradiated skin sample of said subject. In another embodiment, DNA-PK inhibition is assessed in a tumor biopsy or aspirate of a subject having a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple myeloma. In one ment, inhibition is assessed by measuring the amount of phosphorylated DNA-PK S2056 (also known as pDNA-PK S2056) before and after administration of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein.

In certain embodiments, provided herein are methods for measuring inhibition of phosphorylation of DNA-PK S2056 in a skin sample of a subject having a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma orme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary , pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or le myeloma, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form , Form 6, Form 7 or Form 8) provided herein to said subject, measuring the amount of phosphorylated DNA-PK S2056 present in the skin sample and ing said amount of phosphorylated DNA-PK S2056 to that in a skin sample from said subject prior to administration of an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein. In one embodiment, the skin sample is irradiated with UV light.

] In n ments, provided herein are methods for inhibiting DNA-dependent protein kinase (DNA-PK) activity in a skin sample of a subject having a solid tumor (for example, a neuroendocrine tumor, non-small cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple a, comprising administering an effective amount of the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) ed here into said subject and comparing the amount of phosphorylated DNA-PK in a biological sample of a subject obtained prior to and after administration of said solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein, wherein less phosphorylated DNA-PK in said biological sample obtained after administration of said solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) ed herein relative to the amount of phosphorylated DNA-PK in said biological sample obtained prior to administration of said solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein indicates inhibition.

The solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein can be combined with radiation therapy or surgery.

In certain embodiments, the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein are stered to subject who is undergoing radiation therapy, has previously undergone radiation therapy or will be undergoing radiation therapy. In certain embodiments, the solid form of Compound 1 (e.g., Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) provided herein are stered to a subject who has undergone tumor removal surgery (e.g., surgery to remove a GBM tumor).

Further provided herein are s for treating subjects who have been previously treated for a solid tumor (for e, a neuroendocrine tumor, non-small cell lung , glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary , pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or multiple myeloma, but are non-responsive to standard therapies, as well as those who have not previously been treated.

Further provided herein are methods for treating subjects who have undergone surgery in an attempt to treat the condition at issue, as well as those who have not. Because subjects with a solid tumor (for e, a neuroendocrine tumor, all cell lung cancer, glioblastoma multiforme, hepatocellular carcinoma, breast cancer, colorectal cancer, salivary cancer, pancreatic cancer, adenocystic cancer, adrenal cancer, esophageal cancer, renal cancer, leiomyosarcoma, or paraganglioma), non-Hodgkin lymphoma or le myeloma have heterogenous clinical manifestations and varying al outcomes, the treatment given to a subject may vary, depending on his/her prognosis.

In n ments, the pharmaceutical itions provided herein comprising a solid form of Compound 1 can be used for the treatment or prevention of a disease disclosed in U.S. Pat. Appl. Publ. No. 2010/0216781 (see, e.g., paragraphs [0415]-[0437]), the sure of which is incorporated herein by reference in its entirety.

In certain embodiments, the pharmacokinetic ters set forth herein are mean values ed from multiple subjects. .5 PHARMACEUTICAL COMPOSITIONS Solid forms of Compound 1 provided herein are useful for the preparation of pharmaceutical compositions, comprising an effective amount of a solid form of Compound 1 and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical compositions described herein are suitable for oral, parenteral, mucosal, transdermal or topical administration.

In one embodiment, provided herein are pharmaceutical compositions comprising a solid form of Compound 1 and one or more pharmaceutically able excipients or carriers.

In one embodiment, the pharmaceutical itions provided herein comprise Form 1 and one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions ed herein comprise Form 2 and one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions provided herein comprise Form 3 and one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical itions provided herein comprise Form 4 and one or more pharmaceutically acceptable ents or rs. In one embodiment, the pharmaceutical compositions provided herein comprise Form 5 and one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions provided herein comprise Form 6 and one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions provided herein comprise Form 7 and one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions provided herein comprise Form 8 and one or more pharmaceutically acceptable excipients or carriers.

With respect to the pharmaceutical compositions provided herein, each reference to “a solid form of Compound 1” is contemplated as including Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8 and a mixture of solid forms of Compound 1 provided herein.

] In one embodiment, the pharmaceutically acceptable excipients and rs are selected from binders, diluents, disintegrants and lubricants.

] In certain embodiments, the binders include, but are not limited to, cellulose (e.g., microcrystalline cellulose, such as AVICEL® PH 101, AVICEL® PH 102 and AVICEL® PH 112) and starch (e.g., pregelatinized starch (STARCH ). In one embodiment, the binder is cellulose. In another embodiment, the binder is microcrystalline cellulose. In yet another embodiment, the binder is AVICEL® PH 101. In yet another embodiment, the binder is AVICEL® PH 102. In yet another ment, the binder is AVICEL® PH 112. In yet another ment, the binder is starch. In yet another embodiment, the binder is pregelatinized starch. In still another embodiment, the binder is STARCH 1500®.

In certain embodiments, the ts include, but are not limited to, e (e.g., lactose drate (FAST FLO® 316) and lactose anhydrous), cellulose (e.g., microcrystalline cellulose, such as AVICEL® PH 101, AVICEL® PH 102 and AVICEL® PH 112). In one embodiment, the diluent is lactose. In another embodiment, the diluent is lactose monohydrate. In yet another embodiment, the diluent is FAST FLO® 316. In yet another embodiment, the diluent is lactose ous. In yet r embodiment, the diluent is ose. In yet another embodiment, the diluent is microcrystalline cellulose. In yet another embodiment, the diluent is AVICEL® PH 101. In still another embodiment, the diluent is AVICEL® PH 102. In still r embodiment, the diluent is AVICEL® PH 112.

In certain embodiments, the disintegrants include, but are not limited to, starch (e.g., corn starch) and carboxymethyl cellulose (e.g., croscarmellose sodium, such as SOL®). In one embodiment, the disintegrant is starch. In another embodiment, the disintegrant is corn starch. In yet another embodiment, the disintegrant is carboxymethyl cellulose. In yet another embodiment, the disintegrant is croscarmellose sodium. In still another embodiment, the disintegrant is AC-DI-SOL®.

In certain embodiments, the lubricants include, but are not d to, starch (e.g., corn starch), magnesium te, and c acid. In one embodiment, the lubricant is starch.

In another embodiment, the lubricant is corn starch. In yet another embodiment, the lubricant is magnesium stearate. In still another embodiment, the lubricant is stearic acid.

In another ment, the pharmaceutical compositions ed herein comprise a solid form of Compound 1 and one or more ceutically acceptable excipients or carriers, each independently selected from carboxymethyl cellulose, cellulose, lactose, magnesium stearate, starch, and stearic acid.

In another embodiment, the pharmaceutical itions provided herein comprise a solid form of Compound 1 and one or more pharmaceutically acceptable excipients or carriers, each independently selected from carboxymethyl cellulose, cellulose, e, magnesium stearate and starch.

In yet r embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1 and one or more pharmaceutically acceptable excipients or carriers, each independently selected from croscarmellose sodium, microcrystalline cellolose, lactose anhydrous, lactose monohydrate, magnesium stearate, corn starch, pregelatinized starch, and stearic acid.

In yet another embodiment, the ceutical compositions provided herein comprise a solid form of Compound 1 and one or more pharmaceutically able excipients or rs, each ndently selected from croscarmellose sodium, microcrystalline cellolose, lactose anhydrous, lactose monohydrate, magnesium stearate, corn starch and pregelatinized starch.

In certain embodiments, the pharmaceutical compositions provided herein do not comprise stearic acid.

] In yet another embodiment, the pharmaceutical compositions ed herein comprise a solid form of Compound 1 and one or more pharmaceutically acceptable excipients or carriers, each independently ed from AC-DI-SOL®, AVICEL PH 101®, AVICEL PH 102®, lactose anhydrous, FAST FLO 316®, magnesium stearate, corn starch, STARCH 1500®, and stearic acid.

In yet another embodiment, the ceutical compositions provided herein comprise a solid form of Compound 1 and one or more pharmaceutically acceptable excipients or carriers, each independently selected from AC-DI-SOL®, AVICEL PH 101®, AVICEL PH 102®, lactose anhydrous, FAST FLO 316®, magnesium stearate, corn starch and STARCH 1500®.

In one embodiment, the pharmaceutical compositions ed herein comprise a solid form of Compound 1, a diluent(s)/binder(s), a disintegrant(s), and a lubricant(s).

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, stearic acid and lactose monohydrate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1 and lactose monohydrate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, stearic acid, e monohydrate and microcyrstalline cellulose.

In one embodiment, the pharmaceutical itions provided herein comprise a solid form of nd 1, lactose monohydrate and microcyrstalline ose.

In another embodiment, the pharmaceutical itions provided herein comprise a solid form of Compound 1, lactose monohydrate, microcrystalline cellulose, ymethyl ose, and magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose drate, microcrystalline cellulose, croscarmellose sodium, stearic acid and magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose drate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 102®, AC-DI-SOL®, c acid and magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 112®, AC-DI-SOL® and magnesium stearate.

In one embodiment, the ceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 70-90% by weight of diluent(s)/binder(s), about 1-5% by weight of disintegrant(s), and about 0.1-2% by weight of ant(s).

In one ment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 80% by weight of diluent(s)/binder(s), about 3% by weight of disintegrant(s), and about 1.4% by weight of lubricant(s).

In another embodiment, the pharmaceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 30-60% by weight of lactose, about 20-40% by weight of microcrystalline cellulose, about 1-5% by weight of carboxymethyl cellulose, about 0.1-2% by weight of c acid and about 0.5-3% by weight of magnesium te.

In another embodiment, the pharmaceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 30-60% by weight of lactose, about 20-40% by weight of microcrystalline cellulose, about 1-5% by weight of carboxymethyl cellulose and about 0.5-3% by weight of magnesium stearate.

In another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 49% by weight of lactose, about 31% by weight of microcrystalline ose, about 3% by weight of carboxymethyl cellulose, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 49% by weight of lactose, about 31% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium stearate.

In yet another ment, the pharmaceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 30-60% by weight of e monohydrate, about 20-40% by weight of microcrystalline cellulose, about 1-5% by weight of croscarmellose sodium, about 0.1-2% by weight stearic acid and about 0.5-3% by weight of ium te.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 30-60% by weight of lactose monohydrate, about 20-40% by weight of microcrystalline ose, about 1-5% by weight of croscarmellose sodium and about 0.5-3% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 49% by weight of lactose monohydrate, about 31% by weight of microcrystalline cellulose, about 3% by weight of croscarmellose sodium, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In yet another embodiment, the ceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 49% by weight of lactose monohydrate, about 31% by weight of rystalline cellulose, about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium stearate.

In still another ment, the pharmaceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 30-60% by weight of FAST FLO 316®, about 20-40% by weight of AVICEL PH 102®, about 1-5% by weight of ACDI-SOL ®, about 0.1-2% by weight of stearic acid and about 0.5-3% by weight of magnesium In still another embodiment, the pharmaceutical compositions provided herein comprise about 10-20% by weight of a solid form of Compound 1, about 30-60% by weight of FAST FLO 316®, about 20-40% by weight of AVICEL PH 112®, about 1-5% by weight of ACDI-SOL ® and about 0.5-3% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 49% by weight of FAST FLO 316®, about 31% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL®, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 49% by weight of FAST FLO 316®, about 31% by weight of AVICEL PH 112®, about 3% by weight of AC-DI-SOL® and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose, starch, carboxymethyl cellulose, stearic acid and ium stearate.

In one ment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, e, starch, carboxymethyl cellulose and magnesium stearate.

] In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose monohydrate, pregelatinized starch, croscarmellose sodium, stearic acid and magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose monohydrate, atinized starch, croscarmellose sodium and magnesium stearate.

In still another embodiment, the pharmaceutical itions provided herein comprise a solid form of Compound 1, FAST FLO 316®, STARCH 1500®, AC-DI-SOL®, stearic acid and magnesium stearate.

] In still another embodiment, the pharmaceutical compositions provided herein se a solid form of nd 1, FAST FLO 316®, STARCH 1500®, AC-DI-SOL® and magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, from about 55% to about 80% by weight of t(s)/binder(s), from about 20% to about 30% by weight of disintegrant(s), and about 1% by weight of lubricant(s).

In another ment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 55% by weight of lactose, about 25% by weight of starch, about 3% by weight of carboxymethyl cellulose, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 55% by weight of lactose, about 25% by weight of starch, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium stearate.

] In yet another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 55% by weight of lactose drate, about 25% by weight of pregelatinized starch, about 3% by weight of croscarmellose sodium, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 55% by weight of lactose monohydrate, about 25% by weight of pregelatinized starch, about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium stearate.

In still another ment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 55% by weight of FAST FLO 316®, about 25% by weight of STARCH 1500®, about 3% by weight of AC-DI-SOL®, about 0.4% by weight of stearic acid and about 1% by weight of ium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 55% by weight of FAST FLO 316®, about 25% by weight of STARCH 1500®, about 3% by weight of AC-DI-SOL® and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical itions provided herein se a solid form of Compound 1, lactose, rystalline cellulose, carboxymethyl cellulose, stearic acid and magnesium stearate.

In one ment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose, microcrystalline cellulose, carboxymethyl cellulose and magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose drate, microcrystalline cellulose, croscarmellose sodium, stearic acid and ium te.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 102®, AC-DI-SOL®, about 0.4% by weight of stearic acid and magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 112®, AC-DI-SOL® and magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 80% by weight of diluent(s)/binder(s), about 3% by weight of disintegrant(s), and about 1% by weight of ant(s).

In r embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl ose, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium te.

In yet r embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of rmellose sodium, about 0.4% by weight of stearic acid and about 1% by weight of ium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of rmellose sodium and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions ed herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL®, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of nd 1, about 50% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 112®, about 3% by weight of AC-DI-SOL® and about 1% by weight of ium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose, microcrystalline cellulose, corn starch, carboxymethyl cellulose, stearic acid and magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose, microcrystalline cellulose, corn starch, carboxymethyl cellulose and magnesium stearate.

In another embodiment, the pharmaceutical compositions ed herein comprise a solid form of Compound 1, lactose drate, microcrystalline cellulose, corn starch, croscarmellose sodium, stearic acid and magnesium stearate.

In another embodiment, the pharmaceutical compositions ed herein comprise a solid form of nd 1, lactose monohydrate, microcrystalline cellulose, corn starch, croscarmellose sodium and magnesium stearate.

In still another embodiment, the pharmaceutical compositions ed herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 102®, corn starch, ACDI-SOL ®, stearic acid and magnesium stearate.

In still another embodiment, the ceutical itions provided herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 102®, corn , ACDI-SOL ® and magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, from about 85% to about 90% by weight of diluent(s)/binder(s), from about 1% to about 10% by weight of disintegrant(s), and from about 1% to about 6% by weight of lubricants.

In r embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 45% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of carboxymethyl cellulose, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 45% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium stearate.

In yet r embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 88% by weight of lactose, about 25% by weight of microcrystalline cellulose, about 4% by weight of corn , about 4% by weight of carboxymethyl cellulose, about 0.4% by weight of stearic acid and about 1.5% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 88% by weight of lactose, about 25% by weight of rystalline cellulose, about 4% by weight of corn starch, about 4% by weight of ymethyl ose and about 1.5% by weight of magnesium te.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 45% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of croscarmellose sodium, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 45% by weight of e monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn , about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium stearate.

In yet r embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 88% by weight of lactose monohydrate, about 25% by weight of microcrystalline cellulose, about 4% by weight of corn starch, about 4% by weight of croscarmellose sodium, about 0.4% by weight of stearic acid and about 1.5% by weight of magnesium stearate.

In yet another embodiment, the ceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 88% by weight of lactose monohydrate, about 25% by weight of microcrystalline cellulose, about 4% by weight of corn starch, about 4% by weight of croscarmellose sodium and about 1.5% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 45% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of corn starch, about 3% by weight of AC-DI-SOL®, about 0.4% by weight of stearic acid and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions ed herein comprise about 15% by weight of a solid form of Compound 1, about 45% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of corn , about 3% by weight of AC-DI-SOL® and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 88% by weight of FAST FLO 316®, about 25% by weight of AVICEL PH 102®, about 4% by weight of corn starch, about 4% by weight of AC-DI-SOL®, about 0.4% by weight of stearic acid and about 1.5% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of nd 1, about 88% by weight of FAST FLO 316®, about 25% by weight of AVICEL PH 102®, about 4% by weight of corn starch, about 4% by weight of AC-DI-SOL® and about 1.5% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, e, microcrystalline cellulose, corn starch, carboxymethyl cellulose, stearic acid, and ium te.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, e, microcrystalline cellulose, corn starch, carboxymethyl cellulose and magnesium stearate.

In one embodiment, the ceutical compositions provided herein comprise about 5% by weight of a solid form of Compound 1, about 90% by weight of diluent(s)/binder(s), from about 3% to about 6% by weight of disintegrant(s), and from about 1.5% to about 5% by weight of lubricants.

In another embodiment, the pharmaceutical compositions provided herein comprise about 5% by weight of a solid form of Compound 1, about 60% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of carboxymethyl cellulose, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein se about 5% by weight of a solid form of Compound 1, about 60% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 5% by weight of a solid form of Compound 1, about 60% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn , about 3% by weight of croscarmellose sodium, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 5% by weight of a solid form of Compound 1, about 60% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium In still another embodiment, the pharmaceutical compositions provided herein comprise about 5% by weight of a solid form of Compound 1, about 60% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of corn starch, about 3% by weight of AC-DI-SOL®, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium te.

In still r embodiment, the pharmaceutical compositions ed herein comprise about 5% by weight of a solid form of nd 1, about 60% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of corn starch, about 3% by weight of SOL® and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions ed herein comprise a solid form of Compound 1, lactose, microcrystalline ose, carboxymethyl cellulose, stearic acid, and magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose, rystalline cellulose, carboxymethyl cellulose and magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, stearic acid, and magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium te.

In still another ment, the pharmaceutical compositions provided herein comprise a solid form of Compound 1, FAST FLO 316®, AVICEL PH 102®, AC-DI-SOL®, stearic acid, and ium stearate.

] In still another embodiment, the pharmaceutical compositions ed herein comprise a solid form of nd 1, FAST FLO 316®, AVICEL PH 102®, AC-DI-SOL® and ium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 12% by weight of a solid form of Compound 1, from about 80% to about 85% by weight of diluent(s)/binder(s), about 3% by weight of disintegrant(s), and about 1.5% by weight of lubricant(s).

In another embodiment, the pharmaceutical compositions provided herein comprise about 12% by weight of a solid form of Compound 1, about 52.5% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions ed herein comprise about 12% by weight of a solid form of Compound 1, about 52.5% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium stearate.

] In yet another embodiment, the ceutical compositions provided herein comprise about 12% by weight of a solid form of nd 1, about 52.5% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of croscarmellose sodium, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

] In yet another embodiment, the pharmaceutical compositions provided herein comprise about 12% by weight of a solid form of Compound 1, about 52.5% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 12% by weight of a solid form of nd 1, about 52.5% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL®, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein se about 12% by weight of a solid form of Compound 1, about 52.5% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL® and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 12% by weight of a solid form of Compound 1, about 80% by weight of t(s)/binder(s), about 3% by weight of disintegrant(s), and about 4% by weight of ant(s).

In another embodiment, the pharmaceutical compositions ed herein comprise about 12% by weight of a solid form of Compound 1, about 63% by weight of lactose, about 18% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose, about 3% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In another ment, the pharmaceutical compositions ed herein comprise about 12% by weight of a solid form of Compound 1, about 63% by weight of lactose, about 18% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose and about 1% by weight of ium stearate.

In yet another embodiment, the pharmaceutical compositions ed herein comprise about 12% by weight of a solid form of Compound 1, about 63% by weight of lactose monohydrate, about 18% by weight of microcrystalline cellulose, about 3% by weight of croscarmellose sodium, about 3% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In yet another embodiment, the ceutical compositions provided herein comprise about 12% by weight of a solid form of Compound 1, about 63% by weight of lactose monohydrate, about 18% by weight of microcrystalline cellulose, about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium stearate.

In still another embodiment, the ceutical itions provided herein comprise about 12% by weight of a solid form of Compound 1, about 63% by weight of FAST FLO 316®, about 18% by weight of AVICEL PH 102®, about 3% by weight of SOL®, about 3% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 12% by weight of a solid form of Compound 1, about 63% by weight of FAST FLO 316®, about 18% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL® and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 80% by weight of a diluent/binder, about 3% by weight of a disintegrant, and about 1.5% by weight of lubricants.

In another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of nd 1, about 50% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose and about 1% by weight of magnesium stearate.

] In yet another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose monohydrate, about 30% by weight of microcrystalline cellulose, about 3% by weight of rmellose sodium, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of lactose drate, about 30% by weight of rystalline cellulose, about 3% by weight of croscarmellose sodium and about 1% by weight of magnesium te.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL®, about 0.5% by weight of stearic acid, and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical itions provided herein comprise about 15% by weight of a solid form of Compound 1, about 50% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL® and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of Form 1 of a solid form of Compound 1, about 80% by weight of dilent(s)/binder(s), about 3% by weight of disintegrant(s), and about 1% by weight of lubricant(s).

In another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 50% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of carboxymethyl cellulose, and about 1% by weight of magnesium stearate.

] In yet another ment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 50% by weight of lactose monohydrarte, about 30% by weight of microcrystalline cellulose, about 3% by weight of rmellose sodium, and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 50% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 101®, about 3% by weight of AC-DI-SOL®, and about 1% by weight of ium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, from about 55% to about 80% by weight of (s)/binder(s), from about 20% to about 30% by weight of disintegrant(s), and about 1% by weight of lubricant(s).

] In another ment, the pharmaceutical compositions ed herein comprise about 17% by weight of a solid form of Compound 1, about 55% by weight of lactose, about 25% by weight of starch, about 3% by weight of carboxymethyl cellulose, and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 55% by weight of lactose monohydrarte, about 25% by weight of atinized starch, about 3% by weight of croscarmellose sodium, and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 55% by weight of FAST FLO 316®, about 25% by weight of STARCH 1500®, about 3% by weight of AC-DI-SOL®, and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 80% by weight of dilent(s)/binder(s), about 3% by weight of disintegrant(s), and about 1% by weight of lubricant(s).

In another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 50% by weight of e, about 30% by weight of microcrystalline ose, about 3% by weight of carboxymethyl cellulose, and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical itions provided herein comprise about 17% by weight of a solid form of nd 1, about 50% by weight of lactose monohydrarte, about 30% by weight of microcrystalline cellulose, about 3% by weight of croscarmellose sodium, and about 1% by weight of magnesium stearate.

In still another embodiment, the pharmaceutical compositions ed herein comprise about 17% by weight of a solid form of Compound 1, about 50% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of AC-DI-SOL®, and about 1% by weight of magnesium stearate.

In one embodiment, the pharmaceutical compositions ed herein comprise about 17% by weight of a solid form of Compound 1, from about 85% to about 90% by weight of dilent(s)/binder(s), from about 3% to about 9% by weight of disintegrant(s), and from about 1% to about 6% by weight of lubricants.

In another embodiment, the pharmaceutical compositions provided herein se about 17% by weight of a solid form of Compound 1, about 45% by weight of lactose, about 30% by weight of microcrystalline cellulose, about 3% by weight of corn starch, about 3% by weight of carboxymethyl cellulose, and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 88% by weight of lactose, about 25% by weight of microcrystalline cellulose, about 4% by weight of corn starch, about 4% by weight of carboxymethyl cellulose, and about 1.5% by weight of magnesium te.

In yet another embodiment, the pharmaceutical compositions provided herein se about 17% by weight of a solid form of Compound 1, about 45% by weight of lactose monohydrarte, about 30% by weight of rystalline cellulose, about 3% by weight of corn , about 3% by weight of croscarmellose sodium, and about 1% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 88% by weight of lactose monohydrarte, about 25% by weight of microcrystalline cellulose, about 4% by weight of corn starch, about 4% by weight of croscarmellose , and about 1.5% by weight of magnesium stearate.

In yet another embodiment, the pharmaceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 45% by weight of FAST FLO 316®, about 30% by weight of AVICEL PH 102®, about 3% by weight of corn starch, about 3% by weight of AC-DI-SOL®, and about 1% by weight of magnesium stearate.

In still another embodiment, the ceutical compositions provided herein comprise about 17% by weight of a solid form of Compound 1, about 88% by weight of FAST FLO 316®, about 25% by weight of AVICEL PH 102®, about 4% by weight of corn starch, about 4% by weight of AC-DI-SOL®, and about 1.5% by weight of magnesium stearate.

In n embodiments, provided herein are pharmaceutical compositions comprising a solid form of Compound 1 and stearic acid. In certain embodiments, stearic acid is t in an amount of about , 0.1 to 1%, or 0.4% by weight. Without being limited by theory, it was found that the addition of stearic acid improved lubrication ed sticking) without ing disintegration and compressability.

In certain embodiments, provided herein are ceutical compositions comprising a solid form of Compound 1 and lactose monohydrate. In certain embodiments, lactose monohydrate is present in an amount of about 40-60%, 45-55%, 49.2% or 49.6% by weight. Without being limited by theory, it was found that lactose monohydrate provided better flowability than lactose anhydrous.

In certain embodiments, provided herein are pharmaceutical compositions comprising a solid form of Compound 1 and AVICEL PH 102®. In certain embodiments, AVICEL PH 102® is t in an amount of about 20-40%, 25-35%, or 31% by weight.

Without being limited by theory, it was found that AVICEL PH 102® provided better flowability than AVICEL PH 101®.

In certain embodiments, provided herein are ceutical compositions comprising a solid form of Compound 1 and AVICEL PH 112®. In certain embodiments, AVICEL PH 112® is present in an amount of about 20-40%, about 25-35%, or about 31% by weight. It was unexpectedly found that a solid form of Compound 1 is susceptible to hydrolysis.

Without being limited by theory, it is thought that AVICEL PH 112®, being a low-moisture grade microcrystalline cellulose, can reduce hydrolysis of a solid form of Compound 1.

In n embodiments, provided herein are pharmaceutical compositions comprising a solid form of Compound 1, c acid, lactose drate and AVICEL PH 102®. In certain embodiments, ed herein are pharmaceutical compositions comprising a solid form of Compound 1, stearic acid (in an amount of about 0.1-5%, 0.1 to 1%, or 0.4% by ), lactose monohydrate (in an amount of about 40-60%, 45-55%, or 49.2% by weight) and AVICEL PH 102® (in an amount of about 20-40%, 25-35%, or 31% by weight).

In n embodiments, provided herein are pharmaceutical compositions comprising a solid form of nd 1, lactose monohydrate and AVICEL PH 102®. In certain embodiments, provided herein are pharmaceutical compositions comprising a solid form of Compound 1, lactose monohydrate (in an amount of about 40-60%, 45-55%, or 49.2% by weight) and AVICEL PH 102® (in an amount of about 20-40%, 25-35%, or 31% by weight).

In certain embodiments, provided herein are ceutical compositions comprising an opaque coating. Without being limited by theory, it was found that a more opaque coating protected the drug product from degradation. In some embodiments, the ceutical composition is formulated as a tablet. In some such embodiments, the tablet is film coated. In some embodiments, the tablet is film coated to a weight gain of 1-8%. In others, the film coating is about 4% by weight of the .

In n embodiments, provided herein are pharmaceutical compositions comprising a solid form of Compound 1 that do not comprise stearic acid. Without being limited by , a lack of picking or sticking of certain tablet formulations by visual observation indicated that acceptable tablet formulations could be produced without the use of stearic acid.

In certain embodiments, ed herein are pharmaceutical compositions as set forth in Table 22-Table 30, Table 33-Table 35, Table 38-Table 40 and Table 43-Table 46, wherein the amounts of the recited components can independently be varied by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20% or 25%.

In certain embodiments, provided herein are liquid formulations comprising a solid form of Compound 1, an alcohol and polyethylene glycol. In certain embodiments, the alcohol and hylene glycol are present in a ratio of about 80:20 to about 20:80. In certain embodiments, the alcohol and polyethylene glycol are present in a ratio of about 50:50. In certain embodiments, the alcohol is ethanol. In certain embodiments, the polyethylene glycol is PEG 400. In one embodiment, provided herein are capsules filled with a liquid formulation comprising a solid form of Compound 1, an alcohol and polyethylene . In one embodiment, a solid form of Compound 1 is an isotopologue of 2-hydroxypropan yl)pyridinyl)((trans)methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

In some embodiments, the isotopologue is enriched in 14C.

The ceutical compositions provided herein can be ed in a unitdosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired eutic effect, in ation with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an individually packaged tablet or capsule. A unit-dosage form may be administered in fractions or multiples thereof. A le-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated osage form. In certain embodiments, the unit dosage forms provided herein comprise about 1 mg to about 100 mg of a solid form of Compound 1. In other embodiments, the unit dosage forms provided herein comprise about 5 mg to about 50 mg of a solid form of Compound 1. In other embodiments, the unit dosage forms provided herein comprise about 1 mg, about 5 mg, about 20 mg, about 45 mg, about 50 mg, about 75 mg or about 100 mg of a solid form of Compound 1. In other embodiments, the unit dosage forms provided herein comprise about 5 mg, about 15 mg, about 20 mg, about 30 mg, about 45 mg, and about 50 mg of a solid form of Compound 1.

In certain ments, provided herein are methods for preparing a composition provided , comprising: (i) weighing out the desired amount of a solid form of Compound 1 (such as Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) thereof and the desired amount of excipients (such as lactose monohydrate, croscarmellose sodium and microcrystalline cellulose); (ii) mixing or blending a solid form of Compound 1 and the excipients; (iii) passing the mixture of a solid form of Compound 1 and excipients through a screen (such as an 18 mesh or 1000 m screen); (iv) mixing or blending a solid form of Compound 1 and the excipients after passage through the screen; (v) weighing out the desired amount of lubricating agents (such as stearic acid and/or magnesium te); (vi) passing the lubricating agents through a screen (such as a 30 mesh or 600 m screen); (vii) mixing or ng a solid form of Compound 1, the ents and the lubricating ; (viii) ssing the mixture of a solid form of Compound 1, the excipients and the lubricating agents (such as into a tablet form); and (ix) coating the compressed mixture of a solid form of Compound 1, the excipients and the lubricating agents with a coating agent (such as Opadry pink, yellow or .

In certain embodiments, provided herein are methods for preparing a composition provided herein, comprising: (i) weighing out the desired amount of a solid form of Compound 1 (such as Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) thereof and the d amount of excipients (such as lactose monohydrate, croscarmellose sodium and microcrystalline cellulose); (ii) mixing or blending a solid form of Compound 1 and the excipients; (iii) passing the mixture of a solid form of Compound 1 and excipients through a screen (such as an 18 mesh or 1000 m screen); (iv) mixing or blending a solid form of Compound 1 and the excipients after passage through the screen; (v) ng out the desired amount of lubricating agents (such as stearic acid and/or magnesium stearate); (vi) passing the lubricating agents through a screen (such as a 60 mesh or 250 m ); (vii) mixing or blending a solid form of Compound 1, the excipients and the lubricating agents; (viii) ssing the mixture of a solid form of Compound 1, the excipients and the lubricating agents (such as into a tablet form); and (ix) coating the compressed mixture of a solid form of nd 1, the excipients and the lubricating agents with a coating agent (such as Opadry pink, yellow or beige).

In certain ments, provided herein are methods for ing a ition provided herein, comprising: (i) weighing out the desired amount of a solid form of Compound 1 and the desired amount of excipients (such as lactose monohydrate, croscarmellose sodium and microcrystalline cellulose); (ii) passing the excipients through a screen (such as an 18 mesh or 1000 m screen); (iii) mixing or blending (such as at 26 revolutions per minute for 20 s) a solid form of Compound 1 (such as Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) thereof and the excipients; (iv) passing the mixture of a solid form of Compound 1 and excipients through a screen (such as an 18 mesh or 1000 m ); (v) mixing or blending (such as at 26 revolutions per minute for 10 minutes) a solid form of Compound 1 and the excipients; (vi) weighing out the desired amount of lubricating agents (such as stearic acid and/or ium stearate); (vii) passing the lubricating agents through a screen (such as a 30 mesh or 600 m screen); (viii) mixing or blending (such as at 26 revolutions per minute for 3 minutes) a solid form of Compound 1, the excipients and the lubricating agents; (ix) compressing the mixture of a solid form of Compound 1, the excipients and the lubricating agents (such as into a tablet form); and (x) coating the compressed mixture of a solid form of Compound 1, the excipients and the lubricating agents with a coating agent (such as Opadry pink, yellow or beige).

] In certain embodiments, provided herein are methods for preparing a composition provided herein, comprising: (i) weighing out the desired amount of a solid form of Compound 1 and the desired amount of excipients (such as lactose monohydrate, croscarmellose sodium and microcrystalline cellulose); (ii) passing the excipients through a screen (such as an 18 mesh or 1000 m screen); (iii) mixing or blending (such as at 26 revolutions per minute for 20 minutes) a solid form of Compound 1 (such as Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7 or Form 8) thereof and the excipients; (iv) g the mixture of a solid form of Compound 1 and excipients through a screen (such as an 18 mesh or 1000 m screen); (v) mixing or blending (such as at 26 revolutions per minute for 10 minutes) a solid form of Compound 1 and the excipients; (vi) weighing out the desired amount of lubricating agents (such as stearic acid and/or magnesium stearate); (vii) passing the lubricating agents through a screen (such as a 60 mesh or 250 m screen); (viii) mixing or blending (such as at 26 tions per minute for 3 minutes) a solid form of Compound 1, the excipients and the ating agents; (ix) compressing the mixture of a solid form of Compound 1, the excipients and the lubricating agents (such as into a tablet form); and (x) coating the compressed mixture of a solid form of Compound 1, the excipients and the ating agents with a coating agent (such as Opadry pink, yellow or In certain embodiments, the ceutical compositions provided herein comprise Form 1, including substantially pure Form 1.

In certain embodiments, the pharmaceutical compositions provided herein comprise Form 2, including substantially pure Form 2.

In certain embodiments, the ceutical compositions provided herein comprise Form 3, including substantially pure Form 3.

In certain embodiments, the pharmaceutical compositions ed herein se Form 4, ing substantially pure Form 4.

] In certain embodiments, the pharmaceutical compositions provided herein comprise Form 5, including substantially pure Form 5.

In certain embodiments, the pharmaceutical compositions provided herein comprise Form 6, including substantially pure Form 6.

In certain embodiments, the pharmaceutical compositions provided herein comprise Form 7, including substantially pure Form 7.

In certain embodiments, the pharmaceutical compositions provided herein comprise Form 8, including substantially pure Form 8.

Further provided herein are kits comprising a pharmaceutical composition of a solid form of Compound 1 provided herein. In particular embodiments, provided herein are kits comprising a unit dosage form of a solid form of Compound 1 provided herein. In n embodiments of the kits ed herein, a solid form of Compound 1 is provided as Form 1. In certain ments of the kits provided herein, a solid form of Compound 1 is provided as Form 2. In certain embodiments of the kits provided herein, a solid form of Compound 1 is provided as Form 3. In certain embodiments of the kits provided herein, a solid form of Compound 1 is provided as Form 4. In certain embodiments of the kits provided herein, a solid form of Compound 1 is provided as Form 5. In certain embodiments of the kits ed herein, a solid form of Compound 1 is provided as Form 6. In n embodiments of the kits provided herein, a solid form of Compound 1 is provided as Form 7. In n embodiments of the kits ed herein, a solid form of Compound 1 is provided as Form 8. 6. EXAMPLES The following Examples are presented by way of illustration, not limitation. The following abbreviations are used in descriptions and examples: 2MXETOH: 2-Methoxyethanol AAC: Accelerated aging conditions (48 hours at 40°C and 75% RH) ACN: Acetonitril Am: Amorphous AmPhos: p-Dimethylamino phenylditbutylphosphine API: Active Pharmaceutical ient AS: ID for olvent crystallization experiment Boc: tert-Butoxycarbonyl dba: Dibenzylidene e DCM: Dichloromethane DIPEA: N,N-Diisopropylethylamine DMF: N,N-Dimethylformide DMSO: Dimethylsulfoxide DSC: Differential Scanning Calorimetry ECP: ID for ative experiment EDTA: Ethylenediamine tetraacetate ESI: Electronspray ionization EtOH: Ethanol FTIR: Fourier Transform Infra Red Spectroscopy GRP: Grinding experiment HF: ID for hot-filtration crystallization experiment HPLC: High performance liquid chromatography IPA: 2-Propanol LCMS: Liquid Chromatography with Mass Spectroscopy MeOH: Methanol mp: Melting point MS: Mass spectrometry Ms: Mesylate or methanesulfonyl MTBE: tert-Butyl methyl ether MTBE: methyl tert-butyl ether NBS: N-Bromosuccinimide NMP: N-Methylpyrrolidone NMP: N-methylpyrrolidinone NMR: Nuclear magnetic nce PSU: ID for cooling-evaporative crystallization ment QSA: ID for Phase 1 experiments RH: Relative Humidity RT: Room Temperature S: t SDTA: Single Differential l Analysis SLP: ID for slurry experiment SM: Starting material TA: Thermal Analysis TCP: ID for thermocycling and reflux experiment Tf: triflate or trifluoromethanesulfonyl TFA: Trifluoroacetic acid TFE: 2,2,2-Trifluoroethanol TGA: Thermogravimetric Analysis TGA-MS/TGMS: Thermogravimetric Analysis coupled with Mass oscopy THF: Tetrahydrofuran TLC: Thin layer chromatography VDL: ID for vapor diffusion into ons experiment VDS: ID for vapor diffusion onto solids experiment XRPD: X-Ray Powder Diffraction 6.1 Analytical Methods XRPD patterns were obtained using the Crystallics T2 high-throughput XRPD set-up. The plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector. The XRPD platform was calibrated using Silver Behenate for the long d-spacings and Corundum for the short d-spacings. Data collection was carried out at room temperature using romatic CuKα radiation in the 2θ region between 1.5o and 41.5o, which is the most distinctive part of the XRPD pattern. The diffraction pattern of each well was collected in two 2θ ranges (1.5o ≤ 2θ ≤ 21.5o for the first frame, and 19.5o ≤ 2θ ≤ 41.5o for the second frame) with an exposure time of 90s for each frame. No background subtraction or curve smoothing was applied to the XRPD patterns. The carrier material used during XRPD analysis was transparent to X-rays and buted only slightly to the ound.

DSC analyses were performed on a DSC822e instrument (Mettler-Toledo GmbH, Switzerland). The DSC822e was calibrated for temperature and enthalpy with a small piece of indium (m.p. is 156.6°C; ΔHf is 28.45 J/g). s were sealed in standard 40µl aluminum pans, pin-holed and heated in the DSC from 25 °C to 300 °C, at a heating rate of 10 °C/min. Dry N2 gas, at a flow rate of 50 ml/min was used to purge the DSC equipment during measurement.

The cycling DSC’s were measured in standard 40µl aluminum pans, pin-holed and heated in the DSC from 25°C to 190°C, then cooled back to 25°C. The heating and cooling rate was °C/min. Dry N2 gas, at a flow rate of 50 ml/min was used to purge the DSC equipment during measurement.

TGA/SDTA analysis was adopted to determine mass loss caused by solvent or water loss from crystals. ring the sample weight, during heating in a TGA/SDTA851e instrument (Mettler- Toledo GmbH, Switzerland), results in a weight vs. temperature curve.

The TGA/SDTA851e was calibrated for ature with indium and aluminum. Samples were d into 100 µL aluminum crucibles and sealed. The seals were pin-holed and the crucibles heated in the TGA from 25°C to 300°C at a heating rate of 10°C/min. Dry N2 gas was used for g. The gases evolved from the TGA samples were analyzed by a mass spectrometer Omnistar GSD 301 T2 (Pfeiffer Vacuum GmbH, Germany). The latter is a quadrupole mass spectrometer, which analyses masses in the range of 0-200 amu.

Digital images were automatically collected for all the wells of each well-plate, employing a s PCVC 840K CCD camera controlled by Crystallics lider software.

FTIR spectra were recorded on a ThermoFischer Scientific FT-IR: Nicolet 6700.

Morphology analysis of the samples was d out on an Olympus microscope.

Small amounts of samples were sed in mineral oil on a glass slide with cover slips and viewed with 20x or 50x magnification.

Hygroscopicity was determined on a Surface Measurement s DVS.

Typically a sample size of 2-10 mg was loaded into the DVS instrument sample pan and the sample was analyzed on a DVS automated sorption analyzer at room temperature. The relative humidity was increased from 0 % to 90 %RH at 10%RH step then 95 %RH. The relative ty was then decreased in a similar manner to accomplish a full adsorption/desorption cycle. For selected ed forms, the analysis started at 50 %RH and increased to 90 %RH at %RH step. The relative ty was then decreased in a similar manner to 0 %RH followed by increasing to 50 %RH.

High Performance Liquid Chromatography (HPLC) was performed according to the conditions in Table 1 and gradient program in Table 2.

Table 1. High mance Liquid Chromatography (HPLC) experimental conditions Manufacturer Agilent HPLC HP1200sl UV-detector HP DAD MS-detector HP1100 API-ES MSD e Column Waters Sunfire C18 (100 x 4.6mm; 3.5µm) Column Temperature 40 °C Mobile Phase A 10 mM ammonium acetate Mobile Phase B Acetonitrile 100% Flow Rate 1.0 ml/min Post time 1 min UV-Detector DAD Range 200 – 400 nm Wavelength 220 nm Slit width 4 nm Time 0-17 min MS-Detector MSD Scan positive Mass Range 70 – 1000 amu Fragmentator 70 Time 0-20 min Autosampler: Temperature Not controlled Injection mode loop Injection volume 5 µL Needle wash 2/3; Acetonitrile/H2O (v/v) on solvent Acetonitrile Table 2. High Performance Liquid Chromatography (HPLC) experimental nt program Time (mins) %A %B 0 90 10 16 10 90 10 90 21 90 10 The nd integrity is expressed as a peak-area percentage, calculated from the area of each peak in the chromatogram, except the ‘injection peak’, and the total peak-area, as follows: peak  area peak  area %  100% total  area The peak-area percentage of the compound of interest is employed as an indication of the purity of the component in the sample.

Crystal16® multiple-reactor system (Avantium logies) holds 16 (4 x 4) standard HPLC glass vials (11.5 mm diameter, flat ed, 1.8 mL volume). A unit consists of four independently heated aluminum reactor blocks encased in a robust bench top setup.

These blocks are electrically heated and cooled by a ation of Peltier elements and a cryostat. In order to prevent condensation of water on the reactor blocks and electronics during runs at temperatures below 10°C, the Crystal16® system provides an inlet for a dry purge gas (typically nitrogen). Operating Parameters are provided in Table 3.

Table 3. Operating Parameters of Crystal16® multiple-reactor system Temperature range -15°C to 150°C Heating/cooling Individually programmable per reactor block Temperature profile Unlimited heating/cooling/hold steps per run programmable Temperature control accuracy 0.1°C Heating/cooling ramps Programmable between 0°C and 20°C/min Stirrer speed (magnetic stirrer bars) Programmable from 0 - 1250 rpm Turbidity measurement Per individual reactor in transmission 6.2 Summary of Cocrystal Formation Screen A total of 314 cocrystal formation experiments were divided over four different crystallization methods. Based on the al structure of Compound 1, 10 different coformers were ed (Table 5). The cocrystal formation experiments were performed as described in § 6.3.

Physical ity of all samples was studied by exposing all solids to rated ageing conditions (40°C/75% RH for 48 hours) followed by re-analysis by XRPD and digital imaging. After exposure to accelerated ageing ions, all solids were re-classified on the basis of their new XRPD patterns. The assignment of solid forms was primarily based on the XRPD analysis.

The cocrystals formed with fumaric acid (Form 1 and Form 2), benzoic acid (Form 3 and Form 4), ic acid (Form 5 and Form 6) and maleic acid (Form 7 and Form 8) appear to be stable at rated aging conditions (40°C and 75%RH, 48 hours). TGMS, FTIR and HPLC analysis of the potential cocrystals from fumaric acid, benzoic acid, gentisic acid and maleic acid confirmed that these XRPD patterns belong to new cocrystals of Compound 1. Of those cocrystals only the l with fumaric acid (Form 1) is a non- solvated ous cocrystal. More complex crystal structures for instance were found in the other fumaric acid cocrystal (Form 2), which turned out to be a monohydrate of the fumaric acid cocrystal of Compound 1. The above described results clearly trates that co-crystals n Compound 1 and both aliphatic and aromatic carboxylic acids can be formed. ding remarks per analysis of these solids are given in Table 4.

Table 4. Summary table of the analytical experiments, s and conclusions of the cocrystals of Compound 1 Form 1 Form 2 Form 3 Form 4 XRPD Unique pattern Unique pattern Unique pattern Unique pattern TGMS No significant mass 1.12% mass loss 5% mass loss 1.7% mass loss loss (water) (water) (acetone) SDTA Single melting point Endothermic Series of Single melting point (Tpeak is 187.6°C) dehydration event endothermic events (Tpeak is 83.2°C) (Tpeak is 146°C) – individual events Single melting not interpreted point (Tpeak is 193.5°C) HPLC Highly pure Cmpd 1 Highly pure Highly pure Highly pure Cmpd 1 (100%) Cmpd 1 (98.9%) Cmpd 1 (99.9%) (99.5%) FTIR Changes in the Changes in the Changes in the Changes in the um as spectrum as spectrum as spectrum as compared to that of compared to that of compared to that of ed to that of Compound 1 - Cmpd 1 - 1800- Cmpd 1 - 1800- Cmpd 1 - 1800- 1800-1600cm-1 1600cm-1 shift 1600cm-1 shifts 1600cm-1 shifts shifts (tertiary doubled (tertiary (tertiary amines) ary ) amines) amines) Conclusion Cocrystal of Monohydrate Cocrystal of Cocrystal of Cmpd 1 Cmpd 1 with cocrystal of Cmpd 1 with with benzoic acid fumaric acid Cmpd 1 benzoic acid fumarate salt Form 5 Form 6 Form 7 Form 8 XRPD Unique pattern Unique pattern Unique pattern Unique pattern TGMS 4.6% mass loss 0.9% mass loss 4% mass loss 1% mass loss (water and acetone) (acetonitrile) (water and (ethylacetate) acetonitrile) SDTA Single melting point Single melting pointSingle melting point Single g point (Tpeak is ) (Tpeak is 148°C) (Tpeak is 86°C) (Tpeak is 118.8°C) HPLC Highly pure Cmpd 1 Pure Cmpd 1 Highly pure Low purity Cmpd 1 (99.3%) (96.55%) Cmpd 1 (98.3%) (87.2%) FTIR Changes in the Changes in the Changes in the Changes in the spectrum as spectrum as spectrum as spectrum as compared to that compared to that compared to that compared to that of of Cmpd 1 - 1800- of Cmpd 1 - 1800- of Cmpd 1 - Cmpd 1 – 1800- 1600cm-1 shifts 1400cm-1 shifts 1800-1600cm-1 -1 shifts (tertiary amines) (tertiary amines, shifts (tertiary (tertiary amines) but also presence amines) of an impurity) Conclusion Cocrystal of Cocrystal of Cocrystal of Cocrystal of Cmpd 1 Cmpd 1 with Cmpd 1 with Cmpd 1 with maleic with maleic acid, gentisic acid gentisic acid acid although high although not although high solvent content preferred because of solvent content high ty levels Form 1 is believed to be a cocrystal of Compound 1 free base with a 1:1 stoichiometry as concluded by the single le of fumaric acid identified by FT-IR (see and – shift between 1800-1600cm-1). Form 2 crystal structure was determined by single crystal X-ray diffraction. In contrast with Form 1, Form 2 appears to be a fumaric acid cocrystal of Compound 1 fumarate salt, which has also one molecule of water per unit. The FT-IR spectrum (see and ) y shows a doubled shift at around 1800-1600cm-1 indicating the interaction of two molecules of fumaric acid with the nitrogens of Compound 1.

TGMS analysis of Form 4, Form 6 and Form 7 revealed that these stals are ed (see , and ). HPLC is of Form 6 and Form 8, showed the presence of an impurity with a retention time of 6.05 min in HPLC is (see and ).

Further research is needed to identify the nature and cause of the impurity. Although the XRPD pattern of Form 3 is unique, the SDTA signal does not support the presence of a single solid phase. The FTIR spectra (see and ) of Form 3 showed peak shifts; however; their interpretation is rather complicated. LCMS analysis of Form 3 showed that nd 1 is present in the sample, which is 99.9% pure (see ). 6.3 Experimental Methods In total, 324 ments were performed, ing 126 cooling evaporative ments, 66 slurry experiments, 66 powder in saturated solution experiments and 66 ng experiments. In all methods, 11 solvents (see Table 6) and 10 coformers were tested (see Table ), including 6 blank experiments per method. The coformers and the solvents used were the same for all four methods, while the solvents per method differed due to differences in solubility of Compound 1 in the solvents. The coformers have been selected on the basis of their H- bonding capability, diversity, pharmaceutical acceptability and solubility in the proposed solvents. An overview of the combination of methods and solvents used is provided in Table 5 and Table 6. The solvents used in the polymorph screen were either HPLC or t grade.

Table 5. Coformers used in the cocrystal screen # Cocrystal former # tal former 1 Meglumine 6 Gentisic acid 2 namide 7 Fumaric acid 3 Tromethamine 8 Glutamic acid 4 L-Lysine 9 Benzoic acid Maleic acid 10 L-Arginine Table 6. ts used in the cocrystal screen # Solvents 1 Ethanol 2 Ethanol/water (10/90) 3 Ethanol/water (50/50) 4 Methanol/water (50/50) Tetrahydrofuran/water (50/50) 6 Acetonitrile 7 Ethyl acetate 8 Acetone and water (10/90) 9 Cyclohexane p-xylene 11 Water 6.3.1 Cooling evaporative ments The cooling ative experiments employed 4 coformers, 6 solvents and two Compound 1:coformer ratios (see Table 8). Compound 1 free base (the starting material) and coformers were solid dosed in 1.8 mL experimental vials. A suitable volume of solvent was added to reach a close-to saturated solution. Following, the HPLC vials were capped and placed in the Crystal16® system to undergo the temperature profile as described in Table 7. Also 6 control experiments were med. At the end of the temperature profile, the solids were separated from the liquids, dried and analyzed by XRPD and digital imaging. The mother liquids after separation of solids were evaporated and the remaining solids ed by XRPD and l imaging too.

Subsequently, all solids were placed in a climate chamber at 40°C and 75% RH for 70 hours and again analyzed by XRPD and digital imaging.

Table 7: Temperature profiles (Tprofile) for the cocrystallization experiments Tstart (°C) Heating rate Tmax (°C) Hold Cooling Tend (°C) Age time (h) (°C/min) (minute) rate (°C/h) 10 40 60 1 2 48 Table 8: Experimental conditions of the cocrystal cooling ation experiments Molar Mass of Mass of Solvent Dissolved Solids Ratio Coformer Solvent Cmpd 1 Coformer volume before after (Cmpd 1: (mg) (mg) (µL) Tprofile Tprofile Coformer) EtOH 30.4 10.30 750 No No EtOH/Water 30.8 9.80 400 Yes No (50/50) MeOH/Water 29.8 9.70 400 1:1.1 Yes No (50/50) THF/Water 30.9 10.00 400 Yes No (50/50) Acetonitrile 29.5 9.60 1000 No Yes Maleic acid Ethyl acetate 29.5 9.70 1000 No Yes EtOH 29.7 35.60 750 Yes No EtOH/Water 29.9 35.80 400 Yes No MeOH/Water 30.3 36.60 400 Yes No (50/50) 1:4 ter 30.1 35.70 400 Yes No Acetonitrile 30.2 35.30 1000 No Yes Ethyl acetate 29.9 35.70 1000 No Yes Gentisic acid EtOH 29.5 12.80 750 1:1.1 No Yes EtOH/Water 29.5 13.50 400 (2,5- No No (50/50) Dihydroxy MeOH/Water 29.9 12.80 400 No Yes (50/50) benzoic acid) THF/Water 30.9 13.50 400 No No (50/50) itrile 29.7 13.00 1000 No Yes Ethyl acetate 30.9 13.50 1000 No No EtOH 30.5 47.50 750 No No EtOH/Water 30.1 48.20 400 No Yes (50/50) MeOH/Water 29.7 47.40 400 1:4 No Yes (50/50) ter 31 47.20 400 No No (50/50) Acetonitrile 30.2 47.80 1000 No Yes Ethyl acetate 30.4 47.20 1000 No Yes EtOH 30.2 9.80 750 No Yes EtOH/Water 30.2 9.90 400 No Yes (50/50) MeOH/Water 30.6 10.00 400 (50/50) 1:1.1 No Yes THF/Water 29.9 10.10 400 No No Acetonitrile 29.8 10.00 1000 No Yes c acid Ethyl acetate 30 10.20 1000 No Yes EtOH 30.1 35.20 750 No Yes EtOH/Water 31 35.20 400 No Yes (50/50) MeOH/Water 30.3 35.30 400 (50/50) 1:4 No Yes THF/Water 30.1 35.80 400 Yes No (50/50) Acetonitrile 30.4 35.60 1000 No Yes Ethyl acetate 30 35.80 1000 No Yes Benzoic acid EtOH 30.4 10.80 750 No No EtOH/Water 400 .8 10.40 No No (50/50) MeOH/Water 400 29.8 10.70 1:1.1 No No (50/50) THF/Water 400 .9 10.60 No No (50/50) Acetonitrile 29.5 10.50 1000 No Yes Ethyl acetate 29.5 10.60 1000 No No EtOH 29.7 37.50 750 1:4 No No EtOH/Water 400 29.9 37.60 No No (50/50) MeOH/Water 400 .3 38.00 No Yes (50/50) THF/Water 400 .1 38.00 No No (50/50) itrile 30.2 37.70 1000 No No Ethyl acetate 29.9 37.50 1000 No No EtOH 30.2 - 750 No Yes EtOH/Water 30.2 - 400 No No MeOH/Water 30.6 - 400 No Yes none ) - THF/Water 29.9 - 400 Yes No (50/50) Acetonitrile 29.8 - 1000 No Yes Ethyl acetate 30 - 1000 No Yes Volume of solvent is 1000 µL. 6.3.2 Cocrystal formation slurry experiments nd 1 free base was solid dosed in 1.8 mL scale experimental vials. The coformer was added at a ratio of 1:1.1 (Compound 1:coformer). The solvent and a stirring bar were added to the vials. The experiments used 4 coformers and 6 solvents (see Table 9) and 6 control experiments without coformer were also performed. Then, the vials were capped and stirred at ambient conditions for 3 days. After the solids were ted from the liquids, the solids were analyzed wet by XRPD and digital imaging. Subsequently, both the solids and mother liquors were dried and evaporated under vacuum at ambient temperature (10 mbar for 24 hours). The solids obtained were then analyzed by XRPD and digital imaging. Subsequently, the solids were incubated in a climate chamber at 40°C and 75% RH for 48 hours and again ed by XRPD and digital imaging.

Table 9. Experimental conditions of the cocrystal slurry ments Coformer Solvent Mass of Mass of Dissolved Solids Cmpd 1 Coformer before after (mg) (mg) Tprofile Tprofile Acetonitrile 31.0 9.50 No Yes Acetone/water 29.4 10.00 No No (10/90) Maleic acid Cyclohexane 29.9 10.00 No Yes p-Xylene 31.1 9.80 No Yes Water 30.7 10.00 No No Ethanol/water 30.7 10.00 No No (10/90) itrile 30.8 13.10 No Yes Acetone/water 29.2 13.00 No Yes (10/90) Gentisic acid Cyclohexane 30.1 13.40 No Yes (2,5- Dihydroxy p-Xylene 30.8 13.50 No Yes benzoic acid) Water 31.1 13.40 No Yes l/water 31.0 13.20 No Yes (10/90) Acetonitrile 31.2 10.40 No Yes Acetone/water 31.1 10.20 No Yes (10/90) Fumaric acid Cyclohexane 30.2 10.30 No Yes p-Xylene 30.8 10.10 No Yes Water 30.5 10.00 No Yes Ethanol/water 29.2 10.00 No Yes (10/90) Acetonitrile 30.5 10.70 No Yes Acetone/water 29.7 11.00 No Yes (10/90) Benzoic acid Cyclohexane 30.5 10.20 No Yes p-Xylene 30.8 10.80 No Yes Water 29.2 11.00 No Yes Ethanol/water .3 10.30 No Yes (10/90) Acetonitrile 30.8 - No Yes Acetone/water .7 - No Yes (10/90) Cyclohexane 29.1 - No Yes none p-Xylene 29.8 - No Yes Water 30.8 - No Yes Ethanol/water 29.2 - No Yes (10/90) Volume of solvent is 500 µL. 6.3.3 Powder in saturated solutions experiments In these experiments 4 coformers and 6 ts were tested (see Table 10). In each solvent, saturated solutions of Compound 1 were prepared. To the saturated solutions the solid ers were added until the coformer did not dissolve anymore or precipitation occurred. The s remained for 4 hours at ambient temperature with stirring. In addition, 6 control experiments were performed. uently, the solids were separated from the liquids.

The solids were dried and mother liquors were evaporated under vacuum. All obtained solids were then analyzed by XRPD and digital imaging. Subsequently, the solids were placed in a climate chamber at 40°C and 75% RH for 3 days after which they were analyzed by XRPD and digital g again.

] Table 10. Experimental conditions for the powder in saturated solutions experiments Coformer Solvent Mass of Mass of Solvent Dissolved Solids after Cmpd 1 Coformer volume before Tprofile (mg) (mg) (µL) Tprofile EtOH 30.0 20.00 950 No No EtOH/Water .0 20.00 1000 No No (50/50) MeOH/Water Maleic acid 30.0 20.00 1000 No No (50/50) THF/Water .0 20.00 250 No Yes (50/50) Acetonitrile 30.0 20.00 1000 No Yes Ethyl acetate 30.0 20.00 1000 No Yes EtOH 30.0 20.00 950 No Yes EtOH/Water .0 20.00 1000 No No (50/50) Gentisic acid (2,5- MeOH/Water .0 20.00 1000 No Yes Dihydroxy (50/50) benzoic acid) THF/Water .0 20.00 250 No Yes (50/50) Acetonitrile 30.0 20.00 1000 No Yes Ethyl acetate 30.0 20.00 1000 No Yes EtOH 30.0 20.00 950 No Yes EtOH/Water .0 20.00 1000 No Yes (50/50) MeOH/Water c acid 30.0 20.00 1000 No Yes (50/50) .0 20.00 250 No Yes (50/50) Acetonitrile 30.0 20.00 1000 No Yes Ethyl acetate 30.0 20.00 1000 No Yes Benzoic acid EtOH 30.0 20.00 950 No No EtOH/Water .0 20.00 1000 No No MeOH/Water .0 20.00 1000 No No (50/50) THF/Water .0 20.00 250 No No (50/50) Acetonitrile 30.0 20.00 1000 No Yes Ethyl acetate 30.0 20.00 1000 No No Ethyl acetate 30.0 20.00 1000 No Yes EtOH 30.0 - 950 No No EtOH/Water .0 - 1000 No No (50/50) ater .0 - 1000 No No none (50/50) THF/Water .0 - 250 No No (50/50) Acetonitrile 30.0 - 1000 No No Ethyl acetate 30.0 - 1000 No No Volume of t is 1000 µL; Molar ratio of Compound 1 and coformer is 1:1. 6.3.4 Grinding ments 66 single-solvent-drop grinding experiments were performed using 4 coformers and 6 solvents. Moreover 6 control experiments were performed. Compound 1 free base was weighed into metal grinding vials, containing two stainless steel grinding balls. The coformers and solvents were added (see Table 11). The molar ratio of compound 1 free base and the coformer is 1:1.1. The experiments were shaken for 1 hour at a frequency of 30 Hz. After the 1- hour shaking, the samples were analyzed by XRPD and digital imaging. Subsequently the s were exposed to rated aging conditions (40°C, 75% RH) for 3 days and reanalyzed by XRPD and digital imaging.

] Table 11. Conditions of grinding experiments Coformer Solvent Mass of Mass of Solids after Cmpd 1 (mg) Coformer (mg) Tprofile Acetonitrile 29.4 9.90 Yes Acetone/Water (10/90) 31.3 9.80 No Maleic acid Cyclohexane 30.8 10.10 Yes p-Xylene 29.8 10.00 Yes Water 30.2 10.40 Yes Ethanol/Water (10/90) 30.8 10.20 Yes ic acid (2,5- Acetonitrile 30.8 13.30 Yes Dihydroxy Acetone/Water (10/90) 31.3 13.50 Yes benzoic acid) Cyclohexane 31.2 13.40 Yes p-Xylene 29.2 13.30 Yes Water 30.5 13.30 Yes Ethanol/Water (10/90) 30.0 13.50 Yes Acetonitrile 30.5 10.20 Yes Acetone/Water (10/90) 31.3 10.20 Yes Fumaric acid Cyclohexane 30.2 10.20 Yes ne 30.9 10.20 Yes Water 29.8 10.20 Yes Ethanol/Water (10/90) 31.3 10.20 Yes Acetonitrile 29.8 10.70 Yes Acetone/Water (10/90) 29.9 10.70 Yes Benzoic acid Cyclohexane 30.6 10.50 Yes ne 30.4 10.80 Yes Water 30.1 10.30 Yes Ethanol/Water (10/90) 30.2 10.30 Yes Acetonitrile 29.8 - Yes Acetone/Water (10/90) 30.7 - Yes Cyclohexane 30.7 - Yes none p-Xylene 30.6 - Yes Water 30.4 - Yes Ethanol/Water (10/90) 29.8 - Yes Volume of solvent is 10 µL. 6.3.5 Cocrystal Solid Form 1 Form 1 was prepared in cooling evaporative experiments when fumaric acid was used as the coformer and ethyl acetate was used as the solvent. Form 1 is an anhydrous tal form of Compound 1 and fumaric acid in a 1:1 stoichiometric ratio. provides an y of XRPD patterns of Compound 1, Form 1, Form 2 and fumaric acid (from bottom to top). A list of X-Ray ction Peaks for Form 1 is provided below in Table 12.

Table 12. X-Ray Diffraction Peaks for Form 1 Two-theta angle (°) d Space (Å) Relative Intensity (%) 7.14 12.37 62.24 11.42 7.74 24.68 12.82 6.9 20.15 14.66 6.04 8.32 16.1 5.5 9.11 22.7 3.91 89.49 .5 3.49 15.76 and provide TGMS data and TGA/SDTA data of Form 1, respectively. No mass loss of the sample was observed between 25°C and 100°C when heated from 25°C to 300°C. According to the SDTA signal in an ermic melt event was observed at 187.6°C, followed by ate decomposition. provides HPLC and MS data of Form 1. The peak retention time is 8.1 s. HPLC data indicates that the sample purity is 100.0% (area%). es an FTIR overlay of Compound 1 (top), Form 1 (middle) and fumaric acid (bottom). The overlay indicates that the main shifts take place in the spectra in the region 1800-1500cm-1 and 1600-1400cm-1. provides an FTIR overlay of Compound 1 (top), Form 1 (middle) and c acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the H-bonding is taking place between the coformer and Compound 1. 6.3.6 Cocrystal Solid Form 2 Form 2 was prepared in cooling evaporative experiments when fumaric acid was used as the coformer and a e of methanol and water (50/50) was used as the solvent. Form 2 is a monohydrated cocrystal form of Compound 1 and fumaric acid. es an overlay of XRPD patterns of Compound 1, Form 1, Form 2 and fumaric acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 2 is provided below in Table 13. Form 2 appears to be a fumaric acid co-crystal of Compound 1 fumarate salt, which has also one molecule of water per unit.

Table 13. X-Ray ction Peaks for Form 2 Two-theta angle (°) d Space (Å) Relative Intensity (%) 7.42 11.9 44.47 .38 8.51 12.43 13.7 6.46 8.85 .94 5.55 14.52 17.9 4.95 10.79 18.3 4.84 23.68 19.42 4.57 12.54 22.42 3.96 9.8 eta angle (°) d Space (Å) Relative Intensity (%) 23.38 3.8 7.15 23.82 3.73 58.81 .46 3.49 8.34 26.78 3.33 12.38 and provide TGMS data and TGA/SDTA data of Form 2. A mass loss of 1.12% by weight of the sample corresponding to water was observed between 35°C and 175°C during an endothermic event with Tpeak at 146°C suggesting the solvated nature of the sample, when heated from 25°C to 300°C. According to the SDTA signal in an endothermic melt event was ed at 193.5°C, followed by immediate decomposition. provides HPLC and MS data of Form 2. The peak ion time is 8.1 s. The HPLC data indicates that the sample purity is 98.9% (area%). provides an FTIR overlay of Compound 1 (top), Form 2 (middle) and fumaric acid (bottom). The overlay indicates that the main shifts take place in the spectra in the region 1800-1500cm-1 and 400cm-1. provides an FTIR overlay of Compound 1 (top), Form 2 e) and fumaric acid (bottom) in the region of 1800-400 cm-1. The y emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 ponding to tertiary amines shifts where the H-bonding is taking place between the coformer and Compound 1. and clearly show a doubled shift at around 1800-1600cm-1 indicating the interaction of two molecules of fumaric acid with the nitrogens of Compound 1.

The crystal structure of Form 2 was successfully determined from the single crystal X-ray diffraction data. Compound 1 is protonated and forms a fumarate salt; the salt is also H-bonded with another molecule of fumaric acid forming a fumarate co-crystal of a fumarate salt. Moreover, a water molecule was also determined g H-bonds with nd 1. provides a representative way of the bonds formed by Compound 1 with fumaric acid and water. depicts the molecular structure and atom numbering scheme for protonated Compound 1 and its chemical first co-ordination sphere with nitrogen 13(b) being protonated (see ).

] The crystal structure of Form 2 comprises of 5 chemically different components: Compound 1 as free base, Compound 1 with protonated nitrogen atom named nitrogen 13(b), fumaric acid, fumarate anion and water. These components exist in the following ratio: 1 (Compound 1) :1 (Compound 1●H+):1.5 (fumaric acid):1 (fumaric acid anion):1 (water). shows the crystal packing and H-bond scheme of Form 2. Different components found in the asymmetric unit are marked by different colors (Compound 1●H+ - green, Compound 1 – red, c acid- blue, c acid anion - orange and water - purple).

The H-bond pattern is presented below in Table 14. The closed packing has almost no void for solvent molecules besides water. The fumaric acid bonds to Compound 1 tertiary nitrogens to form the fumarate co-crystal. The fumarate salt is also formed at a nitrogen atom (N13b).

Table 14. Hydrogen bonds formed by Form 2 D-H...A D-H [Å] H...A [Å] D...A [Å] D-H...A [°] O(1A)-H(1A)...O(1) 0.83(3) 1.96(3) 2.779(2) 173(2) N(15A)-H(15A)...O(37B)i 0.89(2) 2.03(2) 2.916(2) 172(2) O(1B)-H(1B)...O(1A) 0.88(3) 1.96(3) 2) 169(2) N(13B)-H(13B)...O(32B) 0.98(2) 1.65(2) 2.619(2) 172(2) N(15B)-H(15B)...O(31B) 0.88(2) 1.94(2) 2.810(2) 172(2) O(38A)-H(38A)...N(6A)ii 0.89(4) ) 2.736(2) 162(3) O(32A)-H(32A)...N(6B) 0.91(4) 1.81(4) 2.713(2) 170(3) O(38B)-H(38B)...N(13A)iii ) 1.72(3) 2.636(2) 168(2) O(31C)-H(31C)...O(32B)iv 0.90(3) 1.72(3) 2) 175(3) O(1)-HW1...O(31B)iv 0.87(3) ) 2.808(2) 164(3) O(1)-HW2...O(26A)v 0.85(4) 2.03(4) 2.854(2) 164(3) Symmetry ormations: (i) x - 1, y - 1, z - 1; (ii) x - 1, y + 1, z; (iii) x + 1, y + 1, z + 1; (iv) 2 - x, 2 - y, 1 - z; (v) x, y+1, z Table 15 shows that Form 2 is crystallizing in a triclinic symmetry with P-1 space group and having a Z equal to 2.

] Table 15. Crystal structure data of Form 2 Empirical formula C21H28N5O3+·C4H3O4-·C21H27N5O3·1.5(C4H4O4) ·H2O F.W. 1103.15 T [K] 296(2) λ [Å] 0.71073 Crystal system Triclinic Space group P -1 Unit cell dimensions a [Å] 11.0259(6) b [Å] 12.0731(6) c [Å] 21.0851(9) α [°] (3) β [°] 91.681(3) γ [°] 94.433(3) V [Å] 2762.6(2) Z 2 Dc [g/cm3] 1.326 µ [mm-1] 0.100 F(000) 1168 Crystal size [mm3 ] 0.35 x 0.32 x 0.25 θ range for data collection [°] 3 to 32.7 Reflections collected 28571 Independent reflections 19825 [Rint is 0.0275] Completeness to θ is 32.7° [%] 97.8 Max. and min. ission 0.9753 and 0.9657 Data / restraints / parameters 19825 / 0 / 1006 Goodness-of-fit on F2 1.035 Final R indices [I>2 (I)] R1 is 0.0685, wR2 is 0.1682 R indices (all data) R1 is , wR2 is 0.2022 shows an overlay between the experimental data (red) recorded for Form 2 and the simulated XRPD data (black) from the determined crystal ure. The fit emphasizes the successful crystal structure determination of Form 2. 6.3.7 Cocrystal Solid Form 3 Form 3 was ed in slurry experiments when benzoic acid was used as the coformer and water was used as the solvent. Form 3 is a hydrated cocrystal form of Compound 1 and benzoic acid. provides an overlay of XRPD patterns of Compound 1, Form 3, Form 4 and benzoic acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 3 is provided below in Table 16.

Table 16. X-Ray Diffraction Peaks for Form 3 Two-theta angle (°) d Space (Å) Relative ity (%) 7.3 12.1 69.57 8.02 11.01 14.1 11.86 7.45 24.84 12.78 6.92 46.84 14.38 6.15 18.41 16.9 5.24 24.27 18.74 4.73 20.06 21.14 4.2 18.24 21.9 4.05 80.08 23.78 3.74 18.47 .14 3.54 19.88 .82 3.45 8.81 26.74 3.33 18.86 and provide TGMS data and TGA/SDTA data of Form 3. between 25°C and 100°Cwhen heated from 25°C to 300°C. According to the SDTA signal in , three endothermic melt event were observed at 67.7°C, 108°C and 158°C indicating a possible ation step followed by melting and decomposition. provides HPLC and MS data of Form 3. The peak retention time is 8.1 minutes. The HPLC data tes that the sample purity is 99.9% (area%). provides an FTIR overlay of nd 1 (top), Form 3 (middle) and benzoic acid (bottom). The overlay indicates that the main shifts take place in the a in the region 1800-1500cm-1 and 1600-1400cm-1. provides an FTIR overlay of Compound 1 (top), Form 3 (middle) and benzoic acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the H-bonding is taking place between the coformer and Compound 1. 6.3.8 Cocrystal Solid Form 4 Form 4 was prepared in slurry experiments when benzoic acid was used as the coformer and a e of acetone and water (10/90) was used as the solvent. Form 4 is an acetone solvated cocrystal form of Compound 1 and benzoic acid. provides an y of XRPD patterns of Compound 1, Form 3, Form 4 and c acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 4 is provided below in Table 17.

Table 17. X-Ray ction Peaks for Form 4 Relative Two-theta angle (°) d Space (Å) Intensity (%) 8.02 11.01 52.13 8.86 9.97 14.72 9.74 9.07 18.4 12.78 6.92 17.12 13.82 6.4 54.86 .58 5.68 45.57 17.94 4.94 18 19.82 4.47 46.44 .5 4.33 10.22 21.02 4.22 32.95 22.58 3.93 9.81 24.38 3.65 25.92 .02 3.55 90.27 27.66 3.22 15.92 and e TGMS data and TGA/SDTA data of Form 4. A mass loss of 1.7% corresponding to acetone was observed between 35°C and 110°C during an endothermic event with Tpeak at 83.2°C, suggesting the solvated nature of the sample, when heated from 25°C to 300°C. According to the SDTA signal in , an endothermic melt event was observed at 83.2°C, followed by decomposition starting from 180°C. provides HPLC and MS data of Form 4. The peak retention time is 8.1 minutes. The HPLC data indicates that the sample purity is 99.4% (area%). provides an FTIR overlay of Compound 1 (top), Form 4 (middle) and benzoic acid (bottom). The overlay indicates that the main shifts take place in the spectra in the region 1800-1500cm-1 and 1600-1400cm-1. es an FTIR overlay of Compound 1 (top), Form 4 (middle) and benzoic acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the H-bonding is taking place between the coformer and Compound 1. 6.3.9 Cocrystal Solid Form 5 Form 5 was prepared in slurry ments when gentisic acid was used as the coformer and a mixture of acetone and water ) was used as the solvent. Form 5 is an acetone and water solvated cocrystal form of Compound 1 and gentisic acid. provides an overlay of XRPD patterns of Compound 1, Form 5, Form 6 and gentisic acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 5 is provided below in Table 18.

Table 18. X-Ray Diffraction Peaks for Form 5 Two-theta angle (°) d Space (Å) Intensity (%) 4.1 21.53 82.42 6.34 13.92 11.62 8.3 10.64 11.9 .78 5.61 21.32 .06 4.42 18.44 .7 4.29 11.59 .78 3.45 66.24 ] and provide TGMS data and TGA/SDTA data of Form 5. A mass loss of 4.6% between 25°C and 120 °C corresponding to water and acetone was ed suggesting the solvated nature of the sample, when heated from 25°C to 300°C. According to the SDTA signal in , an endothermic melt event was observed at 95.5°C, followed by decomposition starting from 180°C. provides HPLC and MS data of Form 5. The peak retention time is 8.1 minutes. The HPLC data indicates that the sample purity is 99.4% (area%). provides an FTIR overlay of Compound 1 (top), Form 5 e) and gentisic acid (bottom). The overlay tes that the main shifts take place in the spectra in the region 1800-1500cm-1 and 1600-1400cm-1. es an FTIR overlay of Compound 1 (compound), Form 5 (middle) and gentisic acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the H- bonding is taking place between the coformer and Compound 1. 6.3.10 Cocrystal Solid Form 6 Form 6 was ed in slurry experiments when gentisic acid was used as the coformer and acetonitrile was used as the solvent. Form 6 is an acetonitrile solvated cocrystal form of Compound 1 and gentisic acid. provides an overlay of XRPD patterns of nd 1, Form 5, Form 6 and gentisic acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 6 is ed below in Table 19.

Table 19. X-Ray Diffraction Peaks for Form 6 Relative Two-theta angle (°) d Space (Å) Intensity (%) 4.26 20.72 80.42 13.02 6.79 16.8 13.5 6.55 16.09 14.22 6.22 12.52 17.78 4.98 54.7 19.22 4.61 14.68 21.7 4.09 33.93 .82 3.45 70.97 provides TGMS data of Form 6. A mass loss of 0.9% corresponding to acetonitrile was observed n 70°C and 160°C during an endothermic event with Tpeak at 148°C suggesting the solvated nature of the sample, when heated from 25°C to 300°C.

According to the SDTA signal in , an ermic melt event was observed at the above mentioned temperatures, 148°C, followed by immediate decomposition. provides HPLC and MS data of Form 6. The peak retention time is 8.1 minutes. The HPLC data indicates that the sample purity is 96.6% (area%). provides an FTIR overlay of Compound 1 (top), Form 6 (middle) and gentisic acid (bottom). The overlay indicates that the main shifts take place in the a in the region 1800-1500cm-1 and 1600-1400cm-1. provides an FTIR overlay of nd 1 (top), Form 6 (middle) and gentisic acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the ing is taking place between the coformer and nd 1. 6.3.11 Cocrystal Solid Form 7 Form 7 was prepared in slurry experiments when maleic acid was used as the coformer and acetonitrile was used as the solvent. Form 7 is an acetonitrile and water solvated cocrystal form of Compound 1 and maleic acid. provides an overlay of XRPD patterns of Compound 1, Form 7, Form 8 and maleic acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 7 is provided below in Table 20.

Table 20. X-Ray Diffraction Peaks for Form 7 Relative Two-theta angle (°) d Space (Å) Intensity (%) 6.54 13.5 91.09 9.42 9.38 15.17 13.66 6.47 25.83 18.42 4.81 20.05 26.02 3.42 55.38 26.82 3.32 18.98 provide TGMS data of Form 7. A mass loss of 4% corresponding to water and acetonitrile was ed between 35°Cand 110°C during an ermic event with Tpeak at 86°C, suggesting the solvated nature of the sample, when heated from 25°C to 300°C.

According to the SDTA signal in , an endothermic melt event was observed at 86°C, followed by decomposition starting from 115°C. provides HPLC and MS data of Form 7. The peak retention time is 8.1 minutes. The HPLC data tes that the sample purity is 98.3% (area%). provides an FTIR overlay of Compound 1 (top), Form 7 (middle) and maleic acid (bottom). The overlay indicates that the main shifts take place in the spectra in the region 1800-1500cm-1 and 1600-1400cm-1. provides an FTIR overlay of Compound 1 (top), Form 7 e) and maleic acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the H-bonding is taking place between the coformer and Compound 1. 6.3.12 Cocrystal Solid Form 8 Form 8 was prepared in cooling evaporative experiments when maleic acid was used as the coformer and ethyl acetate was used as the t. Form 8 is an ethyl acetate solvated cocrystal form of Compound 1 and maleic acid. provides an overlay of XRPD patterns of nd 1, Form 7, Form 8 and maleic acid (from bottom to top). A list of X-Ray Diffraction Peaks for Form 8 is ed below in Table 21.

Table 21. X-Ray Diffraction Peaks for Form 8 Relative Two-theta angle (°) d Space (Å) ity (%) 6.14 14.38 86.12 7.42 11.9 18.12 .5 5.71 12.36 17.3 5.12 32.94 18.46 4.8 14.03 26.78 3.33 33.16 28.38 3.14 19.56 provide TGMS data of Form 8. A mass loss of 1% corresponding to ethyl acetate was observed between 35°C and 110°C during an endothermic event with Tpeak at 118.8°C, suggesting the solvated nature of the sample, when heated from 25°C to 300°C.

According to the SDTA signal in , an ermic event was observed at 118.8°C, ed by osition. provides HPLC and MS data of Form 8. The peak retention time is 8.1 minutes. The HPLC data indicates that the sample purity is 87.2% ). provides an FTIR overlay of Compound 1 (top), Form 8 (middle) and maleic acid m). The overlay indicates that the main shifts take place in the spectra in the region 1800-1500cm-1 and 1600-1400cm-1. provides an FTIR overlay of Compound 1 (top), Form 8 (middle) and maleic acid (bottom) in the region of 1800-400 cm-1. The overlay emphasizes the area between 1800-1500cm-1 and 1600-1400cm-1 corresponding to tertiary amines shifts where the H-bonding is taking place between the coformer and Compound 1. 6.4 BIOLOGICAL EXAMPLES 6.4.1 Biochemical assays TOR HTR-FRET Assay. The following is an e of an assay that can be used to determine the TOR kinase inhibitory activity of solid forms of Compound 1. A solid form of Compound 1 is dissolved in DMSO and prepared as 10 mM stocks and diluted appropriately for the experiments. Reagents are ed as follows: “Simple TOR buffer” (used to dilute high glycerol TOR fraction): 10 mM Tris pH 7.4, 100 mM NaCl, 0.1% Tween-20, 1 mM DTT. Invitrogen recombinant TOR enzyme (cat# PV4753) is diluted in this buffer to an assay concentration of 0.200 µg/mL.

ATP/Substrate solution: 0.075 mM ATP, 12.5 mM MnCl2, 50 mM Hepes, pH 7.4, 50 mM -GOP, 250 nM Microcystin LR, 0.25 mM EDTA, 5 mM DTT, and 3.5 µg/mL GST- p70S6.

Detection t solution: 50 mM HEPES, pH 7.4, 0.01% Triton X-100, 0.01% BSA, 0.1 mM EDTA, 12.7 µg/mL Cy5-GST Amersham (Cat#PA92002V), 9 ng/mL phospho p70S6 (Thr389) (Cell Signaling Mouse Monoclonal #9206L), 627 ng/mL mouse Lance Eu (Perkin Elmer Cat#AD0077).

To 20 µL of the Simple TOR buffer is added 0.5 µL of test solid form in DMSO.

To initiate the reaction 5 µL of ATP/Substrate solution is added to 20 µL of the Simple TOR buffer solution ol) and to the compound solution prepared above. The assay is stopped after 60 minutes by adding 5 µL of a 60 mM EDTA solution; 10 µL of detection reagent solution is then added and the mixture is allowed to sit for at least 2 hours before reading on a Perkin- Elmer Envision late Reader set to detect LANCE Eu TR-FRET (excitation at 320 nm and emission at 495/520 nm).

DNA-PK assay. DNA-PK assay is performed using the procedures supplied in the Promega DNA-PK assay kit (catalog # V7870). DNA-PK enzyme can be purchased from Promega (Promega cat#V5811). 6.5 FORMULATION EXAMPLES Certain formulations comprising solid forms of Compound 1 are prepared and tested for a number of physical and chemical properties. Modifications are then made and subsequent formulations are also tested, until formulations possessing desirable physical and chemical properties are found. The following example describes these formulations and their testing.

A solid form of Compound 1 is formulated as tablets containing about 5 mg, mg, and 50 mg of a solid form of Compound 1 as an active pharmaceutical ient. The excipients and carriers that are used in the tablet formulations are summarized in Table 22, along with their intended functions.

Table 22. Pharmaceutical able Excipients and rs Ingredients Function Lactose monohydrate, NF (Fast Flo 316) Diluent Microcrystalline cellulose, NF (Avicel pH 101) t/binder Microcrystalline cellulose, NF (Avicel pH 102) Diluent/binder Corn starch, NF Disintegrant/lubricant Pregelatinized starch, NF (Starch 1500) Binder/Disintegrant Lactose anhydrous, NF Diluent Croscarmellose sodium, NF (Ac-Di-Sol) egrant Stearic acid, NF Lubricant Magnesium Stearate, NF Lubricant General method for tablet preparation. Tablets are produced at batch size g from 0.5 to 2.2 kg. A solid form of Compound 1 is first mixed/blended with binders, diluent(s), and/or disintegrant (e.g., lactose monohydrate (NF), croscarmellose sodium (NF), and/or microcrystalline cellulose (NF)) using a Globepharma 4-8 quart Bin Blender. The mixture is then sieved via 18 mesh . The sieved mixture is r mixed/blended with a Globepharma 4-8 quart Bin Blender. After lubricant(s) (e.g., stearic acid (NF) and/or magnesium stearate (NF)) are sieved via 30 mesh screen, the lubricant(s) are then added to the mixture. The resulting mixture is then mixed/blended with a Globepharma 4-8 quart Bin Blender. The mixture is then compressed into tablets with a rotary table press, and then coated in an Ohara 8" pan. The tablets thus produced are evaluated for their powder characteristics, tablet characteristics, drug product photostability/short term stability, and manufacturing process.

Tablet formulations I to VIII of a solid form of Compound 1 are summarized in Table 23 to Table 30. The process parameters for tablet preparation (blending/compression) are ized in Table 31 and Table 32. The addition of stearic acid in Formulations V to VIII can improve lubrication t impacting disintegration and compressibility. Lactose monohydrate, NF (Fast Flo 316) can be used as an alternate diluent.

Table 23. Tablet Formulation I Amounts Ingredients mg % A solid form of Compound 1 50.0 16.7 Lactose drate, NF (Fast Flo 316) 145.1 48.3 Microcrystalline ose, NF (Avicel pH 101) 93.1 31.0 rmellose sodium, NF (Ac-Di-Sol) 9.0 3.0 Magnesium te, NF 3.0 1.0 Total 300.0 100 Table 24. Tablet Formulation II Amounts Ingredients mg % A solid form of Compound 1 50.0 16.7 Lactose monohydrate, NF (Fast Flo 316) 168.0 56.0 Pregelatinized starch, NF (Starch 1500) 70.1 23.3 Croscarmellose sodium, NF (Ac-Di-Sol) 9.0 3.0 Magnesium Stearate, NF 3.0 1.0 Total 300.0 100 Table 25. Tablet Formulation III Amounts ients mg % A solid form of Compound 1 50.0 16.7 Lactose anhydrous, NF 145.1 48.3 Microcrystalline cellulose, NF (Avicel pH 101) 93.1 31.0 Croscarmellose sodium, NF (Ac-Di-Sol) 9.0 3.0 Magnesium Stearate, NF 3.0 1.0 Total 300.0 100 Table 26. Tablet Formulation IV Ingredients mg % A solid form of Compound 1 50.0 16.7 Lactose monohydrate, NF (Fast Flo 316) 145.0 48.3 Microcrystalline cellulose, NF (Avicel pH 102) 93.0 31.0 Croscarmellose sodium, NF (Ac-Di-Sol) 9.0 3.0 ium Stearate, NF 3.0 1.0 Total 300.0 100 Table 27. Tablet Formulation V Amounts ients mg % A solid form of Compound 1 50.0 11.9 Lactose monohydrate, NF (Fast Flo 316) 220.48 52.5 Amounts Ingredients mg % Microcrystalline cellulose, NF (Avicel pH 102) 130.20 31.0 Croscarmellose sodium, NF (Ac-Di-Sol) 12.6 3.0 Stearic acid, NF 2.52 0.6 ium Stearate, NF 4.20 1.0 Total 420.0 100 Table 28. Tablet Formulation VI Amounts Ingredients mg % A solid form of Compound 1 50.0 11.9 Lactose monohydrate, NF (Fast Flo 316) 182.20 63.1 Microcrystalline cellulose, NF (Avicel pH 102) 54.0 18.0 Croscarmellose sodium, NF (Ac-Di-Sol) 9.0 3.0 Stearic acid, NF 1.80 3.0 ium te, NF 3.0 1.0 Total 300.0 100 Table 29. Tablet Formulation VII Amounts Ingredients Mg % A solid form of Compound 1 50.0 16.7 e monohydrate, NF (Fast Flo 316) 265.0 88.3 Microcrystalline cellulose, NF (Avicel pH 102) 75.60 25.2 Corn starch, NF 12.6 4.2 Croscarmellose sodium, NF (Ac-Di-Sol) 12.6 4.2 Magnesium Stearate, NF 4.20 1.4 Total 420.0 100 Table 30. Tablet Formulation VIII Amounts Ingredients Mg % A solid form of Compound 1 50.0 16.7 Lactose monohydrate, NF (Fast Flo 316) 136.0 45.3 Microcrystalline cellulose, NF (Avicel pH 102) 93.0 31.0 Corn starch, NF 9.0 3.0 Croscarmellose sodium, NF (Ac-Di-Sol) 9.0 3.0 Magnesium Stearate, NF 3.0 1.0 Total 300.0 100 Table 31. Tablet Process Parameters Equipment/Process Parameters I II III IV Batch size (kg) 0.5 0.5 0.5 0.5 Bin r (quart) 4 4 4 4 Pre-blending time (min) 20/10 20/10 20/10 20/10 Lubrication time (min) 3 3 3 3 299 301 307 297 Actual weight (mg) 291-309 295-310 301-311 290-300 Bulk density (g/cc) 0.4 0.53 0.37 0.42 Tooling (round, SC) 12/32 12/32 12/32 12/32 Hardness (average in Kp) 7.9 4.1 7.9 7.4 Thickness ge in mm) 3.95 3.86 3.98 3.86 Friability (4 min) (%) 0 0.1 0 0.1 Disintegration time (max) (sec) 18 75 55 21 Observation g Picking g Picking Table 32. Tablet Process Parameters Equipment/Process Parameters V VI VII VIII Batch size (kg) 0.5 0.5 0.5 0.5 Bin blender used (quart) 4 4 4 4 ent/Process Parameters V VI VII VIII Pre-blending time (min) 20/10 20/10 20/10 20/10 ation time (min) 3 3 3 3 418 299 419 301 Actual weight (mg) 413-421 293-307 413-426 296-305 Bulk density (g/cc) 0.45 0.43 0.48 0.43 Tooling (round, SC) 12/32 12/32 12/32 12/32 Hardness (average in Kp) 9.1 8.5 9.0 8.4 Thickness (average in mm) 5.20 3.8 4.12 3.86 Friability (4 min) (%) 0.3 0.2 0.2 0.1 Disintegration time (max) (sec) 31 30 29 20 Observation None None None None Tablet ations IX to XI of a solid form of Compound 1 are summarized in Table 33 to Table 35. The process parameters for their preparation are summarized in Table 36 and Table 37.

Table 33. Tablet Formulation IX Amounts Ingredients mg % A solid form of Compound 1 50.0 15.4 Lactose monohydrate, NF (Fast Flo 316) 151.5 46.6 Microcrystalline cellulose, NF l pH 102) 100.75 31.0 Corn starch, NF 9.75 3.0 Croscarmellose sodium, NF (Ac-Di-Sol) 9.75 3.0 Magnesium Stearate, NF 3.25 1.0 Total 325.0 100 Opadry pink 03K140004 4% weight gain Table 34. Tablet Formulation X Amounts Ingredients mg % A solid form of nd 1 50.0 15.4 Lactose monohydrate, NF (Fast Flo 316) 149.55 46.0 Microcrystalline ose, NF (Avicel pH 102) 100.75 31.0 Corn starch, NF 9.75 3.0 Croscarmellose sodium, NF (Ac-Di-Sol) 9.75 3.0 Stearic acid, NF 1.95 0.6 Magnesium Stearate, NF 3.25 1.0 Total 325.0 100 Opadry pink 03K140004 4% weight gain Table 35. Tablet Formulation XI Amounts Ingredients mg % A solid form of Compound 1 5.0 3.85 Lactose monohydrate, NF (Fast Flo 316) 74.82 57.55 Microcrystalline cellulose, NF (Avicel pH 102) 40.30 31.00 Corn starch, NF 3.90 3.00 Croscarmellose sodium, NF (Ac-Di-Sol) 3.90 3.00 c acid, NF 0.78 0.60 Magnesium Stearate, NF 1.30 1.00 Total 130.0 100 Opadry beige 03K170001 4% weight gain Table 36. Tablet Process Parameters Equipment/Process ters IX X XI Blending/Compression Batch size (kg) 0.65 0.65 0.52 Bin blender used (quart) 4 4 4 Equipment/Process Parameters IX X XI Blending/Compression Pre-blending time (min) 20/10 20/10 20/10 ation time (min) 3 3 3 323 326 131 Actual weight (mg) 318-328 316-333 130-134 Bulk density (g/cc) 0.40 0.42 0.48 Tooling , SC) 12/32 12/32 1/4 Hardness (average in Kp) 9.3 9.1 5.9 Thickness (average in mm) 4.09 4.12 3.72 Friability (4 min) (%) 0.1 0.1 0.1 Disintegration time (max) (sec) 39 27 24 Observations Picking None None Table 37. Tablet Process Parameters Equipment/Process Parameters IX X XI Coating Batch size (kg) 0.27 0.27 0.30 Weight gain (%) 4 4 4 Solid in suspension (%) 12 12 12 Pan (inch) 8 8 8 Nozzle size (mm) 0.8 0.8 0.8 Atomizing air pressure (PSI) 9-10 10-12 9-10 Pattern (PSI) 12-13 12-13 11-12 Distance gun-ben (inch) 3 3 3 w (CFM) 75 75 75 Pan speed (RPM) 16-18 14-17 14-17 Inlet temperature (°C) 75 75 72-73 Exhaust temperature (°C) 51-53 51-53 49-50 Spray rate 5-7 4-6 4-6 Equipment/Process Parameters IX X XI Coating Observation Acceptable ance The 5 mg and 50 mg tablets (core and coated) are subjected to short term stability and photo-stability evaluations. The short term stability of the 50 mg tablets is tested by storing for 2 weeks at 40 ºC/75%RH in an open bottle.

Tablet formulations XII (50 mg), XIII (20 mg), and XIV (5 mg) are ized in Table 38, Table 39 and Table 40.

Table 38. Tablet Formulation XII (50 mg) Amounts Ingredients mg % A solid form of Compound 1 50.0 15.38 Lactose drate, NF (Fast Flo 316) 159.95 49.22 Microcrystalline cellulose, NF (Avicel pH 102) 100.75 31.00 Croscarmellose sodium, NF (Ac-Di-Sol) 9.75 3.00 Stearic acid, NF 1.30 0.40 Magnesium Stearate, NF 3.25 1.00 Total 325.0 100 Opadry pink 03K140004 13.0 4% weight gain Table 39. Tablet Formulation XIII (20 mg) Ingredients mg % A solid form of Compound 1 20.0 15.38 Lactose monohydrate, NF (Fast Flo 316) 63.98 49.22 rystalline cellulose, NF (Avicel pH 40.30 31.00 102) Croscarmellose sodium, NF (Ac-Di-Sol) 3.90 3.00 Stearic acid, NF 0.52 0.40 Amounts Ingredients mg % Magnesium Stearate, NF 1.30 1.00 Total 130.0 100 Opadry yellow 03K12429 5.2 4% weight gain Table 40. Tablet ation XIV (5 mg) Amounts Ingredients mg % A solid form of Compound 1 5.0 3.80 Lactose monohydrate, NF (Fast Flo 316) 78.98 60.70 Microcrystalline cellulose, NF (Avicel pH 40.30 31.00 102) Croscarmellose sodium, NF (Ac-Di-Sol) 3.90 3.00 Stearic acid, NF 0.52 0.40 Magnesium Stearate, NF 1.30 1.00 Total 130.0 100 Opadry II pink 85F94211 5.2 4% weight gain The 20 mg and 50 mg tablets are compressed at s compression forces to assess compressibility and define a hardness range. The parameters for the preparation of the tablets to assess compressibility are summarized in Table 41 (blending/compression) and Table 42 (coating). The 20 mg tablets are coated with Opadry Yellow 03K12429, whereas the 50 mg tablets are not coated. The core and coated tablets (20 mg) are tested for dissolution.

Table 41. Process Parameters for 50 mg and 20 mg Tablet Formulations (Blending/Compression) Equipment/Process ter 50 mg 20 mg Batch Size (kg) 2.21 n Blend) Bin Blende used (quart) 8 Pre-blending time (min) 20/10 Equipment/Process Parameter 50 mg 20 mg Lubrication time (min) 3 3 327 129 Actual weight (mg) 313-339 124-135 Bulk density (g/cc) 0.41 0.41 Tooling (round, SC) 12/32 ¼ Hig 3.6 High-9.0 Hardness (average in Kp) Low-5.9 Low-3.8 Target-9.9 Target-6.1 Thickness (average in mm) 4.26 3.76 Friability (4 min) (%) 0.09 0.04 Disinegration time (max) (sec) 39 22 Observations None None Table 42. Process ters for Formulation XIII (Coating) ent/Process Parameter 20 mg Batch size (kg) 0.27 Weight gain (%) 4 Solid in suspension (%) 12 Pan (inch) 8 Nozzle size (mm) 0.8 Atomizing air pressure (PSI) 9-10 Pattern (PSI) 11-12 Distance gun-bed (inch) 3 Airflow (CFM) 75 Pan speed (RPM) 14-16 Inlet temperature (°C) 65 Exhaust temperature (°C) 45-47 Spray rate 4-5 Observation Acceptable coating Batch formulations of a solid form of Compound 1 are summarized in Table 43.

Table 43. Batch Tablet Formulations mg 20 mg ients grams grams A solid form of Compound 1 45.0 180.0 Lactose monohydrate 710.82 575.82 Microcrystalline cellulose 362.70 362.70 Croscarmellose sodium 35.10 35.10 Stearic acid 4.68 4.68 Magnesium stearate 11.70 11.70 Total 1170.0 1170.0 Opadry® II Pink 65.52 - Opadry® Yellow - 65.52 Tablet formulation XV (45 mg) is summarized in Table 44. Tablet ation XV are prepared using methodology provided herein or other methods known to one d in the art.

Table 44. Tablet Formulation XV (45 mg) Amounts Ingredients mg % A solid form of Compound 1 45.0 15.38 Lactose monohydrate, NF (Fast Flo 316) 5 49.22 Microcrystalline cellulose, NF (Avicel pH 102) 90.675 31.00 Croscarmellose sodium, NF (Ac-Di-Sol) 8.775 3.00 Stearic acid, NF 1.170 0.40 Magnesium Stearate, NF 2.925 1.00 Total 292.50 100 Opadry pink 03K140004 11.7 4.0% weight gain Additionally, A solid form of Compound 1 can be susceptible to hydrolysis. ingly, without being limited by theory, a low-moisture grade rystalline cellulose (Avicel pH 112) can be used in place of Avicel pH 102 to minimize or prevent hydrolysis.

Tablet ations XVI (15 mg) and XVII (30 mg) are ized in Table 45 and Table 46, below. Tablet formulations XVI and XVII are prepared using blending/sieving via a Comil process. After lubrication, the mixture is then compressed into tablets and film-coated.

Table 45. Tablet Formulation XVI (15 mg) Amounts Ingredients mg % A solid form of Compound 1 15.0 15.38 Lactose monohydrate, NF (Fast Flo 316) 48.37 49.62 Microcrystalline cellulose, NF (Avicel pH .23 31.00 112) Croscarmellose sodium, NF (Ac-Di-Sol) 2.925 3.00 Magnesium Stearate, NF 0.975 1.00 Total 97.50 100 Opadry II pink 85F94211 3.9 4% weight gain Table 46. Tablet Formulation XVII (30 mg) Amounts Ingredients mg % A solid form of Compound 1 30.0 15.38 Lactose drate, NF (Fast Flo 316) 96.75 49.62 Microcrystalline cellulose, NF (Avicel pH 60.45 31.00 112) Croscarmellose sodium, NF (Ac-Di-Sol) 5.85 3.00 Magnesium Stearate, NF 1.95 1.00 Total 195.0 100 Opadry pink 03K140004 7.8 4% weight gain The embodiments disclosed herein are not to be limited in scope by the specific embodiments disclosed in the es which are intended as illustrations of a few aspects of the disclosed embodiments and any embodiments that are functionally equivalent are encompassed by the present sure. Indeed, various modifications of the embodiments disclosed herein are in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

A number of references have been cited, the disclosures of which are incorporated herein by nce in their entirety.

Claims (88)

What is claimed is:

1. A solid form comprising (a) 2-hydroxypropanyl)pyridinyl)((trans)- 4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one; and (b) a er, wherein the coformer is fumaric acid, benzoic acid, gentisic acid or maleic acid.

2. The solid form of claim 1, wherein the coformer is fumaric acid

3. The solid form of claim 1, wherein the coformer is benzoic acid.

4. The solid form of claim 1, wherein the coformer is gentisic acid

5. The solid form of claim 1, n the coformer is maleic acid.

6. The solid form of any one of claims 1–5, which is substantially crystalline.

7. The solid form of any one of claims 1–5, which is substantially a cocrystal.

8. The solid form of any one of claims 1–5, which is greater than 80% by weight, greater than 90% by weight, greater than 95% by weight, greater than 97% by weight, or greater than 99% by weight of a cocrystal.

9. The solid form of any one of claims 1–5, which is substantially physically pure.

10. The solid form of any one of claims 1–5, which is substantially free of other solid forms of 7-(6-(2-hydroxypropanyl)pyridinyl)((trans)methoxycyclohexyl)-3,4- dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

11. The solid form of any one of claims 1–5, r comprising amorphous 7-(6-(2- hydroxypropanyl)pyridinyl)((trans)methoxycyclohexyl)-3,4-dihydropyrazino[2,3- b]pyrazin-2(1H)-one.

12. The solid form of any one of claims 1–5, which is stable.

13. The solid form of any one of claims 1–5, which is substantially crystalline and lly stable.

14. A pharmaceutical composition comprising the solid form of any one of claims 1—

15. The pharmaceutical composition of claim 14, further comprising a pharmaceutically acceptable excipient or carrier.

16. The pharmaceutical ition of claim 15, which is a single unit dosage form.

17. The ceutical composition of claim 16, which is a tablet.

18. The pharmaceutical composition of claim 16, which is a capsule.

19. A crystal form comprising the compound ula (I): \\ (5 I 2 N // N N o Ilf\ N N which has an X-ray powder difl‘raction pattern comprising peaks at approximately 7.14, 11.42 and 22.7 °20.

20. The l form of claim 19 which has an X—ray powder diffraction pattern further comprising peaks at approximately 12.82, 16.1 and 25.5 °20.

21. The crystal form ofclaim 19 which has a thermogravimetric analysis thermogram comprising no significant mass loss of the total mass of the crystal form between approximately 25°C to approximately 100°C when heated from approximately 25°C to approximately 300°C.

22. The crystal form of claim 19 which has a single differential thermal analysis gram comprising an endotherm with a maximum at approximately 187.6°C when heated from approximately 25°C to approximately 300°C.

23. The crystal form ofclaim 19 which is anhydrous. -124—

24. The crystal form of claim 19 which is substantially pure.

25. A crystal form comprising the compound offormula (I): 0H (5 |\ : N/ NNo Ilf\ which has an X—ray powder diffraction pattern comprising peaks at approximately 7.42, 18.3 and 23.82 °29.

26. The crystal form of claim 25 which has an X-ray powder diffraction pattern further comprising peaks at approximately 10.38, 15.94 and 19.42 °20.

27. The crystal form of claim 25 which has a thermogravimetric analysis thermogram comprising a total mass loss ofapproximately 1.12% of the total mass of the crystal form between approximately 35°C and approximately 175°C when heated from approximately 25°C to approximately 300°C.

28. The crystal form of claim 25 which has a single differential thermal is gram comprising an endotherm with a maximum at approximately 193.5°C when heated from approximately 25°C to approximately 300°C.

29. The crystal form of claim 25 which is water solvated.

30. The crystal form of claim 25 which is a monohydrate.

31. The l form ofclaim 25 which is substantially pure.

32. A crystal form sing the compound offormula (I): OH (5 |\ : N/ N N o which has an X-ray powder diffraction pattern comprising peaks at approximately 7.3, 12.78 and 21.9 °20.

33. The crystal form of claim 32 which has an X-ray powder diffraction pattern further sing peaks at approximately 11.86, 16.9 and 18.74 °20.

34. The crystal form of claim 32 which has a gravimetric analysis thermogram comprising a total mass loss of approximately 5% of the total mass of the crystal form between approximately 25°C and approximately 100°C when heated from about 25°C to about 300°C.

35. The crystal form ofclaim 32 which has a single differential thermal analysis thermogram comprising an endotherm with a maximum at approximately 67.7°C when heated from about 25 °C to about 300 °C.

36. The crystal form of claim 35 wherein the single differential thermal analysis thermogram further comprises an endotherm with a maximum at approximately 108°C.

37. The crystal form of claim 35 wherein the single differential thermal is gram further comprises an erm with a maximum at approximately 158°C.

38. The crystal form of claim 32 which is water solvated.

39. The crystal form of claim 32 which is substantially pure.

40. A crystal form comprising the nd offormula (I): OH (5 |\ : N/ N N o which has an X-ray powder diffraction pattern comprising peaks at approximately 8.02, 13.82 and 25.02 °20.

41. The crystal form ofclaim 40 which has an X-ray powder diffraction pattern r comprising peaks at approximately 15.58, 19.82 and 21.02 °20.

42. The crystal form of claim 40 which has a thermogravimetric analysis thermogram comprising a total mass loss ofapproximately 1.7% of the total mass of the crystal form between approximately 35°C and approximately 110°C when heated from about 25°C to about 300°C.

43. The crystal form of claim 40 which has a single differential thermal analysis thermogram comprising an endotherm with a maximum at approximately 832°C when heated from about 25°C to about 300°C.

44. The crystal form of claim 40 which is e solvated.

45. The crystal form m 40 which is substantially pure.

46. A crystal form sing the compound offormula (I): which has an X-ray powder difl‘raction pattern comprising peaks at approximately 4.1, 15.78 and 25.78 °29.

47. The crystal form of claim 46 which has an X-ray powder diffraction pattern further comprising peaks at approximately 6.34, 8.3 and 20.06 °20.

48. The crystal form of claim 46 which has a thermogravimetric analysis gram comprising a total mass loss ofapproximately 4.6% of the total mass of the crystal form between approximately 25°C and approximately 120°C when heated from about 25°C to about 300°C.

49. The crystal form of claim 46 which has a single differential l analysis thermogram comprising an endothenn with a m at approximately 955°C when heated from about 25°C to about 300°C.

50. The crystal form of claim 46 which is acetone solvated.

51. The crystal form of claim 46 which is water solvated.

52. The crystal form of claim 46 which is substantially pure.

53. A crystal form sing the compound offormula (I): OH (5 |\ . N/ NNo which has an X-ray powder diffraction pattern comprising peaks at approximately 4.26, 17.78 and 25.82 °26.

54. The crystal form ofclaim 53 which has an X-ray powder diffraction pattern r comprising peaks at approximately 13.02, 13.5 and 21.7 °20.

55. The crystal form ofclaim 53 which has a thermogravimetric analysis thermogram comprising a total mass loss ofapproximately 0.9% of the total mass of the crystal form between about 70°C and about 160°C when heated from about 25°C to about 300°C.

56. The l form of claim 53 which has a single differential thermal analysis thermogram sing an endotherm with a maximum at approximately 148°C when heated from about 25°C to about 300°C.

57. The crystal form of claim 53 which is acetonitn'le solvated.

58. The crystal form ofclaim 53 which is ntially pure.

59. A crystal form comprising the compound offormula (I): OH (5 |\ . N/ NNo which has an X-ray powder diffraction pattern comprising peaks at approximately 6.54, 13.66, 26.02 °20.

60. The crystal form of claim 59 which has an X-ray powder diffraction pattern r comprising peaks at approximately 9.42, 18.42 and 26.82 °2(-).

61. The crystal form of claim 59 which has a thermogravimetn'c analysis thermogram comprising a total mass loss of approximately 4% of the total mass of the crystal form between approximately 35°Cand approximately 110°C when heated fiom about 25°C to about 300°C.

62. The crystal form of claim 59 which has a single differential thermal analysis thermogram comprising an erm with a maximum at approximately 86°C when heated from about 25°C to about 300°C.

63. The l form of claim 59 which is acetonitn'le solvated.

64. The l form of claim 59 which is water solvated.

65. The crystal form of claim 59 which is substantially pure.

66. A crystal form comprising the compound offormula (I): OH 6 |\ : N/ N N O which has an X-ray powder diffraction pattern comprising peaks at approximately 6.14, 17.3 and 26.78 °20.

67. The crystal form of claim 66 which has an X-ray powder diffraction pattern finther comprising peaks at approximately 7.42, 18.46 and 28.38 °2(-).

68. The crystal form of claim 66 which has a thermogravimetric analysis thermogram sing a total mass loss of approximately 1% of the total mass of the crystal form between about 35°C and about 110°C when heated fiom about 25°C to about 300°C.

69. The crystal form of claim 66 which has a single differential thermal analysis thermogram comprising an endotherm with a maximum at approximately 118.8°C when heated from about 25°C to about 300°C.

70. The crystal form of claim 66 which is ethyl acetate solvated.

71. The crystal form of claim 66 which is ntially pure.

72. Use of a solid form of claim 1 in the manufacture of a medicament for treating or ting , an inflammatory ion, an immunological condition, a neurodegenerative disease, diabete, obesity, a neurological disorder, an age-related disease, a cardiovascular condition, or a conditions treatable or preventable by inhibition of a kinase pathway.

73. The use of claim 72, wherein the kinase pathway is the TOR kinase pathway.

74. Use of a solid form of claim 1 in the manufacture of a medicament for achieving a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of te response, partial response or stable disease in a subject having a solid tumor.

75. Use of a solid form of claim 1 in the manufacture of a medicament for improving International Workshop Criteria (IWC) for NHL, International Uniform Response Criteria for Multiple Myeloma (IURC), Eastern Cooperative Oncology Group Performance Status (ECOG) or Response Assessment for Neuro-Oncology (RANO) Working Group for GBM, in a subject in need f.

76. A solid form according to claim 1, substantially as herein described or exemplified.

77. A ceutical composition according to claim 14, substantially as herein described or exemplified.

78. A crystal form according to claim 19, substantially as herein described or exemplified.

79. A crystal form according to claim 25, substantially as herein described or exemplified.

80. A crystal form according to claim 32, substantially as herein bed or exemplified.

81. A crystal form ing to claim 40, ntially as herein described or exemplified.

82. A crystal form according to claim 46, substantially as herein described or exemplified.

83. A crystal form according to claim 53, substantially as herein described or exemplified.

84. A crystal form according to claim 59, substantially as herein bed or exemplified.

85. A crystal form according to claim 66, substantially as herein described or exemplified.

86. A use according to claim 72, substantially as herein bed or exemplified.

87. A use according to claim 74, substantially as herein described or exemplified.

88. A use according to claim 75, substantially as herein described or exemplified. SIGNAL PHARMACEUTICALS, LLC By their Attorneys HENRY HUGHES Per: c acid Form 2 Form 1 Compound 1